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Breast cancer remains a leading cause of death amongst women worldwide. Despite 
the major diagnostic and therapeutic innovations, the effect on mortality has been modest. 
One of the factors contributing to this effect is the relative lack of understanding about the 
natural history of the disease, mainly the progression from in situ to invasive breast 
carcinoma, which is a life-threatening condition. Ductal carcinoma in situ (DCIS) is the 
precursor lesion for invasive ductal carcinoma (IDC), but the step-wise transformation events 
that drive its progression are unknown. Although not all the DCIS progress to IDC, up to 50% 
of cases progress, constituting a challenge in breast tumorigenesis, not only in order to 
predict which in situ lesions will become invasive and the time frame in which that will 
happen, but also to better tailor the treatment, avoiding the overtreatment or under-treatment 
associated with DCIS management.  
Aiming a deeper understanding into the molecular profiles of in situ and invasive 
breast carcinomas, our first aim was to compare the molecular phenotypes of in situ and 
invasive components of breast cancer coexisting in the same sample. We built a tumor 
series of 189 cases of matched in situ and invasive carcinoma components using tissue 
microarrays and classified them according to their immunoprofiles, into Luminal A and B, 
HER2 over-expressing and Basal-like subtypes. The overall concordance on the molecular 
phenotypes both components was 94%, suggesting that the in situ and invasive carcinomas 
developing in a unique breast cancer patient belong to the same molecular subtype, 
supporting the theory of the parallel disease regarding breast tumorigenesis. This theory 
defends that a specific subtype of DCIS matches a specific subtype of invasive breast 
cancer, contradicting the view of a theory of linear progression, supporting that tumor 
progression follows a linear pattern, where low grade DCIS progresses to high-grade DCIS 
and then to invasive ductal breast carcinoma.  
In an attempt to explore the transcriptional program that drives invasion, our second 
aim was to identify biomarkers that could trigger the progression from in situ to invasive 
breast carcinoma, based on a set of genes that has been previously identified at the mRNA 
level. In order to find out if some of these genes, such as MMP11, Adrenomedullin, 
Synaptotagmin V and UBE2C were differentially expressed between DCIS and IDC, we 
have studied their protein expression by immunohistochemistry in the same series of 
matched DCIS/IDC. In our series, the levels of protein expression were similar between the 
in situ and invasive components, ranging from 75% to 88% of concordance between both 
counterparts, suggesting that alterations in these genes can occur prior to invasion.   
ABSTRACT 
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Actually, during several decades, researchers have only focused their attention in 
tumor cells and the alterations found in these cells have been the center of breast 
tumorigenesis. However, the majority of the studies failed to demonstrate significant 
differences between the expression proteins in the neoplastic cells of DCIS and IDC, 
suggesting that the alterations in the tumor microenvironment would have a more important 
role in the progression from an in situ to an invasive phenotype than the biology of the tumor 
cells per se. Nowadays, it is widely accepted that close interactions between cancer cells 
and stroma are known to regulate breast cancer pathways and thus, the determination of 
differential tumor-stromal metabolic interactions could be an important step in invasiveness. 
Addressing the role of the microenvironment, our third aim was to investigate in the series of 
breast cancer samples, including matched in situ and invasive components, if there was a 
relationship between stromal Caveolin-1, a known metabolic protein involved in the 
progression from DCIS to IDC and MCT4, also involved in metabolism as a transporter of L-
lactate from glycolytic cells. MCT4 is associated with Caveolin-1 in triple negative breast 
cancers, predicting poor clinical outcome. Loss of stromal Caveolin-1 expression in the 
progression to IDC was found in 75% of the cases. In contrast, MCT4 stromal expression 
was acquired in 87% of the IDCs. Additionally, when matched in situ and invasive 
carcinomas were compared, a concomitant loss of Cav-1 and gain of MCT4 was observed in 
the stroma of 75% of the cases, suggesting that alterations in Cav-1 and MCT4 may thus 
mark a critical point in the progression from in situ to invasive breast cancer. 
In summary, the results generated in this work indicate that immunhohistochemical 
profiles do not differ significantly in the transition from in situ to invasive breast cancer. 
Furthermore, the set of genes - MMP11, Synaptotagmin V, Adrenomedullin and UBE2C- 
previously found to characterize the transition from in situ to invasive breast carcinoma, at 
the mRNA level did not differ also significantly between both components at the protein level. 
Finally, we found that the microenvironment seems to play an important role in breast cancer 
progression, since the loss of stromal Cav-1 and the concomitant gain of stromal MCT4 
showed significant differences in the transition from in situ to invasive carcinoma of the 
breast.  
Resumo  
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O carcinoma da mama constitui a principal causa de morte por cancro entre as 
mulheres em todo o mundo. Apesar dos avanços relativos ao diagnóstico precoce e 
terapêutica, o efeito na mortalidade é ainda pequeno. Uma das causas deve-se ao 
conhecimento limitado da história natural da doença, nomeadamente a progressão do 
carcinoma in situ para o carcinoma invasivo da mama. O carcinoma in situ (DCIS) constitui 
a lesão percursora do carcinoma invasivo, contudo a série de eventos que conduz à 
progressão permanece pouco conhecida. Apesar de nem todos os carcinomas in situ 
progredirem para invasivos, até 50% dos casos pode progredir, constituindo um desafio na 
carcinogénese mamária, predizer não só quais são as lesões que progridem, mas também 
a altura em que essa progressão ocorre de forma a adequar o tratamento a cada paciente. 
Na tentativa de compreender os perfis moleculares dos carcinomas in situ e 
invasivos da mama, o nosso primeiro objectivo foi comparar os fenótipos moleculares de 
ambos os componentes, presentes na mesma amostra. Assim, construímos uma série de 
189 casos usando  “Tissue  Microarrays”  e  classificamos os casos de acordo com os perfis 
moleculares em Luminal A e B, com sobre-expressão de HER-2 e basal. A concordância 
global dos fenótipos moleculares entre os componentes in situ e invasivo foi de 94%, 
sugerindo que carcinomas in situ e invasivos que se desenvolvem na mesma paciente, têm 
o mesmo subtipo molecular, suportando a teoria paralela de progressão no carcinoma da 
mama. Esta teoria sugere que um subtipo de DCIS corresponde a um subtipo de carcinoma 
invasivo, contrariando a teoria de progressão linear, que sugere que a progressão tumoral 
ocorre de forma linear, onde o DCIS de baixo grau progride para DCIS de alto grau e 
posteriormente para carcinoma invasivo.   
Numa tentativa de explorar o programa transcripcional que conduz à invasão, o 
nosso segundo objetivo consistiu em identificar biomarcadores que poderiam desencadear 
a progressão de carcinoma in situ para invasivo, com base num conjunto de genes 
previamente identificados por mRNA. De forma a perceber se alguns destes genes, como a 
MMP11, Adrenomedulina, Sinaptotagmina V e a UBE2C estavam diferencialmente 
expressos no DCIS e IDC, estudamos a sua expressão proteica por imunohistoquímica na 
mesma série de DCIS/IDC. Os resultados mostraram que os níveis de expressão da 
proteína foram semelhantes entre os componentes in situ e invasivo, variando de 75% a 
88% de concordância, sugerindo que essas alterações moleculares podem ocorrer em 
estádios pré-invasivos.  
Durante várias décadas, os investigadores focaram a sua atenção nas células 
tumorais e as alterações genéticas encontradas nestas células. Contudo, a maioria dos 
RESUMO 
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estudos falhou em demonstrar diferenças significativas na expressão de marcadores nas 
células do carcinoma in situ e invasivo, sugerindo que as alterações no microambiente 
tumoral poderiam ter um papel mais importante na progressão de carcinoma in situ para um 
fenótipo invasivo do que a biologia das células tumorais. Atualmente é comumente aceite 
que as interações entre as células tumorais e o estroma regulam as vias de sinalização no 
carcinoma da mama e portanto a determinação das interações metabólicas tumor-estroma 
podem constituir uma etapa importante na invasão. Relativamente ao papel do 
microambiente, o nosso terceiro objetivo consistiu em verificar, numa série de casos de 
carcinoma da mama, com áreas correspondentes de in situ e invasivo, se havia uma 
associação no estroma entre a Caveolina-1, metabolicamente envolvida na progressão do 
DCIS para IDC e o MCT4, também associado ao metabolismo devido ao seu papel como 
transportador de lactato das células glicolíticas. O MCT4 está associado com a Cav-1 nos 
tumores de mama triplo-negativos, correlacionando-se com pior prognóstico. A perda de 
expressão da Cav-1 na progressão para o carcinoma invasivo ocorreu em 75% dos casos. 
Pelo contrário, houve ganho de expressão do MCT4 em 87% no carcinoma invasivo. 
Adicionalmente, quando comparamos os casos in situ com o correspondente carcinoma 
invasivo, a perda da Cav-1 e o ganho concomitante de MCT4 foi observado em 75% dos 
casos, sugerindo que as alterações na Cav-1 e no MCT4 possam constituir um ponto crítico 
na progressão do carcinoma in situ para o carcinoma invasivo.  
Em conclusão, os nossos resultados sugerem que os perfis immunohistoquímicos 
não diferem significativamente na transição do carcinoma in situ para o carcinoma invasivo. 
Para além disso, o painel de genes- MMP11, Adrenomedulina, Sinaptotagmina V e UBE2C 
descritos previamente como diferencialmente expressos na progressão in situ e invasivo, a 
nível de mRNA não diferiam significativamente entre as duas componentes em termos 
proteicos. Por fim, sugerimos que o microambiente tem um papel importante na progressão 
da carcinogénese mamária, dado que a perda da Cav-1 e o concomitante ganho de MCT4 
no estroma constituem alterações significativas na progressão do carcinoma in situ para o 
carcinoma invasivo da mama.  
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In Chaper I, a general introduction presents the most current knowledge on breast 
cancer. It summarizes the epidemiology, risk factors, prognostic factors, therapeutic 
strategies and classification, devoting particular attention to breast tumorigenesis, mainly to 
the theories of progression from in situ to invasive carcinoma and the parameters that can 
modulate this progression. A brief description of the importance of tumor microenvironment 
is also described.  
In Chapter II, the rationale and the aims of the thesis are defined whereas, in Chapter 
III, a description of the material and methods used to perform the studies are described.  
Chapters IV, V and VI encloses the three main manuscripts describing the original 
data presented in this thesis, which were already accepted or in preparation for publication in 
international peer reviewed journals. Each chapter contain an introduction, the results and 
the discussion for each proposed aim.  
In Chapter VII, an integrated view of the results is presented, with the general 
discussion. 
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1.1) EPIDEMIOLOGY 
 
Cancer remains the major public health problem worldwide, where one in three 
women and one in two men will develop cancer during lifetime, in developed countries [1]. In 
2008, there was an estimated 3.2 million cases of diagnosed cancer, with approximately 1.7 
million cancer deaths, in Europe [2].   
Breast Cancer is by far the most commonly diagnosed cancer and the leading cause 
of cancer death in women in both developing and developed countries of the world, with an 
estimated 1.4 million new breast cancer cases and 458.000 deaths in 2008 [3] [2]. Actually, 
there is an estimative of about 1 million of new cases per year in the world, being the areas 
of higher risk the ones including populations from North America, Europe and Australia. 
Conversely, the risk for developing breast cancer is lower in African and Asiatic continents 
(Figure 1A). 
 
 
 
Figure 1: A. Breast cancer estimated age-standardised incidence and mortality rates in the World per 100 000.  
B. Incidence and mortality rates of the most common types of cancer for both sexes in Portugal - estimates 
presented for the year 2008. [Adapted from Globocan 2008; Ferlay J et al, 2007]  
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In Portugal, according with the data from Portuguese League Against Cancer 
(www.ligacontracancro.pt) [4] breast cancer is also the first leading cause of cancer related 
deaths amongst Portuguese women, although at a lower rate when compared with the mean 
established for European Union countries. There are around 5333 new cases every year, 
with an incidence rate of 49.9 cases per 100.000 people. Mortality rates are in order of 14.4 
cases per 100.000 people, corresponding to 4.2 deaths daily (1537 deaths/year), with the 
estimate age-standardized mortality rate being lower than the European ratio [2] (Figure 1B). 
This reality has turned breast cancer one of the major interests in the national cancer 
research field However, since the ninety´s, breast cancer incidence and mortality have 
steadily decreased, with this decreased representing the progress in early diagnosis, better 
and more efficient treatment modalities, and a greater awareness and investment in 
education for early disease detection.   
 
  
1.2) RISK FACTORS 
 
Breast Cancer has a multifactorial etiology, resulting in a variety of genetic changes 
and consequently diverse biological behaviors among different patients [5]. The interaction 
between the environment and the individual genetic profile dictate the susceptibility for 
breast cancer and several risk factors are associated with breast cancer development. 
Besides being female, increasing age is the most important risk factor since breast cancer 
incidence rates double about every ten years [6]. There are also marked differences in the 
incidence of breast cancer in different places, being the incidence of breast cancer most 
common among Caucasians living in the colder climates and the more highly industrialized 
countries of the western hemisphere [7]. The observed differences in breast cancer 
incidence rates among countries may reflect demographic variations in modifiable risk 
factors [8]. In fact, earlier age at menarche, post-menopausal obesity, physical inactivity, 
dietary fat and alcohol consumption contributes to increased breast cancer risk [9-11]. 
Certain breast alterations and findings such as high breast tissue density, high bone mineral 
density and biopsy-confirmed hyperplasia, especially atypical hyperplasia, represent 
significant risk factors and increase the probability of malignant development [5, 12].  On the 
other hand, childbearing and breastfeeding seems to have a reduced risk, with higher 
protection for early first birth and a larger number of births [11]. Reproductive factors that 
increase risk include a long menstrual history (menstrual periods that start early and/or end 
later in life), never having children and having one’s  first  child  after  age  30.   
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 Among the hormonal influence, a major role has been attributed to the exposure to 
elevated levels of oestrogens, as has been indicated for a variety of female cancers, namely 
vaginal and endometrial carcinomas, since oestrogens have effects on cell proliferation and 
DNA damage, as well as in the promotion of cancer growth [7]. Similarly, it has been shown 
that the risk for breast cancer development is also increased in women that present high 
blood and tissue levels of oestrogen and progesterone [8]. Regarding the influence of 
endogenous hormones, several studies have explored the effect of endogenous serum 
concentrations of hormones and breast cancer risk. Postmenopausal women with elevated 
levels of serum estradiol, showed an increased risk for breast cancer development [13]. In 
fact, post-menopausal obesity, the late menopause (after the age of 55 years) and the early 
menarche (before than 12 years) are important risk factors, due to the breast exposure to 
elevated levels of oestrogen.  In respect to exogenous hormones, studies concerning the 
use of oral contraceptives and hormonal therapy for the menopause are still inconclusive, 
being the last associated with increased risk of breast cancer, especially when comparing its 
use during short and long periods of time [13] [14].  
 Environmental and lifestyle factors rather than inherited genetic factors account for 
most cases of breast cancer; however, the existence of family inherited germline mutations 
in breast cancer susceptibility genes, like BRCA1 and BRCA2, is a well-established risk 
factor for breast cancer. In fact, approximately 5% to 10% of all breast cancer cases result 
from the presence of mutations on these inherited susceptibility genes. Women with a family 
history of breast cancer, especially in a first-degree relative, have an increased risk of 
developing the disease themselves [15]. Also in men, approximately 15 to 20% of patients 
with breast cancer have a family history. BRCA2 mutations predispose men to breast cancer 
and may account for 4 to 14% of all cases [16].  
 
 
1.3) PROGNOSTIC FACTORS AND THERAPEUTIC STRATEGIES IN BREAST CANCER 
 
The outcome for women with breast cancer varies widely. Whereas some women 
have a normal life expectancy, others have only a 10% change of being alive in 5 years after 
diagnosis. Patient prognosis is mainly determined by pathological characteristics of the 
primary tumor and the status of axillary lymph nodes.  
The pathological examination includes cytological and histological assessment of 
some classical anatomo-pathologic parameters, which give prognostic and predictive 
information, essential for the treatment and follow-up of breast cancer patients, such as 
histological grade and type, axillary lymph nodes status and tumor size [6]. In the absence of 
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distant metastasis, the lymph nodes status represents the major threat to breast cancer 
patient outcome. Patients without nodal involvement have a 10-year disease free-survival 
rate close to 70-80%, falling to 35-40% with one to three positive nodes and 10-15% when 
more than 10 nodes are positive [8]. Tumor size is another powerful independent prognostic 
marker, with larger size associated with worse outcome. The prognostic and predictive 
importance of tumor size is of greatest relevance in node-negative breast cancer patients [8]. 
Women with node-negative carcinomas, with tumors less than 1 cm in size, have a 10-year 
survival rate of 90%, reducing for 77% when the tumor size is higher than 2 cm [17]. The 
histological grade provides important independent prognostic data. Several grading systems 
have been used over the years, and generally include several combinations of tissue 
architectural arrangement, nuclear features and mitotic rate. Many studies have 
demonstrated a significant association between overall survival and histological grade, which 
is now recognised as a powerful prognostic factor and included as a component of the 
minimum data set for histological reporting of breast cancer [8]. 
 The therapeutic strategies for breast cancer include mainly surgery, chemotherapy 
and radiotherapy.  The primary goal of breast cancer surgery is to remove the neoplastic 
lesion, as well as the regional axillary lymph nodes, in order to assess the extent of disease 
spreading and, therefore supporting the decision of therapy regimens. Surgical treatment 
involves breast-conserving surgery or mastectomy. When conserving surgery is 
appropriately used for localized or regional cancers, long-term survival is the same as with 
mastectomy [18]. However, some patients require mastectomy because of large or multiple 
tumors, or because of a reluctance or inability to undergo radiation therapy after breast-
conserving surgery [1]. Systemic adjuvant therapies, like chemo and radiotherapy, given to 
patients after surgery, is designed to eradicate clinically undetectable microscopic deposits 
of cancer cells that may have spread from the primary tumor, which usually result in 
decreased recurrences and improved patient survival [6]. Besides these therapeutic 
strategies, isolated or in combination with the referred prognostic factors, there are some 
factors, predictive of outcome, that potentially direct therapies against molecular targets, like 
nuclear hormone receptors, growth factors and their tyrosine-kinase receptors [19]. The two 
main molecular biomarkers important for therapeutic management in breast cancer are the 
hormonal receptors (ER and PgR) and the Human Epidermal growth factor receptor type 2 
(HER2). The assessment of these proteins is extremely important, as ER and HER2 are 
considered prognostic and predictive markers, not only because they allow the stratification 
of patients for treatment by identifying cases with different outcomes, but also because they 
select patients that are likely to respond to therapy. 
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HORMONAL RECEPTORS 
 
ER is a ligand-activated transcription factor that belongs to the superfamily of nuclear 
receptors for steroid hormones. Current assays use immunohistochemistry to detect 
hormonal receptors, a finding that is commonly correlated with a low breast cancer 
histological grade, better patient outcome and is an important predictor of response to 
hormonal therapy [20]  [21].  There  are  two  types  of  ER:  ERα  and  ERβ.  These  two  receptor  
subtypes vary in structure, and their encoding genes are on different chromosomes [22]. The 
tissue  distributions  of  the  isoforms  also  differ,  although  there  is  some  overlap.  Besides  ERβ  
is expressed in breast cancer cells, its involvement in carcinogenesis is controversial, and 
some studies suggest that in ER-positive   carcinomas,   the  mean   ratio   ERα/ERβ   is   higher  
than in normal tissue [23] [23] [24].  
Oestrogen can influence breast carcinogenesis acting as an initiator, causing DNA 
damage by hydroxylated oestrogen metabolites, or as a promoter, inducing growth of 
transformed cells [25]  [26]. Upon cellular diffusion, oestrogen binds to ER, which alters 
receptor conformation and activates dimerization. The dimers interact with several 
coactivators or corepressors in order to modulate transcription of target genes [22]. 
Since most breast carcinomas are, at least initially, hormone responsive, systemic 
endocrine therapy is an established strategy for adjuvant breast cancer treatment [27]. 
Current endocrine therapies of breast cancer are based on three main known mechanisms 
of action, all of them targeting the ER signalling pathway [20]: antagonizing ER function by 
competitive binding (selective estrogen receptor modulators), downregulating ER (achieved 
by pure antiestrogens) and reducing levels of synthesized estrogen (performed by 
aromatase inhibitors).  
Selective oestrogen receptor modulators (SERMs) are molecules that act like 
agonists of oestrogen in some tissues, but are antagonists to oestrogen action in others [28]. 
Tamoxifen, the first prototypic SERM [29]  was originally developed as an oral contraceptive 
[30], being recognized as an antioestrogenic and the first-line endocrine agent for breast 
cancer treatment. Tamoxifen can reduce the risk of breast cancer in women at high risk for 
developing the disease and is beneficial in pre and post-menopausal women whose tumors 
are ER positive [31] [32]. Therefore, although tamoxifen causes tumor regression in some 
women with metastatic disease [33], this range of activity may account for some of the 
undesirable effects of tamoxifen, such as increased endometrial proliferation and increased 
risk of endometrial carcinoma [34]. In breast, tamoxifen binds to ER and induces 
dimerization, but it impairs the binding of the dimers to DNA and inhibits the binding of 
coactivator proteins. Unfortunately, the treatment with tamoxifen is not effective for more 
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than 5 years, since development of resistance is a very common event [35]. New SERMs 
have been developed, like Raloxifene, which has lower toxicity, decreases breast cancer 
incidence and has no oestrogen-like activity on the uterus [36].   
 Aromatase inhibitors, which prevent the peripheral tissue conversion of adrenal 
androgens into oestrogens, resulting in lower oestrogen levels in the circulation and in tumor 
tissues, have been shown to be superior to tamoxifen and are now incorporated into first line 
therapy of advanced disease [6]  [37]. Most importantly, aromatase inhibitors are effective 
even in postmenopausal women with low oestrogen concentrations [37] and are also 
effective in ER-positive breast cancer patients [38], especially when these tumors also 
express high levels of the oncogene HER2, which is known to increase tamoxifen resistance 
[39]. Additionally, a recent study demonstrated an increased in overall survival in patients 
who had switched from Tamoxifen to aromatase inhibitors therapy [35], and these 
compounds also showed superiority over tamoxifen in the neoadjuvant setting, even 
challenging chemotherapy with regard to response in a selected group of patients [40] [41]. 
Pure antiestrogens, such as ICI 182,780, are agents that competitively inhibit the 
binding of oestrogens to ER, prevent dimerization, promote ER degradation and thereby 
abolish the transcription of target genes [42]. ICI 182,70, commercially known as Fulvestrant, 
has been shown to be efficient in the treatment of metastatic ER-positive breast cancer [43], 
and an appropriate clinical option in ER-positive and HER2 overexpressing tumors [44]. 
Moreover, ICI 182,780 exceeds other ER targeted therapies, since no side effects have 
been observed in premenopausal women with metastatic breast cancer, previously exposed 
to Tamoxifen and aromatase inhibitors [45].  
 
 
HER2 
 
HER2 is a member of the HER family (or ErbB) of receptor tyrosine kinases, which is 
involved in proliferation and survival [46]. This family encompasses four growth receptors 
with a high degree of homology: HER1 to HER4, being HER1 usually designated as EGFR 
(Epidermal Growth Factor Receptor) [47]. Although HER2 has partial homology to EGFR, a 
ligand for HER2 has not been identified to date. However, HER2 is transactivated by EGF-
like ligands [48], resulting in the formation of EGFR/HER2 heterodimers and, in an 
analogous way, neuregulins can induce the formation of HER2/HER3 and HER2/HER4 
heterodimers. This heterodimerization between HER2 and the other receptors of the family 
allows the participation of HER2 in signal transduction. HER2 is overexpressed in 25% to 
30% of human breast cancers [7] and predicts poor prognosis in patients with primary 
disease [49]. Gene amplification is the main cause leading to this overexpression in 
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mammary tumors, although activating mutations have also been described in other cancer 
models [50]. In order to control the malignant growth effects induced by HER2 
overexpression, there has been an attempt to develop drugs that could effectively block the 
activity of this transmembrane protein. 
The targeting of HER2 occurs by the inhibition of the extracellular domain, using 
monoclonal antibodies and/or by the inhibition of the tyrosine kinase domains, through 
tyrosine kinase inhibitors [51]. Trastuzumab is a humanised murine monoclonal antibody that 
was the first genomic research-based product approved for cancer therapy [52]. It displays a 
potent growth inhibitory effect and significantly improves disease-free and overall survival 
rates in patients with HER2 overexpressing breast carcinomas [53] [54]. However, the wide 
range of function mechanisms of trastuzumab give rise to various mechanisms of resistance 
due to the cross-talk of HER2 with other extracellular domains of HER proteins, resulting in 
incomplete inhibition and activation of other proliferative pathways [55]. This led to the 
development of small molecules that bind to the intracellular kinase domain of HER2, 
thereby inhibiting its activity. Lapatinib is one of these molecules, which inhibits both EGFR 
and HER2. Some studies have shown that the use of Lapatinib, in combination with other 
agents, represented survival advantages in patients with HER2overexpressing metastatic 
breast cancer [56]. 
 
 
1.4) MOLECULAR PORTRAITS 
 
Human breast carcinomas represent a heterogeneous group of tumors diverse in 
their natural history and their responsiveness to treatment. In fact, patients with identical 
tumor type and stage of disease can present different responses to therapy and different 
overall outcomes [57] [58]. The limitations of the current system are based on its inability to 
take into account the biological prognosis determinants [57]. Based on the above, in the past 
decade, high throughput microarray technology and gene expression profiling have been 
applied in breast cancer, in an attempt to further clarify its heterogeneity, allowing the linkage 
of molecular expression profiles to clinical patient´s outcomes and responses to therapy, 
generating a tool to better tailor treatment strategies to specific subgroups of patients. 
Another important implication is that molecular profiling may lead to the identification of new 
targets for therapy [6] [59] [60].  
Microarray-based gene expression profiling led to a working model for breast cancer 
molecular taxonomy, where clusters of genes, with coherent expression patterns, could be 
related to specific features of biological variation among tumor samples. Recent cDNA and 
tissue microarrays studies have showed that breast tumors can be classified into specific 
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molecular subtypes, distinguished by differences in their gene expression patterns, providing 
a distinctive portrait of each tumor and the basis for an improved breast cancer taxonomy 
[49] [58] [61]. Variations in growth rate, in the activity of specific signalling pathways, and in 
the cellular composition of the tumors were all reflected in the variation of the expression of a 
specific subset of genes and in the prognosis of the patients  [59] [61] [58]. In summary, the 
breast cancer molecular classification distinguishes three main molecular subtypes of breast 
cancers: the ER positive/luminal-like subtype, a gene expression cluster characteristic of the 
luminal cells; the HER2 overexpressing subtype, usually associated with the gene 
amplification of the HER2 proto-oncogene; and the triple negative carcinomas, that comprise 
mainly “normal breast-like”, claudin-low carcinomas and basal-like, (Figure 2) [62, 63]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A. Hierarchical clustering of breast tissue samples into five subgroups. Dark blue - luminal A subtype; 
yellow - luminal B subtype; pink - HER2 overexpressing subtype; red – basal-like subtype and green – normal 
breast like subtype. B. Overall survival analysis for the five expression-based tumor subtypes based on the 
classification presented in Figure 2A. Adapted from Sorlie T et al, 2001 [49].  
 
A
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The ER positive/luminal-like molecular subtype, which represents the majority of breast 
carcinomas (60-75%), is characterized by relatively high expression of genes that are 
usually associated to ER expression [59] and are generally considered good prognosis 
carcinomas. Luminal A and Luminal B subtypes can be distinguished by some features, 
namely HER2 expression and proliferation rates: Luminal B tumors are HER2 positive and 
display higher levels of proliferation that can be measured by Ki67 staining. Additionally, 
these tumors express lower levels of ER-associated genes and are associated with worse 
prognosis than Luminal A tumors [64] [65] [62] [66]. Therapeutic strategies for these 
subtypes of breast carcinomas involve direct targeting of ER, either by the use of Tamoxifen 
or the administration of aromatase inhibitors. These tumors are generally well or moderately 
differentiated, slow growing and well-responsive to endocrine treatments.  
HER2 overexpressing subtype comprises ER negative carcinomas that overexpress 
HER2/neu protein and represent about 20% of all mammary tumors [67].  In the majority of 
HER2 positive cases, overexpression is due to amplification of a DNA segment including the 
gene ERBB2 in the 17q21 amplicon [68]. These cancers are usually poorly differentiated, 
with high proliferation rates and display poor prognosis [49] [62].  However, these can be 
targeted with the monoclonal antibodies against HER2 (Transtuzumab) or using tyrosine 
kinase inhibitors, such as Lapatinib.  
Triple-negative carcinomas represent 10-17% of all breast carcinomas. They are a 
heterogeneous group of tumors that lack ER, PgR and HER2 expression, being usually 
insensitive to endocrine and HER2 therapies. This group of tumors encompasses normal-
like, claudin-low and basal-like carcinomas. The normal-like subgroup displays high 
expression levels of genes associated with adipose tissue, as well as basal cell genes, 
whereas presents low expression of luminal cell-associated genes. Although these tumors 
usually cluster together with benign mammary lesions and are usually associated with a 
better prognosis [62] [69], this group of tumors is quite controversial, since it is considered by 
several studies as an artefact derived from analysis of tumor specimens with a high 
proportion of normal tissue contamination [64] [70] [71]. Claudin-low tumors are a recently 
described molecular subgroup within the triple negative tumors, defined by the 
downregulation of a cluster of genes involved in cell-cell adhesion, namely Claudins 3, 4, 
and 7, Occludin and E-cadherin. Furthermore, these tumors exhibit low expression of luminal 
genes, inconsistent expression of basal-like genes, and high expression of lymphocyte, 
mesenchymal and endothelial cell markers [72] [73]. Basal-like breast tumors represent one 
of the most intriguing subtypes, comprising a small proportion of breast carcinomas (about 
15%), which exhibit a basal/myoepithelial phenotype, defined by immunohistochemical 
positivity for basal/ myoepithelial markers [74] [75]. These tumors, that fail to express ER, 
PgR and HER2, express basal keratins, p63, P-cadherin,  EGFR,  laminin,  α6β4-integrin and 
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vimentin [76] [77] [78]. This cluster also encompasses the expression of several genes 
involved in cell cycle, invasion, metastasis and angiogenesis [57], which might explain the 
association of these tumors with a poor prognosis signature, development of recurrence 
within the first 5 years after diagnosis, with high proliferative and high grade tumors, short 
patient survival and high mortality rates [17, 79]. Interestingly, these tumors present a 
specific pattern of distant metastasis, with increased frequencies in the lungs and brain [80] 
[81].  When these basal-like breast carcinoma immunoprofiles were compared to familial and 
sporadic origin, it was observed that basal tumors were mostly associated with familial cases 
[76]. Actually, it has been described that tumors from BRCA1-mutated carriers share an 
immunohistochemical profile very similar to that from sporadic basal-type carcinomas (high 
grade, ER-negative, PgR-negative and HER2-negative). Due to their triple-negative 
phenotype, currently chemotherapy and radiotherapy for systemic and local control remains 
the mainstay to treat basal-like cancer, although a high proportion of patients die in a shorter 
time frame due to metastatic disease.  
Recently, the advances in understanding the genomic diversity of breast cancer led 
to the characterization of a new genome-driven integrated classification of breast cancer, 
refining the existing classification systems used. The novel classification integrates 
molecular information on the genomic and transcriptomic landscapes of breast cancer, 
defining 10 integrative clusters [82].  The integrative clusters were each associated with 
distinct copy number variations and gene expression changes, clearly demonstrating the 
heterogeneity present within tumors classified according to ER, PgR and HER2 expression 
[83].  Furthermore, the 10 groups were associated with distinct features and clinical 
outcomes [82, 83].   
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2.1) THE MAMMARY GLAND 
 
The mammary gland in humans and other mammals is a dynamic organ that 
undergoes significant developmental changes during embryonic development, puberty, 
pregnancy, lactation and involution. The adult female mammary gland consists of a 
branching tree-like network of ducts, lined by a double layer of epithelial and myoepithelial 
cells, surrounded by fibroblasts embedded in an extracellular matrix or stroma, mainly 
composed by a dense fibrous connective tissue, admixed with adipose tissue, and 
harbouring vascularity (Figure 3). Stroma, besides the structural support provided to the 
mammary gland, it seems to play an important role in the dynamic induction of the breast 
gland structure morphogenesis and differentiation [84] [85]. 
 
Figure 3: A. Schematic representation of a mature female breast showing the main anatomical structures. 
Adapted from Ali S et al. 2002; B. Histological picture of a normal mature TLDU, composed of acini, surrounded 
by intralobular connective tissue; Haematoxylin-eosin staining; x100 C.  Segmental breast duct. The epithelial 
and myoepithelial cells can be easily identified; Haematoxylin-eosin staining; x1000.  
 
In the ductal-lobular branching system, the lobules of the human breast are 
organized into 15-20 lobes, which are drained by collecting ducts that converge at the nipple 
in a radial arrangement [86, 87]. Each lobule in turn is made up of acini (also called alveoli), 
originating the functional secretory units of the mammary gland, the terminal duct lobular 
units (TDLUs). These secretory units presents essentially two layers: a sheath of contractile 
cells containing myofilaments (myoepithelial or basal cells), which are in contact with the 
2. BREAST TUMORIGENESIS 
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basement membrane, and a second layer of epithelial cells that contours the lumen of the 
ducts (luminal cells) [88]. Myoepithelial cells are responsible not only for assisting milk 
ejection, but also for maintaining the normal structure and function of the lobule and 
basement membrane. Myoepithelial cells are characterized by expressing P-cadherin,   α-
smooth  muscle  actin  (α-SMA) and basal epithelial cytokeratins (CK5 and CK14). The luminal 
cells are secretory cells whose function is to produce milk and can be distinguished by the 
expression of nuclear receptors for steroid hormones oestrogen and progesterone, as well 
as a subset of epithelial cytokeratins, such as CK8, CK18 and CK19 [89].   
Frequently, is at the level of the TDLU, which not only constitutes the functional structure of 
the breast for milk production, but also is highly responsive to hormonal stimulus occurred 
during development and maturation processes like pregnancy and lactation [84], that many 
of the known epithelial benign and malignant lesions are observed [90].  
 
 
2.2) IN SITU BREAST CARCINOMA 
 
In situ breast carcinomas represent a group of malignant lesions that can be confined 
within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or 
LCIS) of the breast.  
 
 
 
 
 
 
 
 
 
 
Figure 4: A. Schematic representation of a ductal carcinoma in situ of the breast, Adapted from Kalluri R. Nature 
Reviews Cancer 6, 392-401 (2006); B. Haematoxylinn-eosin staining of ductal carcinoma in situ (DCIS), (200x).  
 
 
This classification was based on the resemblance of the involved spaces to normal 
ducts or lobules. However, it is now recognized that varied patterns of growths in situ are not 
A.  B.  
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related to the site or cell of origin, but rather reflects differences in tumor cell biology, such 
as whether the tumor cells express the cell adhesion protein E-cadherin or not. Currently, 
“lobular”   refers   to   carcinomas   of   a   specific   type,   and   “ductal”   is   more   generally   used   for  
adenocarcinomas that have no other designation [17]. Besides the nomenclature, both 
lesions share considerable epithelia proliferation rates associated with malignant cellular 
features, such as neoplastic proliferation, but without invasion of the physical barrier formed 
by the basement membrane of the duct or lobule.  
Although the evaluation of tumor size and margin involvement appears valuable for 
the current care of patients, the histologic subtypes of DCIS seem to have influence on its 
behaviour. Until the last few years, the histological classification for DCIS had been based 
on architectural features (papillary, micropapillary, cribriform solid and comedo) [91]. 
However, this division is an oversimplification and does not always stratify patients in those 
with a high risk of local recurrence versus those with low risk. Nuclear grade is a better 
biologic predictor than architecture, and therefore it has emerged as a key histopathologic 
factor for identifying aggressive behaviour [92] [93] [94]. A new DCIS classification was 
introduced [95], based on the presence or absence of high grade and comedo-type necrosis. 
High grade nuclear lesions were more likely to recur at a higher rate and in a shorter time 
period after breast conservation than patients with lower grade lesions [94] [95]. Although 
there is not an established method for DCIS classification, the parameters used rely on 
whether the lesion is high nuclear grade or non-high grade, and just then in the presence or 
absence of necrosis [96].  
DCIS is the most frequently breast in situ carcinoma and represents a heterogeneous 
disease with increased incidence after the introduction of breast screening programmes [97]. 
Before mammography was a routine screening tool, DCIS was rare, representing only 2-5% 
of symptomatic breast cancers, compared with almost 20% of newly diagnosed symptomatic 
cases [98]. The widespread use of mammography changed not only the way DCIS was 
detected, but also changed the nature of the disease. Although the treatment is to prevent 
recurrence or invasive carcinoma, not all the patients with DCIS will progress to invasive 
disease, ranging from 25% to 50% depending on the grade of the lesion [99]. Studies 
concerning the frequency of DCIS in routine autopsy suggests that some non-invasive 
lesions detected mammographically, and subsequently removed, would not have been of 
clinical importance, which raises the uncertainties in biological behaviour and in clinical 
management [100]. Although the risk of death, after any treatment for DCIS is less than 2% 
after 10 years, recurrence rates vary for different treatments [101] [102]. 
Concerning the treatment options, mastectomy is an extreme but highly effective 
treatment for DCIS, if the goal is simply to prevent local recurrence. Most mastectomy series 
reveal local recurrence rates of approximately 1% with mortality rates close to zero [103]. It 
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clearly provides a local recurrence benefit but only a theoretical survival benefit. It is 
indicated in cases of true multicentricity (multiquadrant disease) and when a unicentric DCIS 
is too large to excise with clear margins. Patients who test positive for BRCA1 or 2, and who 
develop DCIS, do not have an absolute contraindication for breast conservation, but many of 
these patients elect bilateral mastectomies. However, mastectomy is an aggressive form of 
treatment for patients with DCIS, confering no survival advantage and representing an 
overtreatment for most DCIS patients. Conversely, breast-conserving surgery alone is 
associated with higher rates of ipsilateral breast tumor recurrence for most subgroups of 
women and half of local recurrences are invasive disease [104].  A molecular risk profile, 
through the identification of molecular and biological markers that provide prognostic and 
predictive information, will be clinically useful if higher-risk patients can be selected for 
specific treatments; those at lower risk can avoid adjuvant therapies, such as radiotherapy 
and tamoxifen. Clinical trials have shown that these therapeutic alternative can reduce the 
risk of invasive recurrence in the ipsilateral breast, but do not represent a benefit in survival 
to DCIS breast cancer patients [105] [106] [107].   
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2.3) INVASIVE BREAST CARCINOMA 
Invasive breast carcinoma is the most common cancer in women and represents a 
heterogeneous group of tumors. The diagnosis of DCIS is, in effect, aimed at the prevention 
of invasive carcinoma, largely because breast cancer has no lethal potential unless it is 
invasive. It is pathologically defined as malignant cells that have gained access to the stroma 
of the breast, no longer being delimited by the natural boundary of the basement membrane, 
the wall that surrounds the entire ductolobular system of the breast [104]. Tumor cells may 
also gain access to the lymphatic or vascular system, potentially metastasizing to distant 
sites.  
 
 
 
 
 
 
Figure 5: A. Schematic representation of an invasive ductal carcinoma of the breast. Adapted from Kalluri R. 
Nature Reviews Cancer 6, 392-401 (2006); B. Haematoxylin-eosin staining of invasive ductal carcinoma of the 
breast, (100x).  
 
The invasive ductal carcinoma (ductal carcinoma NOS-not otherwise specified) 
represents the most frequent histological type, comprising between 70%-80% of all invasive 
breast cancers. It is a heterogeneous group of tumors that do not exhibit distinct 
morphological characteristics to be classified in a more specific way, as invasive lobular 
carcinomas, tubular carcinomas and mucinous carcinomas. The invasive lobular carcinoma, 
is the second most common type of breast cancer and represents 5 to 15% of all invasive 
breast cancers and is associated with lobular carcinoma in situ in 90% of the cases. The 
other types of breast carcinomas, presenting specific morphological characteristics in at 
least in 90% of the tumor mass, are considered special histological types, which include in 
breast: tubular, mucinous, cribriform and micropapilar carcinomas, metaplastic carcinoma 
and medullary carcinoma, among others [8].  
A.  B.  
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Histologic grading is an essential aspect in assessing invasive breast carcinoma and 
has been repeatedly shown to predict overall and disease-free survival in patients [108]. 
Well-differentiated invasive ductal carcinomas confer a better prognosis than those that are 
moderately differentiated, which in turn, confer a better prognosis than those classified as 
poorly differentiated. The grading schemes commonly used are based on the findings of 
Bloom and Richardson [109] and include the assessment of three parameters: amount of 
tubular or glandular formation, degree of nuclear atypia or pleomorfism and mitotic rate. This 
semi-quantitative method of histological graduation, modified by Elston and Ellis [110], 
involves the evaluation of three morphological features-the percentage of tubule formation 
(only the structures exhibiting clear luminal are counted), the degree of nuclear pleomorfism 
(assessed by reference to the regularity of nuclear size and shape of normal epithelial cells 
in adjacent breast tissue) and an accurate mitotic count using a defined field area. A numeric 
scoring system is used and the overall grade is derived from a summation of the scores for 
the three variables. The score produced by the values is defined by grade as follows: Grade 
I, well-differentiated (3 to 5 points); Grade II, moderately differentiated (6 to 7 points) and 
Grade III, poorly differentiated (8 to 9 points).  
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3.1) THEORIES OF PROGRESSION FROM IN SITU TO INVASIVE BREAST CARCINOMA 
 
  Predicting which in situ lesions will become invasive, as well as the time frame in 
which that will happen, is one of the most important issues in breast cancer field. Currently, 
there is a growing interest in developing knowledge regarding the progression from in situ to 
invasive breast carcinoma.   
DCIS is thought to be a precursor lesion of ductal invasive carcinoma based on 
molecular, epidemiological and pathological studies [111].  Although this model is supported 
by clinical and molecular research [112] [113] [114] [115], only serves as a starting point to 
understand breast tumorigenesis, since the relation between preinvasive lesions and 
invasive carcinomas remains unclear [116].  Based on the above, two recent models have 
been proposed to explain the transition from DCIS to invasive breast carcinoma (IBC).  
The theory of linear progression [117] [118] [119], suggests that low grade DCIS 
progresses to high-grade DCIS and just then to invasive ductal breast carcinoma. This 
model supports that tumor progression follows a linear pattern. However, the behavior of 
DCIS is inconsistent: only up to 50% of DCIS lesions progress to IBC, and some DCIS have 
more genetic alterations than some invasive carcinomas [120], which do not fit in this 
multistep model. Thus, the second model, known as the theory of parallel disease, suggests 
that low-grade DCIS tends to progress to low-grade IBC, whereas high-grade DCIS tends to 
progress to high-grade   IBC.  This  models   implies   “commitment”   of   a   subtype  of  DCIS   to  a  
specific subtype of invasive breast carcinoma. Actually, chromosomal-alteration studies 
support this model, suggesting that, in the progression of DCIS to invasive disease, the 
histological grade of DCIS corresponds to the grade of subsequent IBC [112] [121]. Also, a 
CGH study demonstrated that 65% of grade 1 tumors had lost the long arm of chromosome 
16 compared with only 16% of grade 3 tumors, suggesting that grade 1 tumors do not 
progress to grade 3 but rather, low-grade and high grade DCIS progress independently 
[122]. In fact, different stages of progression have been identified for low-grade lesions, and 
recently, high grade DCIS was recognized as a precursor of high-grade breast cancer, 
suggesting that low grade and high grade lesions, are distinct pathways in breast 
tumorigenesis [123, 124].   
Moreover, the majority of molecular changes that are observed in invasive breast cancer are 
already evident in DCIS [125, 126] which is consistent with reports that the tumor is 
comprised of heterogeneous, independent clones that progress independently and coexist 
3. PROGRESSION FROM IN SITU TO INVASIVE BREAST CARCINOMA 
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within the same breast [127]. Moreover, a recent study [128] suggests a convergent 
phenotype evolution in tumor progression, where several combinations of somatic genetic 
and/or epigenetic aberrations result in the acquisition of the biological properties required for 
cancer cells to progress. In fact, this hypothesis constitutes an explanation for the similarities 
found between in situ and invasive carcinomas.    
 
 
3.2) Genetic Alterations in the Progression to Invasive Disease 
 
High-throughput technologies are been applied to premalignant and preinvasive 
breast lesions, in order to identify molecular alterations, having an important role in the 
progression to invasive disease.  
Recently, a study using microarray data of 36 breast cancer patients with different 
pathological stages of disease, revealed a hierarchical portrait of breast cancer progression, 
identifying genes and pathways for each stage, grade and molecular subtype, suggesting 
that the heterogeneity of the disease across molecular subtypes is higher than the 
heterogeneity of the disease progression within a subtype [129]. Using laser-capture 
microdissection in combination with gene expression profiling in patients with premalignant, 
preinvasive and invasive breast disease, it was possible to observe that tumor grade was 
associated with specific gene expression patterns [130]. Several studies are trying to 
evaluate the gene expression profiles of both in situ and invasive components, namely in the 
identification of specific biomarkers that could trigger the transition from in situ to invasive 
carcinoma, but very few studies analyze in situ and invasive components of the same 
patient. Interestingly, a study analyzing nine matched DCIS/IDC was able to identify 18 
genes that were expressed differently between these components [131], showing that 
MMP11 and UBE2C were upregulated in invasive carcinoma and BPGA1 upregulated in in 
situ counterpart.  
Using cells lines, gene expression patterns that correspond to normal, preinvasive and 
invasive breast cancer allowed the identification of 9 genes that differentiated noninvasive 
from invasive cell lines [132]. In other recent study [120], it was identified a set of 35 genes 
that were expressed differentially between DCIS and IBC, mainly involved in signal 
transduction, cell death and metabolism and 43 genes that discriminate between well 
differentiated and poorly differentiated DCIS, finding again MMP11 and UBE2C, but also 
Adrenomedullin, and Synaptotagmin V.  
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3.3) THE ROLE OF MYOEPITHELIAL CELLS IN THE PROGRESSION FROM IN SITU TO INVASIVE 
CARCINOMA 
The major diagnostic criteria that has been used to differentiate in situ from invasive 
carcinomas is the presence or absence of an intact myoepithelial cell layer (myoepithelial 
cells from a continuous layer of cells that surrounds the luminal epithelial cells and separates 
them from the basement membrane and the stroma), which is usually confirmed by 
performing immunohistochemical analyses against myoepithelial cell-specific genes, such as 
smooth muscle actin (SMA), p63 or CD10 [133]. However, it remains unknown what leads to 
the disappearance of the myoepithelial cells in invasive tumors and how this contributes to 
tumor progression [134]. The exposure of myoepithelial cells to low concentrations of 
carrageenans (sulphated polysaccharides used in commercial food preparation) leads to cell 
death, but if the myoepithelial cells are destroyed by these compounds or by other 
environmental agents is not known [135]. Myoepithelial cells have been recognized as 
“natural   tumor suppressors”  and function as gatekeepers of tumor progression [136] [137] 
due to their inhibitory effect on various neoplastic phenotypes, including tumor cell growth, 
invasion and angiogenesis [138] [139] [89]. This phenotype was identified through the ability 
of myoepithelial cells to inhibit the growth and invasion of breast cancer cells in coculture in 
vitro assays and inhibit tumor growth in vivo xenograft assays [138] [140] [141]. These 
effects have been attributed to paracrine factors secreted by myoepithelial cells that exert 
their effects on the tumor epithelial cells and include ECM proteins, protease inhibitors and 
several growth factors [134]. In addition, to better understand the role of myoepithelial and 
stromal cells in the transition from DCIS to IDC, the MCF10DCIS xenograft model, which 
forms DCIS-like lesions that spontaneously progress to IDC, was co-injected with normal 
myoepithelial cells, which efficiently suppressed the growth of MCFDCIS xenografts and the 
transition to invasive carcinoma. These results suggest that the loss of myoepithelial cells 
promotes DCIS to IDC transition. Also, comparing epithelial, myoepithelial, infiltrating 
leucocytes, fibroblasts and myofibroblasts, the myoepithelial cells from normal breast tissue 
and DCIS yielded the highest number of consistently differentially expressed genes [142]. 
Many of the genes specific for normal myoepithelial cells were absent or dramatically 
downregulated in DCIS myoepithelial cells, suggesting that in fact these cells appear to be 
less differentiated and likely have lost some of the functions of normal myoepithelial cells. 
More importantly, tumor associated myoepithelial cells express higher levels of several 
basement membrane degrading enzymes including metalloproteases, compared to their 
normal counterparts [142]. Regarding the progression, many of the genes involved in the 
normal myoepithelial cell differentiation and function were downregulated, including the ones 
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encoding laminin and oxytocin receptors, whereas genes that promote tumorigenesis were 
increased, including CXCL12 and CXCL14. 
Although in DCIS, the ducts are still enclosed by the altered myoepithelial cells 
surrounded by the basement membrane, dramatic changes create a favourable tumor 
microenvironment. Also, DCIS-associated myoepithelial cells demonstrate altered gene 
expression and DNA methylation profiles including loss of differentiation markers and 
elevated levels of pro-angiogenic and invasive genes [143]. The concept of invasive 
carcinoma includes the degradation of the basement membrane, loss of myoepithelial cells 
and consequent invasion of the epithelial cells into the stroma, which occurs due to autocrine 
and paracrine signalling that activated cell migration.  
 
 
3.4) THE ROLE OF STROMA IN THE PROGRESSION FROM IN SITU TO INVASIVE BREAST 
CARCINOMA 
 
Over the past decades, the major focus of breast cancer research has centred on the 
tumor cell itself, whereas the role of the non-neoplastic cells of the tumor microenvironment 
has been largely unexplored.  It is now widely acknowledged that accumulation of genetic 
anomalies contributes to the acquisition of an increasingly aggressive, invasive, or therapy-
resistant tumor phenotype [144]. However, phenotypic and genotypic abnormalities in cancer 
epithelial cells cannot fully delineate tumor phenotypes and clinical behaviour [145]. cDNA 
microarray profiling and hierarchical clustering analyses have been used to classify breast 
cancer subtypes and predict clinical outcome [59] [57]. However, comprehensive gene 
expression and genetic profiling-based studies, comparing in situ, invasive and metastatic 
breast carcinomas have failed, so far, to demonstrate significant differences between 
different stages of breast cancer progression [130] [146] [131] [147], implying that besides 
the intrinsic malignant properties of tumor epithelial cells, other factors such as 
microenvironmental changes may regulate progression to invasion and metastasis.  
Cancer  has  been  referred  as  a  “wound  that  does  not  heal”  and  this  concept  has  been  
redefined at the molecular level as the role of the tumor microenvironment in cancer 
progression is elucidated [148]. A tumor is much more than clusters of transformed cells 
standing alone and the epithelial tumor cells can only develop in an aberrant 
microenvironment composed of altered extracellular matrix and several non-transformed 
cells, such as fibroblasts, immune cells, myoepithelial and epithelial cells that play a role in 
the initiation and progression of the neoplasms [149] [150] [151]. Epithelial-mesenchymal 
interactions in tissue differentiation demonstrated that embryonic mesenchyme strongly 
influences the terminal differentiation of both embryonic and adult epithelia [152]. In cell 
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culture, normal mammary epithelial cells in laminin-rich three-dimensional matrix, form acini 
with a central lumen, become responsive to lactogenic hormones and produce milk proteins 
enhancing the influence of the ECM and other components of the microenvironment in 
mammary duct morphogenesis [153]. Early studies demonstrated that the normal mammary 
microenvironment   is  capable  of   “reverting”   the  neoplastic  phenotype  of  breast  cancer  cells  
by inducing cellular differentiation [154] [155]. Still, the changes in microenvironment 
accompany tumor formation and increased fibroblast proliferation and ECM remodelling are 
often found adjacent to cancer cells [156]. The tumor microenvironment is not just a passive 
bystander that simply reacts to the transformed cells, but rather interacts with epithelial cells 
and has been recognized as a major regulator of carcinogenesis [157], playing a key role in 
defining tumor behaviour and patient outcome [158]. Gene expression changes occur in 
cancer-associated stroma and are known to be implicated in the prognosis, as well as in 
cancer progression [130] [146] [159] [160]. Specifically, evidence from gene expression 
profiling suggests that the stroma co-evolves with the epithelial compartments during 
progression [161]. Several in vitro and in vivo studies, using diverse experimental systems, 
have demonstrated that the growth, survival, polarity and invasive behaviour of breast 
cancer cells can be modulated by myoepithelial and various stromal cells, and several genes 
have been implicated in this process [162] [163] [150, 164]. The influence of stromal cells in 
the epithelial component (Figures 6 and 7) occurs due to the secretion of several ECM 
proteins, cytokines, growth factors, proteases and protease inhibitors, constituting an 
extensive network of cross-talks between cancer cells and the host [165].  
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Figure 6: Alterations of the microenvironment from normal duct to in situ transition. Considering the alterations of 
the microenvironment from normal breast tissue to DCIS, the phenotypic and epigenetically altered DCIS 
myoepithelial cells are surrounded by a still continuous BM. These myoepithelial cells are unable to aid 
polarization and organize the structure of the normal duct and at the same time, the stroma increases the 
production of fibroblasts and leucocytes in order to enhance angiogenesis. Growth factors, cytokines, 
chemokines and MMPs are produced to promote tumor progression. Adapted from Place AE et al, 2011 [166]. 
 
 
Interestingly, when transcriptional profiles of neoplastic cells and stromal cells were 
compared between DCIS and IBC, more robust changes in gene expression were observed 
in the stroma [144]. Isolating multiple cell types from normal breast, DCIS and IBC lesions 
and analysing their gene expression profiles, demonstrated that dramatic gene expression 
changes occur in all cell types, including tumor epithelial, endothelial ad myoepithelial cells, 
fibroblasts and leucocytes during breast cancer progression [142].  
However, some alterations have been identified and relate to processes such as 
proliferation, ECM remodelling and epithelial to mesenchymal transition [167] [144]. In a 
related study, using laser capture microdissection and cDNA microarrays to analyse the 
gene expression profiles of patient-matched samples of normal and tumor-associated 
epithelium and stroma of DCIS and IDC, although the most dramatic changes in both 
compartments were observed in the normal to DCIS transition, several ECM-degrading 
proteases showed elevated expression during in situ to invasive carcinoma which may play 
a role in the destruction of the basement membrane [146] [166].  
 
 
 
Figure 7: Alterations of the microenvironment in breast cancer progression from in situ to invasive carcinoma. 
Invasive carcinoma occurs through the degradation of the basement membrane, loss of myoepithelial cells and 
invasion of epithelial cells into the stroma and vasculature, due to the loss of the structural duct and 
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autocrine/paracrine signaling that activated cell migration. The production of extracellular matrix-degrading 
proteases by the tumor cells and stromal cells is elevated during the in situ to invasive carcinoma transition, 
leading to destruction of the extracellular matrix such that the tumor cells can invade locally and release more 
secreted factors. Aberrantly secreted proteolytic enzymes, chemokines, and cytokines continue to attract 
leukocytes, modulate tumor remodeling. Adapted from Place AE et al, 2011 [166].  
 
 
Despite the alterations in cell types during tumor progression, other genetic 
aberrances also happen in breast tumor stroma, including gene copy number changes, loss 
of heterozygosity (LOH), microsatellite instability (MSI) and point mutations in tumor 
suppressor genes and oncogenes [168] [169] [170] [171].  
The presence of gene expression alterations, but the lack of genetic abnormalities, 
suggests that epigenetic changes including DNA methylation and chromatin modification are 
responsible for the abnormal phenotypes of cancer associated stromal cells. Indeed, the 
analysis of genome-wide methylation profiles identified alterations in DNA methylation 
patterns not only in tumor epithelial cells but also in stroma fibroblasts and DCIS 
myoepithelial cells as well, suggesting that the phenotypic changes observed in tumor 
stromal cells are at least, partially due to epigenetic modifications [143]. Studies in HER2 
overexpressing breast tumors [172] and in prostate cancers [173] also demonstrated 
different methylation patterns in both epithelial and stromal counterparts.  
 
Other key players in stromal component are fibroblasts. Normal fibroblasts are 
responsible for the maintenance of the extracellular environment through the production and 
remodelling of the ECM. Cancer-associated fibroblasts (CAFs) differ from the resident 
fibroblasts of normal tissues in terms of both molecular signatures and functional impact on 
adjacent epithelial cells [174]. CAFs are themselves heterogeneous with a subset of them 
sharing markers of contractility with myofibroblasts, such as alpha smooth muscle actin 
(αSMA),   fibroblast activation protein (FAP), desmin, S100A4 and Thy-1 [175] [166], which 
reflects their acquired motility function. CAF activation is irreversible and in breast cancer, 
almost 80% of stromal fibroblasts acquire an activated phenotype that manifests by 
secretion of elevated levels of growth factors, cytokines and metalloproteinases [176]. The 
origin of CAFs has been actively investigated: one possibility is that they are derived from 
native interstitial fibroblasts whose phenotype has been modified by aberrant signalling from 
neighbouring tumor epithelial cells. Alternatively, can differentiate from bone-marrow-derived 
mesenchymal stem cells that are recruited to the tumor though endocrine stimulation by 
tumor-derived factors [166]. CAFs are commonly found in the cancer stroma [176] and 
promote tumor formation [177] and metastasis [178] in human breast cancers. They are 
essential for ECM deposition and remodelling through the synthesis of several ECM 
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components and of ECM-degrading proteases, such as matrix metalloproteinases (MMPs). 
Using gene-expression profiling of laser capture-microdissected tumor stroma from 53 
breast cancer patients allowed the identification of a stroma-derived prognostic signature, an 
independent prognostic factor that strongly predicts clinical outcome [159]. A similar 
approach was used for predicting chemotherapy resistance in breast cancer, underscoring 
the important role of the tumor stroma as a determinant of clinical outcome and resistance 
[160].  
The prevailing model of breast tumor progression is tumor epithelial cell-driven, since 
tumor cells have acquired genetic changes and demonstrate genomic instability, where the 
cells with the most aggressive phenotype are selected through clonal selection. However, 
this model has been questioned due to several aspects. Genetic alterations in tumor stroma, 
although controversial, raises the possibility that clonal selection occurs in nonepithelial cells 
as well, where the tumor microenvironment may play an active role in driving tumor 
progression. On the other hand, the identification of global gene expression changes and 
epigenetic alterations together with the fact that the genetic background of the host 
influences  metastatic  behaviour,  emphasizes  the  concept  that  progression  is  a  “driving  force”  
with several stakeholders. Several models of in situ to invasive progression have been 
proposed (Figure 8), focusing on the  “seed”  or   the  “soil”   theory   [134].  The  “escape”  model  
suggests that genetic changes and clonal selection in combination will give rise to a 
population of tumor epithelial cells with an ability to invade out of the duct and spread into 
stroma.   The   “release”   model   highlights the role of the stroma and suggests that the 
phenotypic changes of myoepithelial cells, infiltration of leucocytes and fibroblasts will work 
together and lead to the disruption of the basement membrane [134] [145]. To corroborate 
this last model, studies demonstrating increased cancer risk in patients with chronic 
inflammatory disease and decreased risk among users of antiinflammatory drugs, address 
the role of genetically modified stroma in tumorigenesis [179]. Also, focal breakdown of 
myoepithelial cell layer and basement membrane at sites of white blood cell infiltration have 
also been observed in DCIS [180], creating an escape route for the cancer cells [181].  
Because changes in the tumor epithelial cells are likely to induce microenvironmental 
changes, the combination of both models, including the changes in both epithelial and 
stromal  cells  could  explain  progression  to  invasion.    However,  clarifying  the  “chicken  or  egg”  
dilemma about what comes first, if the development of a genetically distinct tumor epithelial 
cell clone or the myoepithelial cell layer disruption will help in understanding the mechanisms 
that underlying the progression from in situ to invasive breast carcinoma.  
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Figure 8: Hypothetical model depicting two views of the progression from in situ to invasive breast carcinoma.  
Adapted from Polyak K et al, 2006 [134]. 
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Breast cancer remains a leading cause of death amongst women worldwide. One of 
the factors contributing to this effect is the relative lack of understanding about the natural 
history of the disease, mainly the progression from in situ to invasive breast carcinoma.   
 
The general aim of the work reported in this thesis was to understand the 
mechanisms of progression from in situ to invasive breast carcinoma. Thus, making use of a 
unique large series of matched in situ and invasive breast cancer cases, the studies were 
performed in order to assess the following three specific aims: 
 
 
i. To determine if there are differences between the tumor molecular 
profiles of matched in situ and invasive breast carcinomas  
It has been demonstrated that the greatest alterations in gene expression are 
seen among the different histological grades of breast cancer. It has also 
been suggested that the expression of several tumor markers correlates with 
grade, but not with the distinction between in situ and invasive breast cancer. 
Based on the above and after the classification of the different cases into 
molecular profiles, the purpose is to understand if the transition from in situ to 
invasive breast carcinoma is (in)dependent from the molecular profile.  
 
 
 
ii. To validate by immunohistochemistry, the expression of specific genes 
that have been previously described as important in the transition from 
in situ to invasive breast cancer 
It is of great interest to understand the transcriptional program that drives 
invasive growth and several studies have been trying to identify genes that 
would mark the transition from in situ neoplastic cells to migrating invasive 
cells. In order to find out if these genes, previously described as 
discriminating between in situ and invasive components, are effectively 
differentially expressed in the counterparts, we aim to study these proteins, by 
immunohistochemistry in our series of matched in situ and invasive 
components.  
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iii. To determine the role of the tumor microenvironment in the step-wise 
transformation from in situ to invasive breast cancer 
It has been demonstrated that interactions between the neoplastic cells and 
the tumor microenvironment may play an important role in breast 
tumorigenesis. Also, microenvironment participates in tumorigenesis even 
before tumor cells invade the stroma, and it may play an important role in the 
transition from pre-invasive to invasive growth. Therefore, we aim to 
investigate in our series of breast cancer samples including matched in situ 
and invasive components, if there was a relationship between stromal Cav-1 
and MCT4, in the progression from in situ to invasive carcinoma.  
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A tumor bank consisting in 189 formalin-fixed paraffin-embedded samples, 
harbouring in situ and invasive breast carcinomas in the same block were collected from the 
archives of the Pathology Institute of Araçatuba, São Paulo, Brazil. Patient´s ages ranged 
from 27 to 96 years old and they were diagnosed from 1996 to 2006. Patient information 
concerns the age of the patients at the time of diagnosis, the histological grade and the 
lymph nodes status for in situ and invasive counterparts.   
The DCIS samples were subdivided into 3 groups: low, intermediate, and high grade, 
according to the nuclear grade and the nuclear grade and the extent of necrosis, as 
previously published [96]. Briefly, tumors harboring nuclear grade 3 were all considered high 
grade, whereas tumors with nuclear grade 1 or 2 with necrosis were considered intermediate 
grade, and those of nuclear grades 1 and 2 without necrosis were considered low grade. 
Invasive breast cancers were classified according to the method described by Elston and 
Ellis [182], as grade I, II, or III.  
All the data was included in an Excel (Microsoft) datasheet, preserving the patient´s 
anonymity. The study was conducted under the national regulative law for handling of 
biological specimens from tumor banks, being the samples exclusively available for research 
purposes in retrospective studies.    
 
 
 
 
 
 
 The 189 in situ and invasive breast carcinomas were arrayed in 22 tissue microarray 
(TMA) blocks.  For the construction of the TMAs, representative areas of the different lesions 
were carefully selected on the H&E (haematoxylin and eosin) and marked on individual 
paraffin blocks. In order to guarantee that the immunostaining results correspond to the 
appropriate case, a grid was generated, containing the original histological number of the 
patient. The grid also includes 3 non-neoplastic breast tissues as controls and one core of a 
non-breast cancer sample (we have used liver), in order to orientate the TMA block. Using a 
Tissue Microarray workstation (TMA builder, Labvision, USA), two tissue cores (2 mm in 
diameter) were obtained from each selected specimen- the donor block, and inserted into a 
recipient paraffin block, each containing 24 cores, arranged in a 4x6 sector.  
1. TUMOR SAMPLES AND TUMOR BANK CONSTRUCTION 
2. TISSUE MICROARRAY CONSTRUCTION  
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In order to homogenise the paraffin of the receptor block and to bind the cores into the block, 
minimizing the loss of the cores during the TMA sectioning, the TMAs were kept at 37ºC 
during approximately 3 hours. The block was carefully covered with a glass slide adhered to 
the cores to obtain a homogenized block with a flat surface suitable to be sectioned. The 
blocks rested at room temperature and the glass slide was removed. Then, 2 to 3-µm tissue 
sections were performed and adhered to a coated glass slide (Superfrost Plus ®, Gerhard 
Menzel, Braunschweig, Germany). An H&E-stained section from each block was reviewed to 
confirm the presence of morphological representative areas of the original sections.  
 
 
 
Figure 9: Stepwise construction of a tissue microarray. A. Representative tumor areas were selected on 
haematoxylin and eosin-stained sections and B. marked on paraffin blocks; C. The receptor block; D. A core of 
tissue was extracted from the marked area of the donor block; E. The extracted tissue is placed in the receptor 
block; F. the TMA grid were the cases are placed; G. Placing the tissues in receptor block was repeated to create 
the organised rows and columns according to the predefined TMA plan; H. Once the TMA was complete, the 
receptor block was slightly melted in order to bind the cores into the block and I. sequential tissue sections (2-
3µm) were cut and adhered to a coated glass slide.  
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IMMUNOHISTOCHEMISTRY TECHNIQUE 
 
 After the deparaffinization of the tissue sections in a xylene substitute (Clear Rite 3®, 
Richard- Allan Scientific, Kalamazoo, MI, USA) and hydration though a decreasing series of 
alcohol concentrations, the epitope retrieval was performed using heat-induced at 98ºC in a 
water-bath during 30 minutes, using commercially available antigen unmasking solutions: 
citrate buffer solution 1:100, pH=6,0 (Labvision, Fremont, CA, USA) or 
ethylenediaminetetraacetic (EDTA) solution 1:10, pH=9,0 (Novocastra, Newcastle, UK), or 
by proteolytic enzyme digestion using a solution of pepsin A in distilled water (4g/L, Sigma 
Aldrich, St. Louis, MO, USA) for 30 minutes at 37ªC. After the respective antigen retrieval 
and washes in phosphate buffer solution (PBS), endogenous peroxidase activity was 
blocked with a 3% hydrogen peroxide solution (Panreac, Spain) in methanol (Sigma-Aldrich, 
USA) during 10 minutes. The slides were then incubated in a blocking serum (LabVision, 
USA) for 15 minutes and then incubated with the respective primary antibodies. Information 
regarding primary antibodies, dilution and suppliers, as well as antigen retrieval and 
respective detection systems are described in Table 1. After the incubation with the primary 
antibodies and the washes, the slides were incubated with a strepatividin-biotin-peroxidase 
complex (Labvision) or with a secondary antibody associated with HRP-labelled (horseradish 
peroxidase) polymer (Envision®- Dako, Carpinteria, CA, USA), with additional amplification 
capability. The slides were revealed with diaminobenzidine (DAB) chromogen (Dako) and 
counterstained with Mayer´s haematoxylin (Richard-Allan Scientific), dehydrated in a 
crescent concentration of alcohol, clarified with xylene substitute (Clear Rite 3®) and then 
cover-slipped using a permanent mounting medium (Zymed, USA). Positive and negative 
controls were also included in each run, in order to guarantee the reliability of the assays.  
To molecularly characterize in situ and invasive breast carcinomas, we evaluated the 
expression of ER (clone SP1, Neomarkers, Fremont, CA, USA), PgR (1A6, Novocastra, 
Newcastle UK), the tyrosine kinase receptors HER2 (SP3 Neomarkers) and EGFR (31G7 
Zymed, San Francisco, CA, USA), the basal markers P-cadherin (clone 56, Transduction 
Labs), CK5 (clone XM26, Neomarkers) and the proliferation marker KI67 (clone SP6, 
Neomarkers).  
To study the proteins that potentially discriminate between the in situ and invasive 
components of breast carcinomas, specific antibodies for MMP-11 (clone SL3.05, Santa 
3. IMMUNOHISTOCHEMISTRY  
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Cruz), Synaptotagmin V -SYTV (polyclonal antibody, Abcam), Adrenomedullin- ADM (clone 
HTA171/E8, Abcam) and Ubiquitin carrier protein 2 (UBE2C, clone AB-209, 
BostonBiochem). 
In order to study the metabolic alterations in breast tumorigenesis in this series, Caveolin-1 
(clone 2297, BD Biosciences) and Monocarboxylate Transporter 4 (MCT4, clone H-90, 
Santa Cruz) immunohistochemistry was performed.  
 
Table 1: Specific antibodies and conditions used for Immunohistochemistry 
Antibody Clone Manufacturer 
Time of 
incubation 
(min) 
Dilution 
Antigen retrieval  
 
Detection 
system 
ER SP1 Neomarkers 60 1:100 Citrate Buffer HRP polymer 
PgR 1A6 Novocastra 60 1:40 Citrate Buffer HRP polymer 
HER2 SP3 Neomarkers 30 1:80 Citrate Buffer LSAB 
P-cad 56 Transduction 60 1:50 Tris-EDTA solution HRP  polymer 
CK5 XM26 Neomarkers 60 1:50 Tris-EDTA solution LSAB 
EGFR 31G7 Zymed 60 1:100 Pepsin A solution HRP polymer 
Ki67 SP6 Neomarkers  60 1:300 Citrate Buffer HRP polymer 
MMP-11 SL3.05 Santa Cruz  60 1:100 Citrate Buffer HRP polymer 
SYTV PAB Abcam 60 1:200 Citrate Buffer HRP polymer 
ADM HTA171/E8 Abcam 120 1:50 Citrate Buffer HRP polymer 
UBE2C AB-209 BostonBiochem 60 1:100 Citrate Buffer LSAB 
Cav-1 2297 BD Bioscienses 60 1:50 Citrate Buffer HRP polymer 
MCT4 H-90 Santa Cruz 60 1:500 Citrate Buffer HRP polymer 
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IMMUNOHISTOCHEMISTRY EVALUATION 
  The evaluation of the immunohistochemical results was performed by a pathologist 
(FS). ER and PgR nuclear expression was evaluated according with 2 parameters: intensity 
ranked from 1 to 3 (1 – weak, 2 – moderate, 3 – strong), and extension ranked from 1 to 10 
(1 – 0-10% cells, 2 – 11-20% cells, 3 – 21-30% cells, 4 – 31-40% cells, 5 – 41-50% cells, 6 – 
51-60% cells, 7 – 61-70% cells, 8 – 71-80% cells, 9 – 81-90% cells, 10 – 91-100% cells), 
using the H-score method [183, 184]. The scores for intensity and extension were multiplied 
and the cases were considered negative when the score was below 4 and positive from 5 to 
30.  
HER2 expression was evaluated according to the DakoCytomation Hercept Test® scoring 
system [185]. Cases with no staining or less than 10% of the cells stained were considered 
negative and cases with incomplete membranar staining in more than 10% of cells were 
considered 1+. Cases with more than 10% of cells with weak to moderate complete 
membrane staining were considered 2+. Cases were considered positive (overexpression) 
when immunostaining was classified as 3+. If a case is classified as 2+ by IHC, FISH 
analysis was performed to determine if the tumor had HER2 amplification. If amplification 
was confirmed, the tumor was classified as positive. If the tumor did not demonstrate 
amplification, it was considered negative. Cases 1+ were also considered negative. EGFR 
staining was also classified according to the Hercept Test scoring system. However, breast 
carcinomas were considered positive whenever the immunostaining was 2+ or 3+. 
Concerning Ki-67, the quantification of cell proliferation was measured with the public 
available web application software ImmunoRatio [186]. Tumors with an unequivocal nuclear 
staining in more than 14% of the cells were classified as high proliferative, whereas tumors 
with less than 14% of positive cells were considered low proliferative [187]. We considered 
positive the cases with membranous staining for P-cad and cytoplasmic staining for CK5 in 
at least 10% of the neoplastic cells [76, 77, 188].  
The classification into the different molecular subtypes of breast carcinoma was 
performed: tumors with positive hormone receptor (ER and PgR), negative for HER2 as well 
as with low proliferative index were considered Luminal A, whereas the ones with positive 
hormone receptors and positive for HER2 or with a high proliferative index (Ki67 positive) 
were considered Luminal B [76, 77, 187, 189, 190]. Breast carcinomas were considered 
HER2 overexpressing whenever the immunohistochemical reaction was classified as 3+ or 
when gene amplification was confirmed by Chromogenic In Situ Hybridization (CISH) in 
the 2+ cases, as previously described [191]. Based on the above, cases lacking hormone 
receptors and with overexpression of HER2 were classified as HER2 overexpressing 
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tumors. Tumors that were negative for ER, PgR and HER2 and positive for EGFR or CK5 or 
P-Cad were considered Basal-like. Cases that lacked expression of all tested markers were 
considered  “unclassified.” 
To evaluate immunostaining intensity for MMP11, SYT5 and ADM, a numeric score 
ranging from 0 to 3 was used, reflecting the cytoplasmic intensity as follows: 0, no reactivity; 
1, weak reactivity; 2, moderate reactivity; and 3, intense reactivity, as previously described 
[192, 193]. The score 0 was considered negative, whereas scores 1, 2 and 3 were 
considered positive. The quantification for UBE2C was performed with the public available 
web application software ImmunoRatio [186]. This methodology was based on fact that this 
marker is nuclear such as Ki67 or ER, and this quantification system has already been 
validated for their expression. The cases without expression of UBE2C were considered 
negative, whereas the cases that showed expression (more than 1%) were considered 
positive. 
Cav-1 and MCT4 expression in stroma were evaluated using the previously 
described methodology [194, 195]. In summary, Cav-1 and MCT4  were semi-quantitatively 
scored  as negative (0, no staining), weak (1, either diffuse weak or strong staining in less 
than 30% of stromal cells per core) or strong (2, defined as strong staining in 30% or more of 
the stromal cells) [196].  
  
 
 
 
 
For statistical analysis, StatView 5.0 (SAS Institute Inc., Cary, North Carolina, USA) 
was used in order to perform contingency tables and chi-square tests and also to estimate 
the associations between the staining pattern of the different antibodies used, as well as 
between other clinicopathological features. In all statistical analyses, a significant level of 5% 
was considered.  
4. STATISTICAL ANALYSIS  
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Breast cancer is the most common cancer in women, with more than one million 
cases occurring worldwide annually [197]. Despite significant diagnostic and therapeutic 
innovations, the effect on the mortality rate has been modest. One of the factors contributing 
to this limited success is the relative lack of understanding of the the natural history of this 
disease [198]. For example, the transition from in situ to invasive carcinoma is still a poorly 
understood event [199].  
Nowadays, it is widely stated that the natural history of breast cancer involves 
progression, through clinical and pathologic stages [111, 199], from premalignant 
hyperplastic breast lesions, with or without atypia, to carcinoma in situ and invasive 
carcinoma [117, 118, 200]. On the basis of molecular, epidemiologic, and pathologic studies, 
ductal carcinoma in situ (DCIS) is thought to be a precursor lesion of ductal invasive 
carcinoma [111].  Although this model is supported by clinical and molecular research [112-
115], it is only a start point to understand breast tumorigenesis, as the relation between 
preinvasive lesions and invasive carcinoma remains unclear [116].  From the available data, 
two models have been proposed to explain the transition from DCIS to invasive breast 
carcinoma (IBC). The first one, the theory of linear progression [117-119], suggests that low 
grade DCIS progresses to high-grade DCIS and then to invasive ductal breast carcinoma. 
This model implies that tumor progression follows a linear pattern. However, there is 
evidence that some in situ carcinomas never progress for invasion and that some DCIS have 
more genetic alterations than some invasive carcinomas [120], a finding which does not fit in 
this multistep model. Consequently, a second model of breast cancer tumorigenesis has 
been proposed: the theory of the parallel disease, wherein low-grade DCIS tends to progress 
to low-grade invasive ductal breast cancer, whereas high-grade DCIS tend to progress to 
high-grade invasive breast cancer [116]. In this model, a specific subtype of DCIS matches a 
specific subtype of invasive breast cancer.  
Gene expression profiling is known to be a powerful tool for identifying tumor 
molecular profiles and for correlating gene expression profiles with outcome in breast cancer 
[120]. In addition, it has been also an important tool to explore the transcriptional program 
that leads to invasion, comparing in situ and invasive carcinomas. Recently, Dalgin et al. 
[129] studied 36 breast cancer patients with different pathological stages of disease and 
revealed a hierarchical portrait of breast cancer progression, identifying genes and pathways 
for each stage, grade and molecular subtype. These authors suggested that the 
heterogeneity of the disease across molecular subtypes is higher than the heterogeneity of 
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the disease progression within a subtype, suggesting that tumors with different molecular 
profiles are in fact distinct diseases.  
Several studies have concentrated on the identification of specific biomarkers that 
could define the subtypes of in situ and invasive breast carcinomas [76, 77, 201]. Our group 
and others demonstrated that is possible to translate the molecular classification, using 
immunohistochemistry (IHC) and tissue microarrays (TMAs) [77], where estrogen and 
progesterone receptors (ER and PgR) and Human Epidermal Growth Factor Receptor 2 
(HER2) expression identify Luminal A, B and HER2 overexpression subtypes, whereas 
tumor protein 63 (p63), Cytokeratin 5 (CK5) and P-Cadherin (P-cad) allow the identification 
of basal-like tumors [76]. Recently, Paredes et al. [77] also demonstrated the importance of 
P-cadherin and CK5 as useful adjunct markers to distinguish basal-like subtype among the in 
situ carcinomas. 
However, it was never determined whether the in situ and invasive carcinomas that 
develop in a particular breast cancer patient belong to the same molecular subtype or are 
different entities belonging to different molecular profiles.  
In this study, our aim was to compare the molecular phenotypes of in situ and 
invasive components of breast cancer in the same sample, using IHC, TMAs and a specific 
panel of biomarkers, previously described by our group [76, 77]. 
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We performed IHC on each set of the 22 TMA slides for ER, PgR, HER2, P-cad, 
CK5, EGFR and Ki-67. Tables 1 and 2 summarize the clustering of a total of 189 
immunohistochemically interpretable cases to allow sample characterization into one of the 
five previously described molecular subtypes.  The molecular classification was made in an 
isolated way for each of the tumor components (in situ and invasive) in the same block.  
 
EVALUATION OF THE IN SITU COMPONENT 
Among the in situ component, we observed that 63% of all tumors were considered 
Luminal A, whereas Luminal B and HER2 overexpressing subtypes comprised 15% and 
12% of the cases, respectively. Basal-like tumors represented 7% and the ones with null 
phenotype/unclassified were 3% (Table 1). 
 
Table 1: Frequencies of the immunohistochemically defined subtypes of in situ and invasive breast 
cancers for the tested markers. 
 
 
 
 
Because Luminal cancer subtypes (A and B) were defined as positive for hormonal 
receptors (ER and/or PgR), the percentage of positive cases for these two 
immunohistochemical markers was extremely high, as expected, with a higher prevalence 
for ER positivity when compared with PgR positive cases (Table 2). For the Luminal A 
cancer subtype, 95% and 66% of the cases were ER and PgR positive, respectively; 
whereas, for Luminal B, 100% were positive for ER and 61% were positive for PgR. As 
initially defined, all Luminal A tumors were negative for HER-2, and Luminal B were positive 
for this marker. In the group of negative cases for hormonal receptors, all the cases 
overexpressing HER2 were included in the HER-2 overexpressing cancer subtype, being the 
triple negative ones (negative for ER, PgR and HER2) divided into Basal-like or unclassified, 
2. RESULTS 
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according to the positivity for P-cad, CK5 and EGFR basal markers. Among the Basal-like 
tumors, P-cad was the most prevalent basal marker, with 92% of the cases being positive, 
whereas only 23% and 38% of the cases were positive for EGFR and CK5, respectively. 
Although basal markers are most commonly expressed in basal-like tumors, these 
can also be present in other cancer subtypes, but in a lower frequency. Concerning EGFR, 
although there were almost no positive cases in Luminal A and B subtypes, 10% of HER-2 
overexpressing tumors also expressed EGFR. Also CK5 was expressed by 17% of the 
HER2 overexpressing in situ carcinomas, whereas only 3% and 7% of the tumors classified 
as Luminal A or B, respectively, showed CK5 expression.  P-cad expression was also highly 
found in HER2 overexpressing tumors, being positive in almost half of the cases (48%). 
Concerning the Luminal cancer subtypes, P-cad expression was more abundant in Luminal 
B (14%) than in Luminal A (8%). 
Concerning cell proliferation indexes, addressed by Ki-67 staining, Basal-like tumors 
were the ones showing higher values (28%), followed by Luminal B (19%). 
 
Table2: Comparison of molecular subtypes and biomarkers for in situ and invasive components  
 
 
 
When we studied the association between the in situ histological grade and molecular 
cancer subtypes (Figure 1), we found that Luminal A tumors were frequently classified as 
low grade (49%), while the majority of Luminal B carcinomas were classified as intermediate 
grade (53%); HER2 overexpressing  and basal-like cases were more often considered of 
high grade (86% and 77%).   
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Figure 1: Comparison of histological grade among molecular subtypes (Luminal A, B, HER-2 and Basal) in situ 
and invasive components.  All the correlations were statistical significant  (p≤0.  05). 
 
EVALUATION OF THE INVASIVE COMPONENT 
For the invasive component (Table 1), the Luminal A subtype represented 61% of all 
the tumors. Luminal B and HER-2 overexpressing invasive tumors corresponded to 16% and 
12%, respectively, while Basal-like tumors comprised 8% of the cases. Only 3% of the 
invasive carcinomas were classified as null phenotype/unclassified. 
For the Luminal A cancer subtype, 93% and 68% of the cases were ER and PgR positive, 
respectively; whereas, for Luminal B, 100% were positive for ER and 42% were positive for 
PgR. Again, all Luminal A tumors were negative for HER-2 as expected, and 45% of Luminal 
B cases were positive for this marker. The invasive carcinomas overexpressing HER2 and 
negative for hormonal receptors were included in the HER2 overexpressing cancer subtype. 
In triple-negative Basal-like invasive tumors, as described for the in situ component, P-cad 
expression was the most prevailing basal marker, with 93% of positive cases, whereas only 
21% and 36% of the cases were positive for EGFR and CK5, respectively (Table 2). 
When we studied the expression of basal markers in cancer subtypes other than the 
Basal-like, we found results similar to the ones described for the in situ component of this 
breast cancer series. Concerning EGFR, exactly the same frequencies were found: 1% and 
0% of the cases expressed this receptor in Luminal A and B subtypes, respectively, whereas 
9% of HER-2 overexpressing tumors co-expressed these two tyrosine-kinase receptors. CK5 
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was expressed by 22% of the HER-2 overexpressing invasive carcinomas, whereas only 2% 
or none of the tumors classified as Luminal A or B, respectively, showed CK5 expression. 
Again, P-cad expression was highly expressed in HER-2 overexpressing tumors (48%), but 
only expressed by 8% of Luminal A and 13% of Luminal B invasive breast carcinomas. 
For Ki-67, the tumors included in the Basal-like and Luminal B subtypes had the 
highest proliferative indexes (29% and 25%, respectively). Regarding the histological grade 
(Figure 1), we found that Luminal A invasive tumors were often considered grade I (55%), 
whereas Luminal B lesions spread from intermediate (41%) to high grade (38%); once more, 
HER-2 overexpressing  and Basal-like tumors were more regularly classified as grade III 
(95% and 86%, respectively).   
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COMBINED EVALUATION OF THE IN SITU AND INVASIVE COUNTERPARTS IN THE SAME PATIENT 
 
Most cases (93%) maintained the molecular classification, when the in situ and 
invasive components were compared (Figure 2).  
 
 
Figure 2: Expression of proteins studied by IHC on TMAs for in situ and invasive components.  A and B, HE 
staining of  Low/I and High grade/III histological grade, respectively (x200); C Positive ER expression (x200);  D 
Lost of ER expression in invasive component (x200); E HER-2 staining  (x100); F P-cad staining (x100).  
 
There were just 13 cases (7%) in which the 2 areas were classified differently (Table 3). One 
of the cases was unclassified for the in situ component (negative for all the markers tested), 
but Basal-like in the invasive counterpart, due to P-cad expression in this fraction. 
Independently of the classification, this tumor was graduated as high grade in both 
components. Other case was classified as an in situ Luminal A carcinoma, but was 
unclassified in the invasive component, due to the lack of expression of both hormonal 
receptors (ER and PgR) (Figure 2D). 
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Interestingly, although both components were graduated as intermediate grade, the 
proliferative index was different between the in situ and invasive components in this case. 
The invasive counterpart had higher proliferative index when compared with the in situ 
counterpart.  Four cases were classified as Luminal B for the in situ component, but Luminal 
A for invasive counterpart due to the low proliferative index in the invasive component, 
except one case that is due to lack of HER-2 also in the invasive counterpart. Interestingly in 
this case, the loss of expression was accompanied by alterations in the histological grade, 
from high grade in situ to grade II in the invasive counterpart.    
Finally, 7 cases that were classified as in situ Luminal A carcinomas were then classified as 
Luminal B in the invasive counterpart due to higher proliferative index in the invasive 
component. Besides the increase in cell proliferation, no alterations were noticed in 
histological grading.   
 
Table 3: Discordant molecular classifications between in situ and invasive components 
 
 
In general terms, we can conclude that there are no important modifications of the 
breast cancer molecular classification in the majority of the cases, when the transition from 
an in situ to an invasive carcinoma occurs in a breast cancer patient. However, when we 
compared individually the expression of the different biomarkers tested (Table 2), we could 
find subtle differences between both components, which can add some biological 
information to the in situ/invasive transition. In the Luminal A cases, besides the increase of 
proliferative rate in the invasive component in 7 cases, just 3 cases showed P-cad 
expression in the invasive component. No alterations in hormonal receptors were found 
between in situ and invasive transition.  In Luminal B tumors no alterations were found for 
ER expression, when the in situ and invasive components were compared. However, there 
were 4 cases that lost PgR expression in the invasive carcinoma, with the transition from a 
high grade in situ carcinoma to a grade II invasive tumor in two cases;  in the remaining two, 
there were no alterations in grading. The other differences were in basal markers, such as 
CK5 and P-cad, with loss of 7% and 3% of expression from in situ to invasive tumors, 
respectively.  Regarding the HER2 overexpression cases, 7 did not show the expression of 
any basal marker, whereas 14 cases showed concomitant expression of EGFR, CK5 or P-
cad together with HER2. From these, P-cad was the most prevalent. There were 3 cases 
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which gained the expression of basal-markers in the transition from the in situ to the invasive 
carcinoma, namely two with CK5 and one with P-cad. Only this last case changed the 
histological grade when both components were compared (from an in situ intermediate 
grade to a grade III invasive tumor). In Basal-like subtype, the majority of the cases were P-
cad positive in both components (eleven cases). However, there was one case which lost P-
cad in the invasive fraction but, since it expressed CK5 in the invasive component; its 
molecular classification did not change.  
Molecular breast cancer subtypes of in situ and invasive tumors did not vary with the 
histological grade of these lesions (p<0,0001 and p=0,0002 for in situ and invasive 
counterparts, respectively). High grade lesions were associated with HER2 overexpressing 
and Basal-like phenotype, both in the in situ and invasive components. Low grade lesions 
were frequently associated with Luminal A phenotype. In Luminal B phenotype, the in situ 
component was more frequently high grade (53%), while the invasive counterpart was 
intermediate (41%). 
As mentioned above, the only cases with alterations in molecular classification were 
not accompanied by differences in histological grade. However, there were some alterations 
in histological grade in some individual cases: nine cases, with histological classification of 
intermediate lesion in the in situ component were grade III in the invasive counterpart, 
whereas five cases classified as in situ low-grade, were grade II lesions when we analyzed 
the invasive component. In cases where there was a decrease in the histological grade, 
twelve cases classified as high grade in the in situ component were grade II in the invasive 
counterpart; one case was high grade in the in situ component and grade I in the invasive 
one and ten cases classified as intermediate grade in the in situ component were grade I in 
the invasive area.  
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Two main branches in breast tumorigenesis have been distinguished: one supports 
the multi-step model of breast cancer and the other the theory of parallel disease, where a 
specific subtype of DCIS matches a specific subtype of invasive breast cancer [116].  In 
1997, Grupta et al. [202], studying 300 patients with invasive breast carcinoma associated 
with DCIS, demonstrated that the degree of differentiation of DCIS was correlated with the 
grade of the invasive carcinoma and the clinical outcome. They also showed that patients 
with invasive breast cancer in that series also displayed the same genetic mutations as 
patients with preinvasive and invasive lesions. In fact, recent data [203] demonstrate that the 
most dramatic alterations in gene expression patterns occur during the transition from 
normal breast tissue to DCIS [125, 126], and not from in situ to invasive transition.  In 
contrast, Tamimi et al. [29], studying 272 DCIS and 2249 invasive independent tumors, 
showed that in situ and invasive phenotypes were differently prevalent. These authors found 
an increased prevalence of Luminal B and HER2 overexpressing profiles among DCIS 
tumors. However, analyzing independent series of in situ and invasive tumors [17, 18], no 
differences were found in molecular subtype prevalence. So, probably, the higher 
percentage of HER-2 phenotype in DCIS in Tamimi et al [204] series was due to 
mammographically screened population and does not represent a basis of progression to 
invasive tumors. 
The great advantage of our series of 189 breast carcinomas, which was 
characterized by several immunohistochemical markers, relies on the existence of in situ 
and invasive components in the same sample. We classified the in situ and invasive tumors 
into four main molecular subtypes (Luminal A, Luminal B, HER2 overexpressing and Basal-
like). When both components were compared, we verified that there were no significant 
differences in molecular classifications of in situ and invasive tumors which lead us to 
conclude that different molecular subtypes have different progression forms, evolving low 
grade in situ tumors to low grade invasive tumors and high-grade in situ tumors to high 
grade invasive tumors [129].  
Differences in molecular profiles from the in situ to invasive carcinoma were 
observed in only 13 cases, which seems more likely to be attributable to technical 
immunohistochemical issues than a reflection of changes in the tumor biology. One case 
classified as Luminal A in the in situ component lost ER expression and became unclassified 
in the invasive component. Another case, which did not express any of the markers used for 
classification (unclassified) in the in situ component, gained expression of P-cad in the 
3. DISCUSSION 
Molecular Profiles of in Situ and Invasive Breast Carcinomas 
 
 
 77 
 
Diana Martins | Doctoral Thesis 
invasive component and could be characterized as having Basal-like phenotype.  In the 
remaining 11 cases, the changes were from Luminal A to B and vice-versa and these 
alterations can be attributed to the fact that the criteria for classification of Luminal B subtype 
are not well established.  Although some Luminal B tumors can be identified by their 
expression of HER2, the major biological distinction between Luminal A and B is the 
proliferative signature, including genes such as Ki-67.  Chang M and collaborators  [187], 
using 14% as a cut-off, supported Ki-67 as a well –established cell proliferation marker in 
cancer and emphasized its role as a biomarker candidate for identification of Luminal B 
tumors. We also used this cut-off, which allowed us to distinguish some Luminal B tumors 
that the standard biomarker panel (ER, PgR and HER2) did not identify. Interestingly, and 
although the percentages are really close to Luminal B subtype, the Basal-like tumors had 
higher proliferative index when compared with the other subtypes, in both in situ and 
invasive components (28% and 29% respectively). Among these fractions, the invasive one 
had a higher proliferative rate, which can be associated with increase of cell proliferation 
when invasion occurs, and with the poor prognosis associated with this molecular subtype.  
An association between histological grade and molecular phenotype has been 
demonstrated, with low-grade invasive tumors usually having the Luminal A phenotype, 
whereas high grade tumors are more prevalent among HER2 overexpressing and Basal-like 
subtypes [204, 205]. Moreover, the HER2 overexpressing and basal-like subtypes are 
associated with poor prognosis. In our series, in in situ breast cancers, HER2 and Basal-like 
subtypes were more frequently high grade than low grade or intermediate (86% and 77% 
respectively).  These results were consistent for invasive tumors, as 95% of HER2 and 86% 
of Basal-like present high histological grades. It was interesting to note the percentages of 
Luminal B histological grade in DCIS and invasive component, where intermediate /II and 
high grade prevail in both, with 36% and 54% for in situ component, as well as 41% and 
38% for invasive counterpart, respectively. This similarity between intermediate /grade II and 
high grade is probably due to the cut-off used that enriched our series in Luminal B cases.  
We also looked for cases that showed alterations simultaneously in biomarker 
expression and in histological grade and found eight cases. It is important to say that these 
alterations were not accompanied by alterations in the molecular classification. Two cases 
graduated as intermediate in situ component were grade III in the invasive component, 
accompanied by gain and loss of P-cad, respectively. Other two cases, with the concordant 
loss of PgR expression classified as high grade in situ component, were grade II in the 
invasive counterpart. One case also lost PgR expression, but changed from intermediate in 
situ to grade I in invasive counterpart. It is also interesting that we had two cases that lost 
PgR expression simultaneously and one basal marker, P-cad or CK5, and were graduated 
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as high grade in situ and as grade II in the invasive component.  Finally, the last case lost 
CK5 and change from intermediate to grade I.  
We have shown that the prevalence of the molecularly defined phenotypes did not 
differ significantly between DCIS and invasive breast cancers; probably, the molecular 
alterations which drive invasion occur before the morphological modification of the lesion 
[147, 206]. Dalgin et al. [129] also confirmed that the cancer phenotype develops early (in 
early hyperplasia or ductal carcinoma in situ stage) and each subtype progresses along its 
own specific pathway, as if each was a distinct disease.  
In conclusion, with this work, we showed that is possible to identify different 
immunohistochemical profiles of in situ and invasive breast cancer, using a small panel of 
biomarkers (ER, PgR, HER2, EGFR, CK5, P-cad and Ki-67) and that the technique of TMA 
is useful, efficient and reliable to the characterization and sub-classification of a large 
number of cases.  Concerning the comparison of in situ and invasive components, we found 
that in 176 (93%) of the 189 cases, the molecular classification was identical in the 2 
components, which supports the theory of the parallel disease; that is, that in the 
progression of most breast cancer cases, there is a commitment of the in situ subtype 
carcinoma to a specific subtype of invasive carcinoma. Otherwise, the finding supports the 
view that the molecular phenotype is established at the DCIS stage. Although there has 
been an improvement in understanding the pathways of breast tumorigenesis, little is known 
about the mechanisms associated with the transition from in situ to invasive carcinomas. 
More than just genetic alterations in the tumor cells, the codependency between epithelial 
cells and the stroma can regulate tumor progression. Recently, it was demonstrated that 
myoepithelial cells can have a particular role in tumor invasion. Studying normal 
myoepithelial cells and the ones associated with DCIS, Schnitt et al. [206, 207] 
demonstrated that the last ones differ substantially from the normal, showing down- 
regulation of genes involved in the normal function of cells and upregulation of genes 
associated with invasion. There is an immediate need to characterize new molecules that 
not only uncover the molecular biology of in situ carcinomas and its transition to invasive 
breast cancer, but also the transcriptional program that drives invasive growth of each 
molecular subtype. 
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 Predicting which lesions will become invasive, as well as the time frame in which the 
progression from in situ to invasive carcinoma will occur, is one of the major focus in breast 
cancer research. Therefore, there is a significant interest in identifying molecular events 
driving invasive progression, in order to identify new molecular targets that could trigger 
cancer progression at early stages [144].  
Recently, Dalgin et al [129], using microarray data from 36 breast cancer patients with 
different pathological stages of disease, were able to reveal a hierarchical portrait of breast 
cancer progression, identifying genes and pathways for each stage, grade and molecular 
subtype, and concluding that tumor molecular profiles are actually distinct diseases. Ma et al. 
[130]  using laser-capture microdissection and gene expression profiling of premalignant, 
preinvasive and invasive breast disease, suggested extensive similarities at the 
transcriptomic level among the distinct stages of progression, as well as concluded that gene 
expression alterations conferring the potential for invasive growth were already present at the 
preinvasive stages. Accordingly, using a series of 189 patient-matched in situ and invasive 
tumor samples, we showed 94% of concordance between in situ and invasive component 
molecular profiles, suggesting there is a commitment of the in situ carcinoma subtype to a 
specific subtype of invasive carcinoma in the progression of most breast cancer cases, 
supporting the view that the molecular phenotype is established at the preinvasive stage  
[208].  
Besides this knowledge, and in an attempt to explore the transcriptional program that 
leads to invasion, some studies have focused their attention in the identification of specific 
biomarkers that could trigger the transition from in situ to invasive carcinoma, evaluating the 
gene expression profiles of both ductal carcinomas in situ (DCIS) and invasive ductal 
carcinomas (IDC) [120, 130-132, 147, 199, 209] (although only few compared both 
components within the same breast tumor).  Analyses of chromosomal aberrations by array-
based comparative genomic hybridization (aCGH) could not discriminate DCIS and IDC from 
the same patients [210-212], showing that these are closely related not only on the basis of 
their gene expression but also on their gene copy number aberrations [128]. 
However, some studies have described significant genetic alterations between DCIS 
and its matched invasive counterpart. Hannemann et al. [120] identified a gene expression 
classifier of 35 genes which were differentially expressed between in situ and IDC, like Matrix 
Metalloproteinase 11 (MMP11), Synaptotagmin V (SYT5), Adrenomedullin (ADM), and 
Ubiquitin carrier protein 2 (UBE2C). Shuetz et al. [131], analyzing nine matched DCIS/IDC, 
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identified 18 genes that were differently expressed between both stages, finding again 
MMP11 and UBE2C upregulated in invasive carcinomas. 
 In order to find out if these proteins could have a role in breast tumorigenesis 
progression, we studied if they are differentially expressed between matched in situ and 
invasive carcinomas in histological sections where we can assess their subcellular 
localization, by immunohistochemistry.  
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IHC quantification for MMP11, SYTV, ADM and UBE2C was performed on each 
set of the 22 TMA slides, using patient-matched DCIS/IDC tumor samples. Data on ER, 
PgR, HER2, P-cad, CK5, EGFR, Ki-67 status, histological grade and lymph node 
metastases were already available and published for this series [208]. 
 
EVALUATION IN NORMAL BREAST  
In normal breast tissue, it can be observed that MMP11, SYTV, ADM and UBE2C 
expression was absent, as observed in Figure 1.  
 
Figure 1: Expression of proteins studied by IHC on TMAs. A. and B. represent MMP-11expression in normal 
breast tissue and in situ and invasive breast carcinoma, respectively, 100x; C. shows Synaptotagmin V 
expression in normal breast and D.  in in situ and invasive counterparts, 100x; E. represents Adrenomedullin 
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expression in normal and F. in in situ and invasive components, 100x; G. and H. shows  UBE2C expression in 
normal and DCIS and IDC, respectively, 100x 
 
EVALUATION OF THE IN SITU COMPONENT 
The evaluation of the DCIS component, in each sample, revealed that , only 9 
cases (5%) had absent expression of MMP11, whereas  34 cases (18%) had weak 
expression, 50 cases (26%) showed intense expression and the majority of the cases (96 
cases, 51%) had moderate expression. Regarding the expression of SYTV, 20 cases 
(10%) showed no reactivity for the marker, 62 cases (33%) showed weak expression, 72 
cases (38%) had moderate expression and 35 cases (19%) had intense expression. For 
ADM, the majority of the cases (121 cases, 66%) were negative, whereas 22 cases (12%) 
showed weak expression, 30 cases (16%) had moderate expression and only 10 cases 
(5%) showed intense expression. Concerning UBE2C, the majority of the cases (101 
cases, 53%) were positive, whereas 88 cases (47%) were negative.  
 
EVALUATION OF THE INVASIVE COMPONENT 
 Regarding the invasive counterpart, we could find that 10 cases (5%) showed no 
reactivity for MMP11, 47 (25%) cases showed weak expression, 81 cases (43%) 
presented moderate expression and 51 cases (27%) showed intense expression. For 
SYTV expression, 21 cases (11%) had absent expression, whereas 72 and 62 cases 
(38% and 33%) showed weak and moderate expression respectively, and 34 cases (18%) 
showed strong expression. Concerning the expression of ADM, the majority of the cases 
(127 cases, 69%) were negative, 22 cases (12%) showed weak expression, 25 cases 
(14%) had moderate expression and only 10 cases (5%) showed intense expression. 
Concerning UBE2C, the majority of the cases (118 cases, 62%) were negative, whereas 
71 cases (38%) were positive for this protein.  
 
COMBINED EVALUATION OF THE IN SITU AND INVASIVE COUNTERPARTS IN THE SAME PATIENT 
The analysis of MMP11 expression in the transition from the in situ to the invasive 
counterpart (Fig. 1A) showed that the majority of the cases (85%) maintained the 
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expression for this marker, whereas only 29 cases showed a differential expression for 
this marker. Among the differences, the majority of cases showed loss of expression in 
the invasive counterpart. Accordingly, we found that 15 cases classified as moderate 
expression in the in situ component, but as weak expression in the invasive counterpart. 
In contrast, 10 cases showed gain of MMP11 expression in the invasive tumor fraction.  
Regarding the expression of SYT V (Fig. 1B), only 22 cases showed different expression 
between both components, meaning that 88% of the cases maintain the expression of this 
marker. The main differences were the loss of SYT5 expression in 14 cases, whereas 8 
cases gained its expression during cancer progression.  
Analyzing individually each case for ADM expression (Fig. 1C), we could show that 38 
cases showed a distinct expression between the two components: 22 cases showed loss 
of expression and 16 cases showed gain of expression. 79% of the cases maintained 
ADM expression between in situ and invasive components.     
The major alterations were found for UBE2C expression between matched in situ and 
invasive tumor parts (Fig. 1D) of breast carcinomas. Although the percentage of 
concordance in the expression of UBE2C was around 75%, 47 cases showed different 
profiles for UBEC2 between both components. 40 cases showed loss of expression in the 
invasive counterpart, whereas only 7 cases showed the gain of expression. The average 
of UBE2C expression in the in situ component was 53.4%, whereas it decreased for 
37.5% in the invasive tumor fraction. 
Concerning the associations found between the proteins studied, we could only describe a 
statistically significant association between HER-2 and UBE2C expression in the in situ 
component (p=0.001). No other significant associations were obtained between the 
markers studied and clinical-pathological features of the tumor series (Table 1). Figure 2 
shows an immunohistochemistry array of the proteins studied, representing the gains and 
losses in the progression from in situ to invasive breast carcinoma.  
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Table 1: Associations between UBE2C with some biomarkers expression and clinical-pathological parameters  
 
UBE2C 
In Situ 
p value 
Invasive 
p value 
Positive n(%) Negative n(%) Positive n(%) Negative n(%) 
 
ER 
Positive 74 (52%) 68 (48%) 
0.52 
54 (39%) 85 (61%) 
0.54 
Negative 27 (57%) 20 (43%) 17(34%) 33 (66%) 
 
PgR 
Positive 50 (51%) 48 (49%) 
0.48 
28 (30%) 66 (70%) 
0.20 
Negative 51 (56%) 40 (44%) 43(45%) 52 (55%) 
 
HER2 
Positive 8(9%) 86 (91%) 
<0.001 
19 (51%) 18 (49%) 
0.001 
Negative 30 (32%) 65 (68%) 52 (34%) 100 (66%) 
 
EGFR 
Positive 4 (67%) 2 (33%) 
0.50 
4 (67%) 2 (33%) 
0.13 
Negative 97 (53%) 86 (47%) 67 (37%) 116 (63%) 
 
CK5 
Positive 10 (67%) 5 (33%) 
0.28 
7 (55%) 5 (42%) 
0.12 
Negative 91 (52%) 83 (48%) 64 (36%) 113 (64%) 
 
P-Cad 
Positive 15 (42%) 21 (58%) 
0.11 
13 (35%) 24 (64%) 
0.73 
Negative 86 (56%) 67 (44%) 58 (38%) 94 (62%) 
 
Ki67 
Positive 8 (53%) 7 (47%) 
0.99 
14 (52%) 13 (48%) 
0.09 
Negative 93 (53%) 81 (47%) 57 (35%) 105 (65%) 
 
Histological 
Grade 
L/I 30 (45%) 37 (55%) 
0.07 
20 (27%) 55 (73%) 
0.05 I/II 30 (45%) 37 (55%) 22 (41%) 32 (59%) 
H/III 44 (69%) 20 (31%) 29 (48%) 31 (52%) 
 
Ganglionar 
Invasion 
Present 
 
26 (32%) 54 (68%) 
0.21 
Absent 22 (43%) 29 (57%) 
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Figure 2: Immunohistochemistry array showing protein expression levels of MMP11 (A.), Synaptotagmin V 
(B.), Adrenomedullin (C.) and UBE2C (D.) in the progression from in situ to invasive carcinomas. Cases are 
arranged along the X-axis and proteins are arranged along the Y-axis. Within the heat map, red represents 
gain of expression whereas green represents loss of expression.  
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It is of great interest to understand the transcriptional program that drives invasive 
growth and several studies have been trying to identify genes that would mark the 
transition from in situ neoplastic cells to migrating invasive cells.  Hannemann et a.l [120] 
identified a gene expression classifier of 35 genes which were differently expressed 
between the in situ and invasive breast cancer components.  
Among these genes, MMP11, a protein of the matrix metalloproteinase family, 
involved in the breakdown of the extracellular matrix in both physiological and disease 
processes, has been described as been upregulated in invasive breast carcinomas [213], 
compared to normal breast tissue [214]. Ma et al. [146] also showed a significant 
increased expression of MMP11 in invasive carcinoma-associated stroma. MMP11 has 
also recently been shown to exhibit protease activity [215] and to promote tumor 
progression [216]. Schuetz and colleagues profiled the epithelium of patient-matched 
DCIS and IDC and found MMP11 to be upregulated in IDC relative to DCIS [131]. In the 
study of Hannemann and colleagues [120], MMP11 was also identified as able to 
distinguish IDC from DCIS.  In our series, the expression of MMP11 was similar in in situ 
and invasive breast components, suggesting that the expression of MMP11 is needed for 
tumor cells already in DCIS stage. 
Synaptotagmins are a family of type 1 membrane proteins that function as calcium 
sensors for the regulated exocytosis of neurotransmitters, neuropeptides and hormones 
[217]. Although a previous study [217] has showed an increase expression of this marker 
in invasive human breast cancer, we showed that the patterns of expression were similar 
between in situ and invasive breast carcinomas harboring in the same patient, suggesting 
that an increased expression may be observed in preinvasive and invasive stages, 
comparing to normal breast tissue.  
ADM is also is expressed in a variety of tumors, including breast, endometrial and 
prostate cancer. ADM has been shown to be a mitogenic factor capable of stimulating 
growth of several cancer cell types, being described as upregulated in invasive breast 
carcinomas, associated with lymph node metastasis and increased tumor size [193]. 
Hsieh et al. [218] suggested that elevated levels of this protein were significantly 
associated with increased expression of potential downstream targets, such as apoptosis 
inhibitors, cell cycle regulators and inducers of tumor angiogenesis. However, our results 
showed that the percentage of expression in both in situ and invasive components were 
highly similar, with a slightly increase of invasive tumors expressing intense expression of 
3. DISCUSSION 
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ADM. Since the percentage of concordance was 79%, ADM expression may be also 
acquired in the DCIS stage.  
UBEC2 is an ubiquitin-conjugating enzyme composing the ubiquitin-proteasome 
system, which is required for the destruction of mitotic cyclins and for cell cycle 
progression. Furthermore, in breast cancer, an increased expression of UBE2C was 
associated with high tumor grade and cancer progression [130]. UBE2C also belongs to 
proliferative genes, which are known to constitute the majority of genes included in 
prognostic gene-expression signatures [219]. However, we could not find any correlation 
with genes involved in proliferation, such as Ki67; but, concerning the expression of 
UBE2C in in situ and invasive breast carcinomas, we observed an increased expression 
in DCIS tumors and a loss of UBE2C expression in the invasive counterpart. Loussouarn 
et al. have also described an upregulation of UBE2C in carcinomas comparing to normal 
breast tissue [220].   
In general, among the losses and gains of the markers studied, the alterations in UBE2C 
were the most consistent ones: 40 cases showed loss of expression from DCIS to 
invasive breast carcinoma, whereas only 7 cases showed a gain of expression. The 
average of UBE2C was higher in the in situ component (53.4%) than in the invasive 
counterpart (37.5%), suggesting that maybe neoplastic cells require the expression of 
UBE2C to disrupt the basal membrane and to invade.  
The only significant association found was between the expression of HER2 and UBE2C 
the in situ component only. However, as HER2 overexpression has been previously 
described as associated with more rapid progression to invasive disease [221], the 
association that we obtained could be mimicked by the overexpression of HER2 in DCIS 
tumors [222]. These results can also raise the hypothesis that the subgroup of DCIS 
tumors that loss the expression of UBE2C in the invasive counterpart may progress more 
rapidly. On the other hand, recently a study [128] focusing the alterations in the 
progression from in situ to invasive breast cancer, suggests a bottleneck effect during the 
progression, where only the subclones harboring a specific repertoire of genetic 
aberrations are selected and pass through the evolutionary bottleneck, maybe explaining 
why some genetic alterations and consequently differences in protein level such as 
UBE2C expression could occur during the progression from in situ to invasive breast 
cancer. The absence of differences in MMP11, SYTV and ADM can occur due a 
convergent phenotype [128], where several combinations of somatic genetic or epigenetic 
aberrations result in the acquisition of the biological properties required for cancer cells to 
progress in situ to invasive disease.  
Based on the above, we have shown that, by immunohistochemistry, the 
expression of these four markers (MMP11, SYTV, ADM and UBEC2) did not differ 
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significantly between DCIS and IDC. Thus, we were not able to validate the set of specific 
candidate genes that were previously identified by microarray analysis, supporting that 
probably the molecular alterations driving invasion occur prior to the morphological 
modifications of the lesions, explaining as well as that alterations are mainly found when 
normal breast tissue and the invasive one are compared. 
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Breast cancer is a heterogeneous and complex disease, encompassing a variety of 
pathological entities with distinct clinical behaviors. The development of new technologies 
has offered the opportunity to explore the molecular complexity of human breast carcinomas 
[144]. However, despite these advances, the mechanisms controlling the transition from an in 
situ to an invasive carcinoma still remain unclear. Therefore, there is a significant interest in 
identifying molecular events driving invasive progression, not only to determine at which 
point the lesion is most likely to progress to malignancy, but also to identify new molecular 
targets that could trigger the progression at early stages [144]. Several studies have 
evaluated the gene expression profiles of both ductal carcinomas in situ (DCIS) and invasive 
ductal carcinomas (IDC) [120, 130-132, 147, 199, 209], but only few compared the in situ 
and invasive components within the same breast tumor [120, 130-132]. In fact, although 
some genes have been described as differentially expressed between in situ and invasive 
components, the majority of the studies failed to demonstrate significant differences between 
the expression of the codified proteins in the neoplastic epithelial cells of DCIS and IDC [131, 
223]. Recently, our group, using patient-matched DCIS/IDC tumor samples, showed 
concordance between in situ and invasive molecular profiles in 94% of the cases [208]. 
These results suggested that the alterations in the tumor microenvironment would have a 
more important role in the progression from an in situ to an invasive phenotype than the 
biology of the tumor cells per se, which showed a tendency to be maintained between these 
both components. 
Actually, it is widely accepted that any cancer is a complex system composed not only by 
neoplastic cells but also by a fine-tuned microenvironment. The first reference to the 
importance of the microenvironment in cancer comes from Paget, with his proposal of the 
“seed  and  soil”  hypothesis.  Unexpectedly,  this  concept  was  “forgotten”  and  only  “recovered”  
several years later. In breast cancer, tumor microenvironment plays a key role in deﬁning 
tumor behaviour and patient outcome [158]. Gene expression changes that occur in cancer-
associated stroma are known to be implicated in prognosis, as well as in cancer progression 
[146, 167, 207]. Ma and colleagues, using gene expression profiling, provided strong 
evidence that the stroma co-evolves with the epithelial compartments during cancer 
progression [146]. Analyzing 14 patients with matched normal epithelium, normal stroma, 
tumor epithelium and tumor-associated stroma, the authors proposed that microenvironment 
participates in tumorigenesis even before tumor cells invade the stroma and it may play an 
important role in the transition from preinvasive to invasive growth[146].   
1. INTRODUCTION 
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Caveolin-1 (Cav-1), a scaffolding protein mainly involved in vesicular transport, 
cholesterol homeostasis and signal transduction, has been associated to the progression 
from in situ to invasive carcinoma [194, 224]. Lisanti and colleagues showed that Cav-1 loss 
in tumor stroma was associated with an increased risk for early recurrence, metastasis and 
decreased overall survival in breast cancer, being also a strong prognostic factor for basal-
like breast carcinomas [225, 226]. In DCIS, a loss of stromal Cav-1 was predictive of disease 
recurrence and progression to invasive cancer, since all the patients with loss of Cav-1 
recurred and 80% of them progressed to invasive disease[194]. Moreover, loss of stromal 
Cav-1 has been related with stromal MCT4 expression in triple-negative breast cancers, also 
predicting for poor clinical outcome [195]. This protein is a major transporter directly 
responsible for L-lactate efflux from glycolytic cells and a functional marker of oxidative 
stress and hypoxia [227]. In addition, it seems to have a role in stromal breast cancer 
metabolism, since it has been demonstrated that breast cancer cells induce MCT4 
overexpression in stromal fibroblasts [196]. 
Since stromal expression of MCT4 and the association between Cav-1 and MCT4 had never 
been implicated in the progression from DCIS to IDC, the aim of this study was to better 
understand the stromal interactions surrounding in situ and invasive components of breast 
carcinomas, evaluating the stromal expression of Cav-1 and MCT4, using patient-matched 
DCIS/IDC tumor samples.  
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CAV-1 AND MCT4 EXPRESSION IN NORMAL BREAST  
In normal breast, it can be observed that Cav-1 expression was absent from the 
epithelium, whereas it was observed expression in the stromal component, as previously 
described [194, 225, 226]. MCT4 expression was absent in both epithelial and stromal 
components, as observed in Figure 1A. 
 
 
Figure 1: IHC expression of stromal MCT4 in normal and in situ component. It can be observed absent 
stromal MCT4 expression in normal breast (A) and in in situ component (B), 200x. 
 
STROMAL CAV-1 EXPRESSION IN THE PROGRESSION FROM IN SITU TO INVASIVE CARCINOMA 
 
In the DCIS component, only 19 cases (13%) showed no Cav-1 expression in the 
stroma, whereas 55 cases (39%) had moderate expression, and the majority had strong 
expression of stromal Cav-1 (67 cases - 48%). Analyzing the association between the 
histological grade of the in situ component and the expression of Cav-1, it was observed 
that the majority of the cases were high grade DCIS tumors (35,5%) and among them 
56% showed strong expression for Cav-1 (p=0,04). 
In the invasive component, the majority (n=108, 76%) of the cases showed absent Cav-1 
expression in the stroma, with only 27 cases (19%) with moderate expression and 7 cases 
(5%) with strong expression. The association between the histological grade and the 
expression of Cav-1 is lost in invasive counterpart due to the majority of the cases have 
shown absent expression of the stromal marker. Figure 2 represents the expression levels 
of stromal Cav-1 in in situ and invasive components, where it can be observed a 
significant decrease of Cav-1 from DCIS to IDC.  An IHC example of Cav-1 in in situ and 
invasive components is shown in Figure 3. 
2. RESULTS 
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Figure 2: Expression levels of stromal Cav-1 in in situ and invasive components of breast carcinomas. It is 
possible to notice a significant decrease of Cav-1 stromal expression from DCIS to IDC. 
 
 
Figure 3: IHC expression of stromal Cav-1 in in situ and invasive components. Note the strong expression of 
Cav-1 in DCIS, from low (A and B, 100x and 200x respectively) to higher magnification (C, 400x). 
 
Regarding the progression from in situ to invasive carcinoma, analyzing each case for 
both matched components, 106 cases (75%) showed loss of stromal Cav-1 expression, 
whereas 35 (25%) cases maintained protein expression. None of the cases showed gain 
of stromal Cav-1 expression.   
 
STROMAL MCT4 EXPRESSION IN THE PROGRESSION FROM IN SITU TO INVASIVE CARCINOMA 
 
Considering the DCIS component, the majority of the cases were negative (n=131; 
93%), 10 cases (7%) showed moderate expression and 5 cases (3%) were classified as 
strong for stromal MCT4. In the invasive component, it was observed a strong expression 
of MCT4 in the stroma of the majority of the cases (n=73; 50%), whereas moderate 
expression was observed in 63 (43%) cases; in the remaining 11 cases (7%), no 
expression of stromal MCT4 was observed. In figure 1B, note the absence expression of 
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MCT4 surrounding DCIS component. Analyzing the histological grade in these cases, it 
was not observed any association between the expression of MCT4 and the grade of the 
tumors.  
Figure 4 depicts the expression levels of stromal MCT4 in situ and invasive components, 
showing an increased expression of stromal MCT4 in the invasive component.  Figure 5 
represents by IHC the strong MCT4 stromal expression in invasive component.  
Concerning the transition from in situ to invasive carcinoma, in terms of gains and losses 
of MCT4 in the stroma, we found that 126 cases (87%) gained expression in the invasive 
component, 19 cases (13%) maintained and none loose the expression.  
 
 
 
 
Figure 4: Expression levels of stromal MCT4 in in situ and invasive carcinomas. There is a significant 
increased expression of stromal MCT4 in the invasive component of breast carcinomas, when compared with 
DCIS. 
 
 
Figure 5: IHC expression of stromal MCT4 in in situ and invasive components. Note the strong MCT4 stromal 
expression in invasive component, from low (A and B, 100x and 200x, respectively) to high magnification (C, 
400x). 
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COMBINING STROMAL CAV-1/MCT4 IN THE PROGRESSION FROM IN SITU TO INVASIVE 
CARCINOMA 
  
Analyzing matched in situ and invasive components for stromal expression 
of Cav-1 and MCT4 (Table 1), it was possible to observe a statistically significant 
association between the loss of stromal Cav-1 and the concomitant gain of MCT4 
in the same case (p<0.0001). Interestingly, 75% of the cases that loss Cav-1 
stromal expression in the transition from in situ to invasive cancer, also gained 
MCT4 expression in the stroma. There were only 4 cases (3%) with loss of Cav-1 
in the stroma that maintained MCT4 expression, and 16 cases (12.5%) that gained 
MCT4 and maintained Cav-1 stromal expression. In 12 cases (10%), there was 
the maintenance of stromal expression for both markers. Figure 6 represents an 
IHC array with the expression levels of these proteins in the progression from in 
situ to invasive carcinoma.  
 
 
Table: Association between stromal Cav-1 and MCT4 expression levels in the transition from in situ to 
invasive breast carcinoma 
  MCT4 
(In Situ to Invasive) 
 
 
Loss of 
expression 
N (%) 
Maintenance 
of expression  
N (%) 
Gain of 
expression 
N (%) 
Cav-1 
(In Situ to 
Invasive) 
Loss of expression 
N (%) 0 (0%) 4 (3%) 94 (75%) 
Maintenance of 
expression  
N (%) 
0 (0%) 12 (10%) 16 (12.5%) 
Gain of expression 
N (%) 0 (0%) 0 (0%) 0 (0%) 
p value: ≤0.001 
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Figure 6: Immunohistochemistry array showing protein expression levels of stromal Cav-1 and MCT4 in the 
progression from in situ to invasive carcinomas. Cases are arranged along the X-axis and proteins are 
arranged along the Y-axis. Within the heat map, red represents gain of expression, green represents loss of 
expression and yellow represents maintained expression from in situ to invasive carcinoma within the same 
case.  
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The mechanisms that mediate the progression from DCIS to IDC in the breast are 
still largely unknown. However, it is now widely acknowledged that accumulation of 
genetic anomalies contributes to the acquisition of an increasingly aggressive, invasive or 
therapy-resistant tumor phenotype [144]. Nevertheless this knowledge did not improve the 
predictive power of standard pathological parameters for breast cancer, nor explained the 
mechanisms of invasiveness.  
Cav-1 plays an important role in tumor stroma and recent studies demonstrate that 
the loss of stromal Cav-1 is associated with advanced tumor and nodal stage, 
lymphovascular invasion, metastasis, early recurrence, tamoxifen resistance and reduced 
progression-free survival in invasive breast cancer [174, 228, 229]  Additionally, loss of 
stromal Cav-1 also has prognostic value in a particularly aggressive subgroup of breast 
cancers, namely the triple-negative and basal-like breast carcinomas, whereas high levels 
of this protein were correlated with reduced tumor size, low grade, reduced metastasis 
and improved survival [226, 229, 230].  
Interestingly, loss of stromal Cav-1 also predicts for recurrence and early disease 
progression in DCIS patients. Witkiewicz et al. reported that 80% of the DCIS patients, 
which underwent surgical excision and recurred with invasive breast cancers, showed 
reduced or absent levels of stromal Cav-1 in these tumors [194]. In our series, using 
patient-matched DCIS/IDC tumor samples, it was observed that the majority of the cases 
showed strong expression of Cav-1 expression in the stroma of DCIS, whereas 76% of 
the cases showed absent expression for this marker in the stroma of the invasive 
counterpart. Thus, regarding the progression to invasiveness, it seems that the loss of 
Cav-1 expression in the stroma is important for tumor invasion.   
Actually, it has been already described that loss of Cav-1 in stromal cells may also 
increase angiogenesis and tumor growth [224]. Goetz et al. demonstrated that in vivo and 
in vitro expression of Cav-1 in cancer-associated fibroblasts facilitates tumor cells invasion 
and accelerate the in vitro proliferation and in vivo tumorigenesis [231, 232]. 
Recent data reveals that loss of Cav-1 induces a metabolic reprogramming of stromal 
cells to support the growth of adjacent epithelial tumor cells - the  “reverse  Warburg  effect”,  
where cancer cells induce upregulation of multiple glycolytic enzymes in neighbouring 
stromal fibroblasts [174, 233, 234]. Cav-1 is degraded resulting in a loss of stromal Cav-1 
expression [195]. At the same time, the breast cancer cells induce MCT4 overexpression 
in stromal fibroblasts [195].  
3. DISCUSSION 
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MCT4 is a monocarboxylate transporter that functions as a shuttle to extrude L-
lactate from cells using aerobic glycolysis for energy metabolism [227].  Although the 
transporter role of MCT4 has been widely accepted in cancer epithelium, the prognostic 
value of MCT4 expression is highly compartment-specific and restricted to the tumor 
stroma, being high stromal MCT4 levels associated to poor patient overall survival [196, 
235, 236]. In our series, analyzing DCIS and IDC separately, it was observed an increase 
of MCT4 expression, since in DCIS the majority of the cases were negative, whereas, in 
the invasive counterpart, 50% of the cases showed strong expression for MCT4. 
Considering the progression from in situ to invasive breast carcinoma, using matched 
DCIS/IDC tumor samples, 87% cases gained MCT4 expression, whereas none showed 
loss of expression, suggesting that the gain of stroma MCT4 provides evidence for the 
existence of a stromal-epithelial lactate shuttle which fuels the tumor growth [196]. 
Regarding the relation between MCT4 and Cav-1 expression, Witkiewicz et al. [195] using 
164 invasive breast cancer samples, verified that stromal MCT4 and stromal Cav-1 levels 
were inversely related, being high levels of stromal MCT4 directly correlated with a loss of 
stromal Cav-1 immunostaining [195]. Most notably, cases with absent stromal Cav-1 are 
most likely to present strong stromal staining for MCT4 and, in contrast, cases with strong 
expression for Cav-1 are most likely to be stromal MCT4 absent.  
Nevertheless, studies regarding the role of Cav-1 and MCT4 in the transition from in situ 
to invasive breast carcinoma were still lacking. In our series, using matched DCIS/IDC 
and analyzing the concomitant expression of stromal Cav-1 and MCT4, 75% of the cases 
showed loss of Cav-1 with simultaneously gain of MCT4 in the stroma, suggesting that 
these events are important for tumor cells to progress and invade.  
Our results are explained by the recently “Two-Compartment  Tumor  Metabolism”  model  
and  the  “Reverse  Warburg  Effect”,  suggesting  that  the  loss  of  Cav-1 causes the metabolic 
reprogramming of stromal cells to support the growth of adjacent epithelial tumor cells 
[174]. In figure 7, a hypothetical model summarizing he alterations in Cav-1 and MCT4 in 
the stroma of matched in situ and invasive breast carcinoma is shown. The oxidative 
stress promoted by the tumor cells induces autophagy in cancer associated fibroblasts 
(CAFS) that degrade Cav-1 in the in situ stromal compartment and also secrete energy-
rich metabolites, such as L-lactate, ketone bodies and pyruvate as a consequence of 
metabolic alterations. During the progression do invasive carcinoma, the loss of Cav-1 
induces MCT4 expression due to the amount of energy metabolites, used to promote 
cancer cell glycolysis, aggressive tumor growth and ultimately invasion of breast cancer 
cells. 
Many of the cited studies quantify one or both markers in breast cancer stroma. However 
one potential limitation of the quantification methodologies used is the lack of a clear and 
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reproducible definition of stroma, especially regarding DCIS cases. In our case, since all 
IHC scoring was performed by the same experienced pathologist, we consider this does 
not affect internal validity and therefore does not affect the results obtained and 
conclusions drawn. 
In summary, it was shown that the loss of stromal Cav-1 and the concomitant gain of 
stromal MCT4 have a putative role in the transition from in situ to invasive carcinoma of 
the breast. Therefore, we propose that Cav-1 and MCT4 may represent valuable 
biomarkers for breast cancer progression. Thus, determining the nature of the cooperation 
between tumor cells and the microenvironment that leads to invasion could identify 
therapeutic strategies to prevent the transition from in situ to invasive breast carcinoma.  
 
 
 
Figure 7: Alterations in Cav-1 and MCT4in the stroma of matched in situ and invasive breast carcinoma. A. 
H&E stained tissue section of human breast cancer, showing in situ and invasive components of breast 
carcinoma (100x). B. Hypothetical model summarizing the importance of Cav-1 and MCT4 in the progression 
from DCIS to IDC. During the progression to invasive carcinoma, Cav-1 is degraded by oxidative stress-
induced autophagy in cancer-associated fibroblasts, resulting in a loss of Cav-1. At the same time, the loss of 
Cav-1 induces a metabolic reprogramming of stromal cells where cancer cells induce upregulation of MCT4 by 
stromal fibroblasts, in invasive counterpart. 
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The work presented throughout this thesis addressed one major topic in breast 
cancer research, which is the progression from in situ to invasive breast carcinoma. 
Herein, we highlight the relevance of both epithelial tumor cells in the progression and 
additionally provide innovative data concerning the microenvironment surrounding the 
tumor cells. We explore the role of the epithelial tumor cells, pushing the borders of the 
knowledge about the molecular profiles of in situ and invasive carcinomas and study if 
previously described genes could effectively discriminate between both components. On 
the other hand, we also explore the role of stromal components in breast tumorigenesis, 
focusing our attention in the dynamic cross-talk interactions between the stroma and the 
cancer cells, both in in situ and invasive components.    
The majority of the studies that explore the mechanisms underlying breast 
tumorigenesis are based in independent series of in situ and invasive breast carcinomas 
in order to find the molecular alterations that could trigger the progression. Although we 
understand that the identification of specific gene expression patterns of DCIS and IDC 
separately could help to elucidate the mechanisms underlying the evolution from in situ to 
invasive breast cancers, this model does not represent a basis of progression to invasive 
tumors, due to the lack of the matched counterpart. The great advantage of our series of 
189 breast carcinomas relies precisely on the existence of in situ and invasive 
components in the same sample.   
Based on the above, and aiming a deeper insight into the molecular profiles of in 
situ and invasive breast carcinomas, both components were classified into the different 
subtypes of breast carcinomas: Luminal A, B, HER2 overexpressing and Basal-like breast 
carcinomas in an attempt to translate the molecular classification, using 
immunohistochemistry and tissue microarrays. The work showed that there were no 
significant differences in molecular classifications of concomitant in situ and invasive 
tumors, as in 94% of the cases the molecular classification was identical between in situ 
and invasive components, suggesting that these tumors are not present as different 
entities belonging to different molecular profiles, but rather belong to the same molecular 
subtype. In fact, the different molecular subtypes have different progression forms, 
evolving low grade in situ tumors to low grade invasive tumors and high-grade in situ 
tumors to high grade invasive tumors. These results also support the theory of the parallel 
disease, which explains that in the progression of the majority of breast cancer cases 
there is a commitment of the in situ subtype carcinoma to a specific subtype of invasive 
carcinoma, contradicting the linear pattern supported by the theory of linear progression.  
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Understanding that effectively the molecular subtypes are similar in in situ and 
invasive components and knowing that the classical histopathology has a limited ability to 
predict which cases are in risk of developing an invasive disease, there is an immediate 
need to characterize new molecules that uncover the molecular biology of in situ 
carcinomas and its transition to invasive breast cancer, and understand if some genetic 
alteration could be able to trigger the transition from in situ neoplastic to migrating invasive 
cells. In the studies that focus their attention in the identification of novel molecular 
markers characterizing the transition, in order to avoid that the expression differences 
could be based on the genetic background of individual patients, DCIS and IDC were 
compared in a matched-pair analysis. Our aim was to found a set of genes that could be 
important in the progression from DCIS to IDC and to validate, by immunohistochemistry, 
if effectively these genes discriminate between the components.  We compared gene 
expression data obtained from different studies and we gather four genes represented in 
the different genes lists, previously found to characterize the transition. It was not 
surprising that the genes were associated with important roles in cancer progression, such 
as epithelial-mesenchymal transition, invasion, cell adhesion and interaction, emphasizing 
the importance of changing intercellular network during the process of invasion. MMP11, 
Synaptotagmin V, Adrenomedullin and UBE2C were the set of genes selected in our 
studies and although all these genes have already been described as upregulated in the 
invasive component, any studies have showed by immunohistochemistry in a series of 
matched in situ and invasive components, if these genes were differently expressed. In 
our series, the expression of the markers did not differ significantly between DCIS and 
invasive breast cancers. We were not able to validate using immunohistochemistry, the 
set of specific candidate genes, namely MMP11, Adrenomedullin, Synaptotagmin V and 
UBE2C, previously found by RT- PCR, suggesting that probably the molecular alterations 
which drive invasion occur prior to the morphological modification of the lesion.  
On the other hand, the understanding of tumor metabolism has evolved 
significantly over the last years. Only recently was recognized that there is a significant 
stromal-epithelial metabolic coupling and our study addresses the question of step-wise 
transformation from DCIS to IDC, comparing the stromal metabolism in regions affected 
by DCIS and IDC in the same patients. Cav-1 and MCT4 emerge as metabolic proteins, 
with Cav-1 involved mainly in vesicular transport, cholesterol homeostasis and signal 
transduction, and MCT4 as a marker of oxidative stress and hypoxia. Loss of Cav-1 is a 
marker of glycolitic metabolism, and it has been associated with high risk of progression 
from DCIS to IDC [194]. In our series, loss of Cav-1 was found in 75% in invasive 
carcinomas compared with the in situ counterpart, with no increase of Cav-1 expression in 
the any case during the progression from DCIS to IDC. Since high stromal MCT4 
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expression was already associated with loss of Cav-1 in triple negative breast cancers 
[195], we found that it was low in 90% of DCIS regions, whereas invasive carcinoma 
showed intense expression in 87% of the cases. Importantly, no decrease in MCT4 
expression was found in the progression from DCIS to IDC in any case. Actually, it has 
been described that the direct contact between breast carcinoma cells and stromal cells is 
sufficient to induce loss of Cav-1 and gain of MCT4 expression in the stroma, increasing 
glycolysis and oxidative stress [196, 237]. Thus, stromal transformation may be a new 
hallmark of progression from DCIS to IDC and it will be important to evaluate inhibitors of 
stromal transformation in this context of breast cancer progression. On the other hand, 
metabolic reprogramming of the microenvironment is a key step in cancer progression 
and may be able to better predict which patients will develop IDC in the setting of DCIS, 
by characterizing stromal metabolism rather than features of carcinoma cells [238].  
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Summary The current system of pathologic classification of human breast cancers does not take into
account the biologic determinants of prognosis, nor is there a consensus regarding the progression
from in situ to invasive carcinoma. The present study compared the molecular phenotypes of in situ
and invasive components of breast cancer in the same sample. We built a series of 189 in situ and
invasive carcinomas using tissue microarrays and classified them according to their immunoprofiles
regarding estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2,
epidermal growth factor receptor, cytokeratin 5, P-cadherin, and the antigen Ki-67 into luminal A and
B, human epidermal growth factor receptor 2 overexpressing, and basal-like carcinomas. We also
correlated the subgroups of carcinomas with some of the classical prognostic factors such as
histologic grade, tumor size, and lymph node metastasis, as well as with the age of the patient at
diagnosis. The overall concordance on the molecular phenotypes between in situ and invasive
components was 94%. For the in situ component, 63% of the cases were luminal A; 15%, luminal B;
12%, human epidermal growth factor receptor 2 overexpressing; and 7%, basal-like. Regarding the
invasive component, 61% of the cases were luminal A; 16%, luminal B; 12%, human epidermal
growth factor receptor 2 overexpressing; and 8%, basal-like. The present study allowed the
identification of different immunoprofiles of in situ and invasive breast carcinomas using a specific
panel of biomarkers and showed that in most cases, there is a concordance between in situ and
invasive component profiles, supporting the theory of parallel disease in breast tumorigenesis.
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1. Introduction
Breast cancer is the most common cancer in women, with
more than 1 million cases occurring worldwide annually [1].
Despite significant diagnostic and therapeutic innovations,
the effect on the mortality rate has been modest. One of the
factors contributing to this limited success is the relative lack
of understanding of the natural history of this disease [2]. For
example, the transition from in situ to invasive carcinoma is
still a poorly understood event [3].
Nowadays, it is widely stated that the natural history of
breast cancer involves progression through clinical and
pathologic stages [3,4] from premalignant hyperplastic
breast lesions, with or without atypia, to carcinoma in situ
and then invasive carcinoma [5-7]. On the basis of
molecular, epidemiologic, and pathologic studies, ductal
carcinoma in situ (DCIS) is thought to be a precursor of
invasive ductal carcinoma [4]. Although this model is
supported by clinical and molecular research [8-11], it is
only a starting point to understand breast tumorigenesis, as
the relation between preinvasive lesions and invasive
carcinoma remains unclear [12]. From the available data, 2
models have been proposed recently to explain the transition
from DCIS to invasive breast carcinoma (IBC). The first one,
the theory of linear progression [5,7,13], suggests that low-
grade DCIS progresses to high-grade DCIS and then to
invasive ductal breast carcinoma. This model implies that
tumor progression follows a linear pattern. However, there is
evidence that some in situ carcinomas never progress to
invasion and that some DCIS have more genetic alterations
than some invasive carcinomas [14], a finding which does
not fit in this multistep model. Consequently, a second model
of breast cancer tumorigenesis has been proposed: the theory
of the parallel disease, wherein low-grade DCIS tends to
progress to low-grade invasive ductal breast cancer, whereas
high-grade DCIS tends to progress to high-grade invasive
breast cancer [12]. In this model, a specific subtype of DCIS
matches a specific subtype of invasive breast cancer.
Gene expression profiling is known to be a powerful tool
for identifying tumor molecular profiles and for correlating
gene expression profiles with outcome in breast cancer [14].
In addition, it has been an important tool to explore the
transcriptional program that leads to invasion, comparing in
situ and invasive carcinomas. Recently, Dalgin et al [15]
studied 36 breast cancer patients with different pathologic
stages of disease and revealed a hierarchical portrait of breast
cancer progression, identifying genes and pathways for each
stage, grade, and molecular subtype. These authors
suggested that the heterogeneity of the disease across
molecular subtypes is higher than the heterogeneity of
disease progression within a subtype, suggesting that tumors
with different molecular profiles are in fact distinct diseases.
Several studies have concentrated on the identification of
specific biomarkers that could define the subtypes of in situ
and IBCs [16-18]. Our group and others demonstrated that it
is possible to translate the molecular classification, using
immunohistochemistry (IHC) and tissue microarrays
(TMAs) [18], where estrogen and progesterone receptors
(ER and PgR) and human epidermal growth factor receptor 2
(HER-2) expression identify luminal A and B and HER-2
overexpression subtypes, whereas tumor protein 63 (p63),
cytokeratin 5 (CK5), and P-cadherin (P-cad) allow the
identification of basal-like tumors [17]. Recently, Paredes et
al [18] also demonstrated the importance of P-cad and CK5
as useful adjunct markers to distinguish the basal-like
subtype among the in situ carcinomas.
However, it was never determined whether the in situ and
invasive carcinomas that develop in a particular breast cancer
patient belong to the same molecular subtype or are different
entities belonging to different molecular profiles.
In this study, our aim was to compare the molecular
phenotypes of in situ and invasive components of breast cancer
in the same sample, using IHC and TMAs and a specific panel
of biomarkers, previously described by our group [17,18].
2. Materials and methods
2.1. Tumor specimens
One hundred eighty-nine formalin-fixed, paraffin-
embedded samples harboring in situ and IBCs in the same
block were collected from the archives of the Pathology
Institute of Araçatuba, São Paulo, Brazil (1996-2006). All
cases were classified from hematoxylin and eosin (H&E)–
stained sections. The DCIS samples were subdivided into 3
groups: low, intermediate, and high grade, according to the
nuclear grade and the extent of necrosis, as previously
published by our group [19]. Briefly, tumors harboring nuclear
grade 3 were all considered high grade, whereas tumors with
nuclear grade 1 or 2 with necrosis were considered
intermediate grade, and those of nuclear grades 1 and 2
without necrosis were considered low grade. Invasive breast
cancers were classified as grade I, II, or III according to the
method described by Elston and Ellis [20]. Some relevant data
were available for analysis, including age and clinicopatho-
logic features such as tumor size and lymph node metastasis.
2.2. TMAs construction
Representative areas of the in situ and IBCs were selected
on H&E-stained sections and marked on the corresponding
paraffin blocks. Two 2-mm tissue cores were obtained from
each selected specimen (donor block) and deposited in a
paraffin (receptor) block using a TMA workstation (TMA
Builder ab1802; Abcam, Cambridge, UK). Twenty-two
TMA blocks were constructed, each containing 24 tissue
cores (4 × 6). In each TMA block, nonneoplastic breast and
liver tissue cores were included as a control and a TMA
guide, respectively. After the construction, 2-μm tissue
sections were cut and attached to Superfrost Plus glass slides.
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An H&E-stained section from each TMA block was
reviewed to confirm the presence of morphologically
representative areas of the original lesions.
2.3. Immunohistochemistry
The sections were immunostained with primary mono-
clonal antibodies against ER, PgR, HER-2, epidermal
growth factor receptor (EGFR), CK5, P-cad, and Ki-67.
Immunostaining for ER, HER-2, and CK5 was performed
using the streptavidin-biotin peroxidase technique (LabVi-
sion, Fremont, CA), whereas for PgR, EGFR, P-cad, and Ki-
67, a horseradish peroxidase–labeled polymer (DakoCyto-
mation, Carpinteria, CA) was used.
Antigen unmasking for ER, PgR, HER-2, and Ki-67 was
carried out using 1:100 commercial citrate buffer, pH 6.0
(Vector Laboratories, Burlingame, CA) at 98°C, whereas a
dilution of 1:10 from tris-ethylenediaminetetraacetic solution
at pH 9.0 (DakoCytomation) was used for CK5 and P-cad.
Epitope retrieval for EGFR was performed by proteolytic
digestion (pepsin A, 4 g/L; Sigma-Aldrich, St. Louis, MO,
USA) at 37°C.
The antigen retrieval time, antibodies, dilutions, and
suppliers are listed in Table 1. After the antigen retrieval
procedure, the slides were washed in phosphate-buffered
saline and submitted to blockage of endogenous peroxidase
activity by incubation of the slides in 3% hydrogen peroxide
(Panreac, Barcelona, Spain) inmethanol (Sigma-Aldrich). The
slides were further incubated with blocking serum (LabVision
Corporation kit) for 15 minutes and then incubated with the
primary antibodies. After washes, the slides were incubated
with biotinylated secondary antibody, followed by streptavi-
din-conjugated peroxidase (LabVision). Diaminobenzidine
was used as a chromogen (DakoCytomation).
For PgR, EGFR, P-cad, and Ki-67 staining, the secondary
antibodywas associated with horseradish peroxidase–labeled
polymer (DakoCytomation) and immediately revealed with
diaminobenzidine. Tissues were then counterstained with
Mayer hematoxylin, dehydrated, and covered using a
permanent mounting solution (Zymed, San Francisco, CA).
Positive controls were included in each run to guarantee
the reliability of the assays. Nonneoplastic breast tissues, as
well as normal breast surrounding the neoplastic cells, were
considered internal controls.
2.4. Quantification of immunostaining
The IHC results were evaluated by 2 pathologists (F.S.,
F.M.). Both ER and PgR were examined for staining intensity,
ranked from 1 to 3 (1, weak; 2, moderate; 3, strong) and extent,
ranked from1 to 10 (1, 0-10% cells; 2, 11%-20%cells; 3, 21%-
30% cells; 4, 31%-40% cells; 5, 41%-50% cells; 6, 51%-60%
cells; 7, 61%-70% cells; 8, 71%-80% cells; 9, 81%–90% cells;
10, 91%-100% cells) using the H-score method, which is used
for other nuclear receptors as well [21,22]. The scores for
intensity and extension were multiplied, and the cases were
considered negative when the score was less than 4 and
positive from 5 to 30. Concerning Ki-67, tumors with
unequivocal nuclear staining in more than 14% of the cells
were classified as highly proliferative, whereas tumors with
less than 14% positive cells were considered to show low
proliferation [23]. We considered positive the cases with
membranous staining for P-cad and cytoplasmic staining for
CK5 in at least 10% of the neoplastic cells. Expression of
HER-2 was evaluated according to the DakoCytomation
Hercept Test scoring system [24]. Cases were considered
positive (overexpression) when immunostaining was classi-
fied as 3+. If a case is classified as 2+ by IHC, fluorescence in
situ hybridization analysis was performed to determine if the
tumor had HER2 amplification. If amplification was con-
firmed, the tumor was classified as positive. If the tumor did
not demonstrate amplification, it was considered negative.
Staining for EGFRwas also classified according to theHercept
Test scoring system. However, breast carcinomas were
considered positive whenever the immunostaining was 2+ or
3+. Cases that were ER+ or PgR+ and HER-2 negative were
classified as luminal A; cases ER+/PgR+ and HER-2+ or ER+
and with a high proliferative index (Ki-67+) were considered
luminal B; ER− and PgR− and HER-2+ cases were classified
as HER-2-overexpressing; cases that were negative for ER,
PgR, and HER-2 and positive for EGFR or CK5 or P-cad were
considered basal-like. Cases that lacked expression of all tested
markers were considered “unclassified.”
2.5. Statistical analysis
StatView 5.0 (SAS Institute Inc, Cary, NC) was used for
statistical analysis. Univariate associations between ER,
PgR, HER-2, EGFR, CK5, P-cad, KI67, tumor size,
Table 1 Sources and dilutions of primary antibodies used in
immunohistochemistry staining
Antibody Clone Manufacturer Time of
incubation
(min)
Dilution Antigen
retrieval
(min)
ER SP1 Neomarkers
(Fremont,
CA, USA)
60 1:100 30
PgR 1A6 Novocastra
(Newcastle,
UK)
60 1:40 30
HER-2 SP3 Neomarkers 30 1:80 30
P-cad 56 Transduction
Labs
(Franklin
Lakes,
NJ, USA)
60 1:50 30
CK5 XM26 Neomarkers 60 1:50 30
EGFR 31G7 Zymed 60 1:100 30
Ki67 SP6 Neomarkers 60 1:300 30
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histologic grade, and lymph node metastases in the presence
of DCIS and invasive breast cancer were assessed using
contingency tables and χ2 tests. In all statistical analyses,
P ≤ .05 was considered significant.
3. Results
We performed IHC on each set of the 22 TMA slides for
ER, PgR, HER-2, P-cad, CK5, EGFR, and Ki-67. Tables 2
and 3 summarize the clustering of a total of 189
immunohistochemically interpretable cases to allow sample
characterization into 1 of the 5 previously described
molecular subtypes. The molecular classification was made
in an individual way for each of the tumor components (in
situ and invasive) in the same block.
3.1. Evaluation of the in situ component
Among the in situ components, we observed that 63%
of all tumors were considered luminal A, whereas the
luminal B and HER-2–overexpressing subtypes comprised
15% and 12% of the cases, respectively. Basal-like tumors
represented 7%, and the ones with null phenotype/
unclassified were 3% (Table 2).
Because luminal cancer subtypes (A and B) were defined
as positive for hormone receptors (ER, PgR), the percentage
of cases positive for these 2 immunohistochemical markers
was extremely high, as expected, with a higher prevalence
for ER positivity (Table 3). For the luminal A subtype, 95%
and 66% of the cases were ER and PgR positive,
respectively, whereas for luminal B, 100% were positive
for ER and 61% were positive for PgR. As initially defined,
all luminal A tumors were negative for HER-2, and all
luminal B lesions were positive for this marker. In the
specimens negative for hormone receptors, all the cases
overexpressing HER-2 were included in the HER-2–over-
expressing cancer subtype, which are being the triple-
negative ones (negative for ER, PgR, and HER-2) divided
into basal-like or unclassified, according to the positivity for
P-cad, CK5, and EGFR. Among the basal-like tumors, P-cad
was the most prevalent marker, with 92% of the cases being
positive, whereas only 23% and 38% of the cases were
positive for EGFR and CK5, respectively.
Although basal markers are most commonly expressed in
basal-like tumors, these can also be present in other cancer
subtypes, if at a lower frequency. Concerning EGFR,
although there were almost no positive cases in the luminal
A and B subtypes, 10% of HER-2–overexpressing tumors
also expressed EGFR. Also, CK5 was expressed by 17% of
the HER-2–overexpressing in situ carcinomas, whereas only
3% and 7% of the tumors classified as luminal A or B,
respectively, showed CK5 expression. Expression of P-cad
also was common in HER-2–overexpressing tumors, which
is being positive in almost half the cases (48%). Concerning
the luminal cancer subtypes, P-cad expression was more
abundant in luminal B (14%) than in luminal A (8%) lesions.
Concerning cell proliferation indexes, addressed by Ki-67
staining, basal-like tumors were the ones showing higher
values (28%), followed by luminal B (19%). When we
studied the association between the in situ histologic grade
andmolecular cancer subtypes (Fig. 1), we found that luminal
A tumors were frequently classified as low grade (49%),
Table 2 Frequencies of immunohistochemically defined
subtypes of in situ and invasive breast cancers
Subtype Frequency in situ
component, n (%)
Frequency invasive
component, n (%)
Luminal A 120/189 (63) 116/189 (61)
Luminal B 28/189 (15) 31/189 (16)
HER-2
overexpressing
23/189 (12) 23/189 (12)
Basal-like 13/189 (7) 14/189 (8)
Unclassified 5/189 (3) 5/189 (3)
Table 3 Comparison of molecular subtypes and biomarkers for in situ and invasive components
Luminal A Luminal B HER-2 overexpressing Basal-like P
In situ Invasive In situ Invasive In situ Invasive In situ Invasive In situ Invasive
ER + 114 (95%) 108 (93%) 28 (100%) 31 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) P ≤ .0001 P ≤ .0001
− 6 (5%) 8 (7%) 0 (0%) 0 (0%) 23 (100%) 23 (100%) 13 (100%) 14 (100%)
PR + 79 (66%) 79 (68%) 17 (61%) 13(42%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) P = .0002 P = .0001
− 41 (34%) 37 (32%) 11 (39%) 18 (58%) 23 (100%) 23 (100%) 13 (100%) 14 (100%)
HER-2 + 0 (0%) 0 (0%) 15 (54%) 14 (45%) 23 (100%) 23 (100%) 0 (0%) 0 (0%) P ≤ .0001 P ≤ .0001
− 120 (100%) 116 (100%) 13 (46%) 17 (55%) 0 (0%) 0 (0%) 13 (100%) 14 (100%)
EGFR + 1 (1%) 1 (1%) 0 (0%) 0 (0%) 2 (10%) 2 (9%) 3 (23%) 3 (21%) P = .004 P = .001
− 119 (99%) 115 (99%) 28 (100%) 31 (100%) 21 (90%) 21 (91%) 10 (77%) 11 (79%)
CK5 + 4 (3%) 2 (2%) 2 (7%) 0 (0%) 4 (17%) 5 (22%) 5 (38%) 5 (36%) P = .001 P ≤ .0001
− 116 (97%) 114 (98%) 26 (93%) 31 (100%) 19 (83%) 18 (78%) 8 (62%) 9 (64%)
P-cad + 9 (7%) 9 (8%) 4 (14%) 4 (13%) 11 (48%) 11 (48%) 12 (92%) 13 (93%) P ≤ .0001 P ≤ .0001
− 111 (93%) 107 (92%) 24 (86%) 27 (87%) 12 (52%) 12 (52%) 1 (8%) 1 (7%)
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whereas most luminal B carcinomas were classified as
intermediate grade (53%); HER-2–overexpressing and basal-
like cases were more often of high grade (86% and 77%).
3.2. Evaluation of the invasive component
For the invasive component (Table 2), the luminal A
subtype represented 61% of all the tumors. Luminal B and
HER-2–overexpressing invasive tumors corresponded to
16% and 12%, respectively, whereas basal-like tumors
comprised 8% of the cases. Only 3% of the invasive
carcinomas were null phenotype/unclassified. For the
luminal A cancer subtype, 93% and 68% of the cases were
ER and PgR positive, respectively, whereas for luminal B,
100% were positive for ER and 42% were positive for PgR.
Again, all luminal A tumors were negative for HER-2, as
expected, and 45% of luminal B cases were positive for this
marker. The invasive carcinomas overexpressing HER-2 and
negative for hormone receptors were included in the HER-2–
overexpressing cancer subtype. In triple-negative basal-like
invasive tumors, as described for the in situ component,
P-cad expression was the most prevalent basal marker, with
93% positive cases, whereas only 21% and 36% of the cases
were positive for EGFR and CK5, respectively (Table 3).
When we studied the expression of basal markers in
cancer subtypes other than the basal-like, we found results
similar to the ones described for the in situ component of this
breast cancer series. Concerning EGFR, exactly the same
frequencies were found: 1% and 0 of the cases expressed this
receptor in luminal A and B subtypes, respectively, whereas
9% of HER-2–overexpressing tumors coexpressed these 2
tyrosine kinase receptors. CK5 was expressed by 22% of the
HER-2–overexpressing invasive carcinomas, whereas only
2% or none of the tumors classified as luminal A or B,
respectively, showed CK5 expression. Again, P-cad expres-
sion was highly expressed in HER-2–overexpressing tumors
(48%), but it was expressed by only 8% of luminal A and
13% of luminal B IBCs.
For Ki-67, the tumors included in the basal-like and
luminal B subtypes had the highest proliferative indexes
(29% and 25%, respectively). Regarding the histologic grade
(Fig. 1), we found that luminal A invasive tumors were often
grade I (55%), whereas luminal B lesions were from
intermediate (41%) to high grade (38%); once more, HER-
2–overexpressing and basal-like tumors were more regularly
classified as grade III (95% and 86%, respectively).
3.3. Combined evaluation of the in situ and
invasive counterparts in the same patient
Most cases (93%) maintained the molecular classification
when the in situ and invasive components were compared
(Fig. 2); there were just 13 cases (7%) in which the 2 areas
were classified differently (Table 4). One of the cases was
unclassified for the in situ component (negative for all
markers), but basal-like in the invasive counterpart in which
P-cad expression was seen. Both components were high
grade. Another case was classified as an in situ luminal A
carcinoma but was unclassified in the invasive component
because of the absence of expression of both hormone
receptors (Fig. 2D). Interestingly, although both components
were intermediate grade, the invasive counterpart had a
higher proliferative index. Four cases were classified as
luminal B for the in situ component but luminal A for
invasive counterpart because of the low proliferative index,
with the exception of one case that lacked HER-2 expression
also in the invasive area. Interestingly, in this case, the loss of
expression was accompanied by a difference in the histologic
grade: high grade in the in situ portion and grade II in the
invasive counterpart.
Finally, 7 cases that were classified as in situ luminal A
carcinomas were classified as luminal B in the invasive
portion because of a higher proliferative index. Other than
the increase in cell proliferation, no alterations were noticed
in histologic grade.
In general terms, we can conclude that there are no
important modifications of the breast cancer molecular
classification in most cases when the transition from an in
situ to an invasive carcinoma occurs. However, when we
compared the expression of the different biomarkers
individually (Table 3), we could find subtle differences
between components, which can add some biologic
information to the in situ/invasive transition. In the luminal
A cases, in addition to the higher proliferative rate in the
invasive component in 7 cases, just 3 cases showed P-cad
expression in the invasive component. No alterations in
hormone receptors were found between in situ and invasive
transition. In luminal B tumors, no alterations were found for
Fig. 1 Comparison of histologic grade among molecular
subtypes (luminal A, luminal B, HER-2, and basal) in situ and
invasive components. All correlations were statistically significant
(P ≤ .05).
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ER expression when the in situ and invasive components
were compared. However, there were 4 cases that lost PgR
expression in the invasive carcinoma, with the transition
from a high-grade in situ carcinoma to a grade II invasive
tumor in 2 cases; in the remaining 2, there were no alterations
in grade. The other differences were in basal markers, such as
CK5 and P-cad, with a loss of 7% and 3% of expression from
in situ to invasive tumors, respectively. Regarding the
HER-2–overexpression lesions, 7 did not show expression
of any basal marker, whereas 14 cases showed concomitant
Fig. 2 Expression of proteins studied by IHC staining on TMAs for in situ and invasive components. A and B, H&E staining of low-/I and
high-grade/III histologic grade, respectively. C, ER expression. D, Loss of ER expression in invasive component. E, HER-2 staining. F, P-cad
staining. Original magnifications: A-D ×200; E, F ×100.
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expression of EGFR, CK5, or P-cad together with HER-2. Of
these, P-cad was the most prevalent. There were 3 cases that
gained expression of basal markers in the transition from in
situ to invasive carcinoma, namely, 2 with CK5 and 1 with P-
cad. Only this last case changed histologic grade (from an
intermediate in situ grade to a grade III invasive tumor). In
the basal-like subtype, most cases were P-cad positive in
both components (11 cases). However, there was 1 case that
lost P-cad in the invasive fraction, but because it expressed
CK5 in the invasive component, its molecular classification
did not change.
Molecular subtypes of in situ and invasive breast cancers
did not differ with the histologic grade (P b .0001 and P =
.0002 for in situ and invasive counterparts, respectively).
High-grade lesions were associated with the HER-2–
overexpressing and basal-like phenotypes in both the in
situ and invasive components. Low-grade lesions were
frequently of the luminal A phenotype. In the luminal B
phenotype, the in situ component was more frequently high
grade (53%), whereas the invasive counterpart was
intermediate grade (41%).
As mentioned above, the only cases with alterations in
molecular classification were not accompanied by differences
in histologic grade. However, there were some alterations in
histologic grade in individual cases: 9 lesions with interme-
diate in situ components were grade III in the invasive
counterpart, whereas 5 classified as in situ low grade were
grade II lesions whenwe analyzed the invasive component. In
cases where there was a decrease in the histologic grade, 12
cases classified as high grade in the in situ component were
grade II in the invasive counterpart; 1 case was high grade in
the in situ component and grade I in the invasive one, and 10
cases classified as intermediate grade in the in situ component
were grade I in the invasive area.
4. Discussion
Two main branches of breast tumorigenesis have been
distinguished: one supports the multistep model and the
other the theory of parallel disease, where a specific subtype
of DCIS matches a specific subtype of invasive breast cancer
[12]. In 1997, Grupta et al [25], studying 300 patients with
IBC associated with DCIS, demonstrated that the degree of
differentiation of DCIS correlated with the grade of the
invasive carcinoma and the clinical outcome. They also
showed that patients with invasive breast cancer displayed
the same mutations as patients with preinvasive and invasive
lesions. In fact, recent data [26] demonstrate that the most
dramatic alterations in gene expression patterns occur during
the transition from normal breast tissue to DCIS [27,28], not
from in situ to invasive. In contrast, Tamimi et al [29],
studying 272 DCIS and 2249 invasive independent tumors,
showed that in situ and invasive phenotypes had different
prevalences. These authors found a higher prevalence of
luminal B and HER-2–overexpressing profiles among DCIS
tumors. However, analyzing independent series of in situ and
invasive tumors [17,18], no differences were found in
molecular subtype prevalence. So probably, the higher
percentage of the HER-2 phenotype in DCIS in the series
described by Tamimi et al [29] was attributable to the
examination of a mammographically screened population
and does not reflect a basis of progression to invasive tumors.
The great advantage of our series of 189 breast
carcinomas, which was characterized by several immuno-
histochemical markers, relies on the existence of in situ and
invasive components in the same sample. We classified the
in situ and invasive tumors into 4 main molecular subtypes
(luminal A, luminal B, HER-2–overexpressing, and basal-
like). When the components were compared, we verified that
there were no significant differences in the molecular
classification of in situ and invasive tumors, which led us
to conclude that different molecular subtypes have different
progression forms, low-grade in situ tumors evolving into
low-grade invasive tumors and high-grade in situ tumors into
high-grade invasive tumors [15].
Differences in molecular profiles between the in situ and
invasive carcinoma areas were observed in only 13 cases,
which seems more likely to be attributable to technical
immunohistochemical issues than a reflection of changes in
tumor biology. One case classified as luminal A in the in situ
component lost ER expression and became unclassified in
the invasive component. Another case, which did not express
any of the markers used for classification (unclassified) in the
in situ component, gained expression of P-cad in the invasive
component and could be characterized as having a basal-like
phenotype. In the remaining 11 cases, the changes were from
luminal A to B or vice versa, and these alterations can be
attributed to the fact that the criteria for classification of the
luminal B subtype are not well established. Although some
luminal B tumors can be identified by their expression of
HER-2, the chief biologic distinction between luminal A and
B is the proliferative signature, including genes such as
Ki-67. Chang and collaborators [23], using 14% as a cutoff,
supported Ki-67 as a well-established cell proliferation
marker in cancer and emphasized its role as a biomarker
candidate for identification of luminal B tumors. We also
used this cutoff, which allowed us to distinguish some
luminal B tumors that the standard biomarker panel (ER,
PgR, and HER-2) did not identify. Interestingly, and
although the percentages are close to that of the luminal B
subtype, the basal-like tumors had higher proliferative
Table 4 Discordant molecular classifications between in situ
and invasive components
No. In situ component Invasive component
7 Luminal A Luminal B
4 Luminal B Luminal A
1 Luminal A Unclassified
1 Unclassified “Basal-like”
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indices than the other subtypes in both the in situ and
invasive components (28% and 29%, respectively). Among
these fractions, the invasive one had a higher proliferative
rate, which can be associated with an increase in cell
proliferation when invasion occurs, and with the poor
prognosis associated with this molecular subtype.
An association between histologic grade and molecular
phenotype has been demonstrated, with low-grade inva-
sive tumors usually having the luminal A phenotype,
whereas high-grade tumors are more prevalent among
HER-2–overexpressing and basal-like subtypes [29,30].
Moreover, the HER-2–overexpressing and basal-like
subtypes are associated with a poor prognosis. In our
series, in in situ breast cancers, HER-2 and basal-like
subtypes were more frequently high grade than low or
intermediate grade (86% and 77%, respectively). These
results were consistent for invasive tumors, because 95%
of HER-2+ and 86% of basal-like tumors had high
histologic grades. It was interesting to note the percen-
tages of the luminal B type among DCIS and invasive
components, where intermediate/II and high grade prevail
in both, with 36% and 54% for the in situ component, as
well as 41% and 38% for the invasive counterpart,
respectively. This similarity between intermediate/grade II
and high grade probably is secondary to the cutoff used,
which enriched our series in luminal B cases.
We also looked for cases that showed alterations
simultaneously in biomarker expression and histologic
grade and found 8 cases. It is important to say that these
alterations were not accompanied by alterations in the
molecular classification. Two cases graded as having an
intermediate in situ component were grade III in the invasive
component, accompanied by gain of P-cad in one case and its
loss in the other. Other 2 cases, with the concordant loss of
PgR expression, classified as high grade in the in situ
component, were grade II in the invasive counterpart. One
case also lost PgR expression but changed from intermediate
in situ to grade I in the invasive counterpart. It is also
interesting that we had 2 cases that lost PgR expression and 1
basal marker, P-cad or CK5, simultaneously and were
classified as high-grade in situ and grade II in the invasive
component. Finally, the remaining case lost CK5 and
changed from intermediate to grade I.
We have shown that the prevalence of molecularly
defined phenotypes did not differ significantly between
DCIS and invasive breast cancers; probably, the molecular
alterations that drive invasion occur before the morphologic
modification of the lesion [31,32]. Dalgin et al [15] also
confirmed that the cancer phenotype develops early (in the
early hyperplasia or DCIS stage), and each subtype
progresses along its own specific pathway, as if each was a
distinct disease.
In conclusion, with this work, we showed that it is
possible to identify different immunohistochemical profiles
of in situ and invasive breast cancer using a small panel
of biomarkers (ER, PgR, HER-2, EGFR, CK5, P-cad, and
Ki-67) and that the technique of TMA is useful, efficient,
and reliable in the characterization and subclassification of
a large number of cases. Concerning the comparison of in
situ and invasive components, we found that in 176 (93%)
of the 189 cases, the molecular classification was identical
in the 2 components, which supports the theory of parallel
disease; that is, that in the progression of most breast
cancer cases, there is a commitment of the in situ subtype
carcinoma to a specific subtype of invasive carcinoma.
Otherwise, the finding supports the view that the
molecular phenotype is established at the DCIS stage.
Although there has been an improvement in understanding
the pathways of breast tumorigenesis, little is known about
the mechanisms associated with the transition from in situ
to invasive carcinomas. More than just genetic alterations
in the tumor cells, the codependency of epithelial cells and
stroma can regulate tumor progression. Recently, it was
demonstrated that myoepithelial cells can have a particular
role in tumor invasion. Studying normal myoepithelial
cells and the ones associated with DCIS, Schnitt [32,33]
demonstrated that the last ones differ substantially from
the normal, showing down-regulation of genes involved in
the normal function of cells and up-regulation of genes
associated with invasion. There is an immediate need to
characterize new molecules that not only uncover the
molecular biology of in situ carcinoma and its transition to
invasive breast cancer, but also the transcriptional program
that drives the invasive growth of each molecular subtype.
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The progression from in situ to invasive breast carcinoma is still an event poorly understood. However, it has been 
suggested that interactions between the neoplastic cells and the tumor microenvironment may play an important role 
in this process. Thus, the determination of di!erential tumor-stromal metabolic interactions could be an important step 
in invasiveness.
The expression of stromal Caveolin-1 (Cav-1) has already been implicated in the progression from ductal carcinoma 
in situ (DCIS) to invasive ductal carcinoma (IDC). Additionally, stromal Cav-1 expression has been associated with the 
expression of stromal monocarboxylate transporter 4 (MCT4) in invasive breast cancer. However, the role of stromal MCT4 
in invasiveness has never been explored, neither the association between Cav-1 and MCT4 in the transition from breast 
DCIS to IDC.
Therefore, our aim was to investigate in a series of breast cancer samples including matched in situ and invasive 
components, if there was a relationship between stromal Cav-1 and MCT4 in the progression from in situ to invasive carci-
noma. We found loss of stromal Cav-1 in the progression to IDC in 75% of the cases. In contrast, MCT4 stromal expression 
was acquired in 87% of the IDCs. Interestingly, a concomitant loss of Cav-1 and gain of MCT4 was observed in the stroma 
of 75% of the cases, when matched in situ and invasive carcinomas were compared. These results suggest that alterations 
in Cav-1 and MCT4 may thus mark a critical point in the progression from in situ to invasive breast cancer.
Loss of caveolin-1 and gain of MCT4 
expression in the tumor stroma
Key events in the progression from an in 
situ to an invasive breast carcinoma
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Introduction
Breast cancer is a heterogeneous and complex disease, encom-
passing a variety of pathological entities with distinct clinical 
behaviors. The development of new technologies has offered the 
opportunity to explore the molecular complexity of human breast 
carcinomas.1 However, despite these advances, the mechanisms 
controlling the transition from an in situ to an invasive carcinoma 
still remain unclear. Therefore, there is a significant interest in 
identifying molecular events driving invasive progression, not only 
to determine at which point the lesion is most likely to progress to 
malignancy, but also to identify new molecular targets that could 
trigger the progression at early stages.1 Several studies have evalu-
ated the gene expression profiles of both ductal carcinomas in situ 
(DCIS) and invasive ductal carcinomas (IDC),2-8 but only few 
compared the in situ and invasive components within the same 
breast tumor.5-8 In fact, although some genes have been described 
as differentially expressed between in situ and invasive compo-
nents, the majority of the studies failed to demonstrate signifi-
cant differences between the expression of the codified proteins in 
the neoplastic epithelial cells of DCIS and IDC.5,9 Recently, our 
group, using patient-matched DCIS/IDC tumor samples, showed 
concordance between in situ and invasive molecular profiles in 
94% of the cases.10 These results suggested that the alterations in 
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the tumor microenvironment would have a more important role 
in the progression from an in situ to an invasive phenotype than 
the biology of the tumor cells per se, which showed a tendency to 
be maintained between these both components.
Actually, it is widely accepted that any cancer is a complex 
system composed not only by neoplastic cells but also by a fine-
tuned microenvironment. The first reference to the importance 
of the microenvironment in cancer comes from Paget, with his 
proposal of the “seed and soil” hypothesis. Unexpectedly, this 
concept was “forgotten” and only “recovered” several years later. 
In breast cancer, tumor microenvironment plays a key role in 
defining tumor behavior and patient outcome.11 Gene expression 
changes that occur in cancer-associated stroma are known to be 
implicated in prognosis, as well as in cancer progression.12-14 Ma 
and colleagues, using gene expression profiling, provided strong 
evidence that the stroma co-evolves with the epithelial compart-
ments during cancer progression.12 Analyzing 14 patients with 
matched normal epithelium, normal stroma, tumor epithelium, 
and tumor-associated stroma, the authors proposed that micro-
environment participates in tumorigenesis even before tumor 
cells invade the stroma, and it may play an important role in the 
transition from pre-invasive to invasive growth.12
Caveolin-1 (Cav-1), a scaffolding protein mainly involved in 
vesicular transport, cholesterol homeostasis, and signal transduc-
tion, has been associated to the progression from in situ to inva-
sive carcinoma.15,16 Lisanti and colleagues showed that Cav-1 loss 
in tumor stroma was associated with an increased risk for early 
recurrence, metastasis, and decreased overall survival in breast 
cancer, being also a strong prognostic factor for basal-like breast 
carcinomas.17,18 In DCIS, a loss of stromal Cav-1 was predictive 
of disease recurrence and progression to invasive cancer, since 
all the patients with loss of Cav-1 recurred, and 80% of them 
progressed to invasive disease.16 Moreover, loss of stromal Cav-1 
has been related with stromal MCT4 expression in triple-negative 
breast cancers, also predicting for poor clinical outcome.19 This 
protein is a major transporter directly responsible for L-lactate 
efflux from glycolytic cells and a functional marker of oxidative 
stress and hypoxia.20 In addition, it seems to have a role in stro-
mal breast cancer metabolism, since it has been demonstrated 
that breast cancer cells induce MCT4 overexpression in stromal 
fibroblasts.21
Since stromal expression of MCT4 and the association 
between Cav-1 and MCT4 had never been implicated in the pro-
gression from DCIS to IDC, the aim of this study was to bet-
ter understand the stromal interactions surrounding in situ and 
invasive components of breast carcinomas, evaluating the stromal 
expression of Cav-1 and MCT4 using patient-matched DCIS/
IDC tumor samples.
Results
IHC quantification for Cav-1 and MCT4 was performed on 
each set of the 22 TMA slides using patient-matched DCIS/IDC 
tumor samples. Data on ER, PgR, HER-2, P-cad, CK5, EGFR, 
Ki-67 status, histological grade, and lymph node metastases were 
already available and published for this series.10
Cav-1 and MCT4 expression in normal breast
In normal breast, it can be observed that Cav-1 expression was 
absent from the epithelium, whereas its expression was observed 
in the stromal component, as previously described.16-18 MCT4 
expression was absent in both epithelial and stromal components, 
as observed in Figure 1A.
Stromal Cav-1 expression in the progression from in situ to 
invasive carcinoma
In the DCIS component, only 19 cases (13%) showed no 
Cav-1 expression in the stroma, whereas 55 cases (39%) had 
moderate expression, and the majority had strong expression 
of stromal Cav-1 (67 cases, 48%). In the invasive component, 
the majority (n = 108, 76%) of the cases showed absent Cav-1 
expression in the stroma, with only 27 cases (19%) with moder-
ate expression and 7 cases (5%) with strong expression. Figure 2 
represents the expression levels of stromal Cav-1 in in situ and 
invasive components, where a significant decrease of Cav-1 from 
DCIS to IDC can be observed. An IHC example of Cav-1in in 
situ and invasive components is shown in Figure 3.
Regarding the progression from in situ to invasive carci-
noma, analyzing each case for both matched components, 106 
cases (75%) showed loss of stromal Cav-1 expression, whereas 
35 (25%) cases maintained protein expression. None of the cases 
showed gain of stromal Cav-1 expression.
Stromal MCT4 expression in the progression from in situ to 
invasive carcinoma
Considering the DCIS component, the majority of the cases 
were negative (n = 131, 93%) (Fig. 1B), 10 cases (7%) showed 
moderate expression, and 5 cases (3%) were classified as strong 
for stromal MCT4. In the invasive component, a strong expres-
sion of MCT4 in the stroma of the majority of the cases (n = 73, 
50%) was observed, whereas moderate expression was observed 
in 63 (43%) cases; in the remaining 11 cases (7%), no expression 
of stromal MCT4 was observed.
Figure 4 depicts the expression levels of stromal MCT4 in 
situ and invasive components, showing an increased expression 
of stromal MCT4 in the invasive component. Figure 5 repre-
sents by IHC the strong MCT4 stromal expression in invasive 
component.
Concerning the transition from in situ to invasive carcinoma 
in terms of gains and losses of MCT4 in the stroma, we found 
that 126 cases (87%) gained expression in the invasive compo-
nent, 19 cases (13%) maintained, and none lose the expression.
Combining stromal Cav-1/MCT4 in the progression from 
in situ to invasive carcinoma
Analyzing matched in situ and invasive components for stro-
mal expression of Cav-1 and MCT4 (Table 1), it was possible 
to observe a statistically significant association between the loss 
of stromal Cav-1 and the concomitant gain of MCT4 in the 
same case (P < 0.0001). Interestingly, 75% of the cases that lost 
Cav-1 stromal expression in the transition from in situ to inva-
sive cancer also gained MCT4 expression in the stroma. There 
were only 4 cases (3%) with loss of Cav-1 in the stroma that 
maintained MCT4 expression and 16 cases (12.5%) that gained 
MCT4 and maintained Cav-1 stromal expression. In 12 cases 
(10%), there was the maintenance of stromal expression for both 
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
2686 Cell Cycle Volume 12 Issue 16
Figure 1. IHC expression of stromal MCT4 in normal and in situ compo-
nent. Absent stromal MCT4 expression can be observed in normal breast 
(A) and in in situ component (B), 200×.
Figure  2. Expression levels of stromal Cav-1 in in situ and invasive 
components of breast carcinomas. It is possible to notice a signi"cant 
decrease of Cav-1 stromal expression from DCIS to IDC.
markers. Figure 6 represents an IHC array with the expression 
levels of these proteins in the progression from in situ to invasive 
carcinoma.
Discussion
The mechanisms that mediate the progression from DCIS 
to IDC in the breast are still largely unknown. However, it is 
now widely acknowledged that accumulation of genetic anoma-
lies contributes to the acquisition of an increasingly aggressive, 
invasive, or therapy-resistant tumor phenotype.1 Nevertheless 
this knowledge did not improve the predictive power of standard 
pathological parameters for breast cancer, nor did it explain the 
mechanisms of invasiveness.
Cav-1 plays an important role in tumor stroma, and recent 
studies demonstrate that the loss of stromal Cav-1 is associated 
with advanced tumor and nodal stage, lymphovascular inva-
sion, metastasis, early recurrence, tamoxifen resistance, and 
reduced progression-free survival in invasive breast cancer.23-25 
Additionally, loss of stromal Cav-1 also has prognostic value in 
a particularly aggressive subgroup of breast cancers, namely the 
triple-negative and basal-like breast carcinomas, whereas high 
levels of this protein were correlated with reduced tumor size, 
low grade, reduced metastasis, and improved survival.18,25,26
Interestingly, loss of stromal Cav-1 also predicts for recurrence 
and early disease progression in DCIS patients. Witkiewicz et al. 
reported that 80% of the DCIS patients, which underwent surgi-
cal excision and recurred with invasive breast cancers, showed 
reduced or absent levels of stromal Cav-1 in these tumors.16 In 
our series, using patient-matched DCIS/IDC tumor samples, it 
was observed that the majority of the cases showed strong expres-
sion of Cav-1 expression in the stroma of DCIS, whereas 76% of 
the cases showed absent expression for this marker in the stroma 
of the invasive counterpart. Thus, regarding the progression to 
invasiveness, it seems that the loss of Cav-1 expression in the 
stroma is important for tumor invasion.
Actually, it has been already described that loss of Cav-1 in 
stromal cells may also increase angiogenesis and tumor growth.15 
Goetz et al. demonstrated that in vivo and in vitro expression 
of Cav-1 in cancer-associated fibroblasts facilitates tumor cells 
invasion and accelerates the in vitro proliferation and in vivo 
tumorigenesis.27,28
Recent data reveals that loss of Cav-1 induces a metabolic 
reprogramming of stromal cells to support the growth of adja-
cent epithelial tumor cells—the “reverse Warburg effect”, where 
cancer cells induce upregulation of multiple glycolytic enzymes 
in neighboring stromal fibroblasts.23,29,30 Cav-1 is degraded result-
ing in a loss of stromal Cav-1 expression.19 At the same time, 
the breast cancer cells induce MCT4 overexpression in stromal 
fibroblasts.19
MCT4 is a monocarboxylate transporter that functions as a 
shuttle to extrude L-lactate from cells using aerobic glycolysis for 
energy metabolism.20 Although the transporter role of MCT4 
has been widely accepted in cancer epithelium, the prognostic 
value of MCT4 expression is highly compartment-specific and 
restricted to the tumor stroma, high stromal MCT4 levels being 
associated to poor patient overall survival.21,31,32 In our series, 
analyzing DCIS and IDC separately, an increase of MCT4 
expression was observed, since in DCIS the majority of the 
cases were negative, whereas, in the invasive counterpart, 50% 
of the cases showed strong expression for MCT4. Considering 
the progression from in situ to invasive breast carcinoma, using 
matched DCIS/IDC tumor samples, 87% cases gained MCT4 
expression, whereas none showed loss of expression, suggest-
ing that the gain of stroma MCT4 provides evidence for the 
existence of a stromal–epithelial lactate shuttle which fuels the 
tumor growth.21
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Regarding the relation between MCT4 and Cav-1 expres-
sion, Witkiewicz et al.,19 using 164 invasive breast cancer sam-
ples, verified that stromal MCT4 and stromal Cav-1 levels were 
inversely related, high levels of stromal MCT4 being directly 
correlated with a loss of stromal Cav-1 immunostaining.19 Most 
notably, cases with absent stromal Cav-1 are most likely to pres-
ent strong stromal staining for MCT4, and, in contrast, cases 
with strong expression for Cav-1 are most likely to be stromal 
MCT4 absent.
Nevertheless, studies regarding the role of Cav-1 and MCT4 in 
the transition from in situ to invasive breast carcinoma were still 
lacking. In our series, using matched DCIS/IDC and analyzing 
the concomitant expression of stromal Cav-1 and MCT4, 75% of 
the cases showed loss of Cav-1 with simultaneous gain of MCT4 
in the stroma, suggesting that these events are important for 
tumor cells to progress and invade.
Our results are explained by the recent “two-compartment 
tumor metabolism” model and the “reverse Warburg effect”, sug-
gesting that the loss of Cav-1 causes the metabolic reprogram-
ming of stromal cells to support the growth of adjacent epithelial 
tumor cells.23 In Figure 7, a hypothetical model summarizing he 
alterations in Cav-1 and MCT4 in the stroma of matched in situ 
and invasive breast carcinoma is shown.
The oxidative stress promoted by the tumor cells induces 
autophagy in cancer-associated fibroblasts (CAFS) that degrade 
Cav-1 in the in situ stromal compartment and also secrete energy-
rich metabolites, such as L-lactate, ketone bodies, and pyruvate 
as a consequence of metabolic alterations. During the progression 
to invasive carcinoma, the loss of Cav-1 induces MCT4 expres-
sion due to the amount of energy metabolites, used to promote 
cancer cell glycolysis, aggressive tumor growth, and, ultimately, 
invasion of breast cancer cells.
Many of the cited studies quantify one or both markers in 
breast cancer stroma. However, one potential limitation of the 
quantification methodologies used is the lack of a clear and repro-
ducible definition of stroma, especially regarding DCIS cases. 
In our case, since all IHC scoring was performed by the same 
experienced pathologist, we consider this does not affect internal 
validity and therefore does not affect the results obtained and 
conclusions drawn.
In summary, it was shown that the loss of stromal Cav-1 and 
the concomitant gain of stromal MCT4 have a putative role in 
Figure 4. Expression levels of stromal MCT4 in in situ and invasive carci-
nomas. There is a signi!cant increased expression of stromal MCT4 in the 
invasive component of breast carcinomas, when compared with DCIS.\
Table 1. Association between stromal Cav-1 and MCT4 expression levels in the transition from in situ to invasive breast carcinoma
MCT4 (in situ to invasive)
Loss of expression N (%) Maintenance of expression N (%) Gain of expression N (%)
Cav-1 (in situ 
to invasive)
Loss of expression N (%) 0 (0%) 4 (3%) 94 (75%)
Maintenance of 
expression N (%) 0 (0%) 12 (10%) 16 (12.5%)
Gain of expression N (%) 0 (0%) 0 (0%) 0 (0%)
P value ≤ 0.001
Figure 3. IHC expression of stromal Cav-1 in in situ and invasive components. Note the strong expression of Cav-1 in DCIS, from low (A and B, 100× and 
200×, respectively) to higher magni!cation (C, 400×).
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the transition from in situ to invasive carcinoma of the breast. 
Therefore, we propose that Cav-1 and MCT4 may represent valu-
able biomarkers for breast cancer progression. Thus, determining 
the nature of the cooperation between tumor cells and the micro-
environment that leads to invasion could identify therapeutic 
strategies to prevent the transition from in situ to invasive breast 
carcinoma.
Material and Methods
Case selection and TMA (tissue microarray) construction
Formalin-fixed and paraffin-embedded samples from 189 
tumors, harboring in situ and invasive carcinoma areas in the 
same block, were consecutively retrieved from our archives. 
Available data included patient’s age and clinicopathological fea-
tures, such as tumor size and lymph nodes status. Representative 
areas of the in situ and invasive breast carcinomas were selected 
on H&E-stained sections and marked on the correspondent 
individual paraffin block. Two tissue cores (2 mm in diameter) 
were obtained from each specimen for TMA construction with 
each TMA block (donor block) and deposited into a paraffin 
block (receptor block) using a TMA workstation (TMA builder 
ab1802, Abcam). In each TMA block, non-neoplastic breast and 
liver tissue cores were also included as controls and TMA guide, 
respectively. An H&E-stained section from each TMA block was 
reviewed to confirm the presence of morphological representative 
areas of the original lesions.
All morphological and IHC assessments were conducted by 
a pathologist (FS). The study was conducted under the national 
regulative law for the handling of biological specimens from 
tumor banks, the samples being exclusively available for research 
purposes in retrospective studies.
Cav-1 and MCT4 immunohistochemistry
IHC was performed using the HRP labeled polymer 
(DakoCytomation) for Cav-1 and with the Ultravision Detection 
System Anti-polyvalent HRP (Lab Vision Corporation) for 
MCT4. Antigen unmasking was performed using a dilution 
of 1:100 from a commercially available solution of citrate buf-
fer, pH = 6.0 (Vector Laboratories) at 98 °C. After the antigen 
retrieval procedure, the slides were washed in a phosphate buf-
fer solution (PBS) and submitted to blockage of the endogenous 
peroxidase activity by incubation of the slides in a 3% hydrogen 
peroxide (Panreac) in methanol (Sigma-Aldrich). The slides were 
further incubated with the primary antibodies for Cav-1 (2297; 
BD Biosciences, diluted 1:50) and for MCT4 (H-90; Santa Cruz 
Biotechnology, diluted 1:500), as previously described.24 All 
Figure 5. IHC expression of stromal MCT4 in in situ and invasive components. Note the strong MCT4 stromal expression in invasive component, from 
low (A and B, 100× and 200×, respectively) to high magni"cation (C, 400×).
Figure 6. Immunohistochemistry array showing protein expression levels of stromal Cav-1 and MCT4 in the progression from in situ to invasive carci-
nomas. Cases are arranged along the x-axis and proteins are arranged along the y-axis. Within the heat map, red represents gain of expression, green 
represents loss of expression, and yellow represents maintained expression from in situ to invasive carcinoma within the same case.
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reactions were revealed with diaminobenzidine (DAB) chromo-
gen (DakoCytomation).
For both IHC assays, positive controls were included in each 
run, in order to guarantee the reliability of the assays. Non-
neoplastic breast tissues, as well as normal breast surrounding the 
neoplastic cells, were considered internal controls.
Cav-1 and MCT4 immunohistochemistry evaluation
Cav-1 and MCT4 expression in stroma were evaluated using 
the previously described methodology.16-19,21 In summary, Cav-1 
and MCT4 were semi-quantitatively scored as negative (0, no 
staining), weak (1, either diffuse weak or strong staining in less 
than 30% of stromal cells per core), or strong (2, defined as 
strong staining in 30% or more of the stromal cells).21
Statistical analysis
Statistical analyses were conducted using StatView 5.0 sof-
ware (SAS Institute Inc). The associations between categorical 
variables were tested for statistical significance using the chi-
square test. A two-tailed significance level of 5% was considered 
as statistically significant (P < 0.05).
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Figure 7. Alterations in Cav-1 and MCT4in the stroma of matched in situ and invasive breast carcinoma. (A) H&E-stained tissue section of human breast 
cancer, showing in situ and invasive components of breast carcinoma (100×). (B) Hypothetical model summarizing the importance of Cav-1 and MCT4 
in the progression from DCIS to IDC. During the progression to invasive carcinoma, Cav-1 is degraded by oxidative stress-induced autophagy in cancer-
associated "broblasts, resulting in a loss of Cav-1. At the same time, the loss of Cav-1 induces a metabolic reprogramming of stromal cells, where cancer 
cells induce upregulation of MCT4 by stromal "broblasts, in invasive counterpart.
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Factors implicated in the progression from 
ductal carcinoma in situ (DCIS) to invasive 
ductal carcinoma (IDC) remain unclear. A new 
study by Martins et al. demonstrates that there 
is di!erential expression of stromal caveolin 
1 (Cav-1) and monocarboxylate transporter 4 
(MCT4) between DCIS and IDC. Loss of Cav-1 
and gain of MCT4 in the stroma are markers of 
oxidative stress and glycolysis, and this pheno-
type is found during the progression from DCIS 
to IDC. Also, loss of stromal Cav-1 and increased 
stromal MCT4 expression is associated with 
aggressive disease and poor outcomes in DCIS, 
IDC, prostate cancer, and head and neck can-
cer. Metabolic modulators and antioxidants 
can rescue Cav-1 expression and downregulate 
MCT4 stromal expression. New clinical trials in 
DCIS and IDC, studying the e"cacy of meta-
bolic modulators, need to be initiated.
Ductal carcinoma in situ (DCIS) is a non-
invasive breast cancer where carcinoma cells 
are con#ned by the basement membrane of 
the breast duct. The natural history of DCIS 
ranges from quiescent disease to the devel-
opment of invasive ductal carcinoma (IDC), 
which is a life-threatening condition. DCIS is 
the precursor lesion for IDC, but the step-wise 
transformation events that drive its progres-
sion are unknown. Only 15% of cases progress 
from DCIS to IDC, so most DCIS lesions will not 
impact survival.
Our understanding of tumor metabolism 
has evolved signi#cantly over the past 5 y, 
and we now recognize that there is signi#-
cant stromal–epithelial metabolic coupling. 
Stromal glycolysis and carcinoma cell mito-
chondrial metabolism via oxidative phosphor-
ylation (OXPHOS) has been termed the reverse 
Warburg e!ect, and this occurs frequently in 
human cancers. The reverse Warburg e!ect 
is associated with aggressive disease and 
poor outcomes in DCIS, IDC, prostate cancer, 
gastric cancer, head and neck cancer, and 
melanoma.1-4
A recent study by Martins et al. seeks to 
address the question of step-wise transfor-
mation from DCIS to IDC. They compared 
the stromal metabolism in regions a!ected 
by DCIS and IDC from the same subjects.5 
Samples from over 180 subjects, with evi-
dence of DCIS and IDC in the same tissue 
blocks were stained for caveolin 1 (Cav-1) and 
monocarboxylate transporter 4 (MCT4). Loss 
of Cav-1 is a marker of glycolytic metabolism, 
stabilization of hypoxia-inducible factor 1 α 
(HIF-1α), lactate generation, high oxidative 
stress, and impaired mitochondrial oxidative 
phosphorylation metabolism. In addition, 
loss of stromal Cav-1 has been associated 
with poor outcomes in IDC and high risk of 
progression from DCIS to IDC.1 Loss of Cav-1 
in IDC compared with DCIS was found in 75% 
of cases.5 No increase in Cav-1 expression was 
found in the progression from DCIS to IDC in 
any of the samples.
Martins et al. also studied MCT4 expres-
sion in the tumor stroma. MCT4 is the main 
exporter of lactate out of cells. Expression of 
MCT4 is directly regulated by HIF-1α and lac-
tate generation. High stromal MCT4 expres-
sion is associated with poor outcomes in 
triple-negative breast cancer.2 Stromal MCT4 
expression was low in over 90% of DCIS 
regions, while low MCT4 levels were observed 
in less than 10% of IDC regions.5 Importantly, 
no decrease in MCT4 expression was found in 
the progression from DCIS to IDC in any of the 
samples.5
Experimentally, direct contact between 
breast carcinoma cells and stromal cells is suf-
#cient to induce loss of Cav-1 and gain of MCT4 
expression in the stroma, which are markers 
of a catabolic state with increased glycolysis 
and oxidative stress6,7 (Fig. 1). FDA-approved 
medications, such as the mitochondrial inhibi-
tor metformin and the antioxidant N-acetyl 
cysteine, can reverse cancer stroma Cav-1 and 
MCT4 expression to that of normal stroma.6,7
Thus, stromal transformation to glycolytic 
metabolism is a new hallmark of progression 
from DCIS to IDC, and it will be important to 
evaluate inhibitors of stromal transformation 
in DCIS and IDC-based clinical trials.
In summary, stromal glycolytic changes 
induce aggressive cancer experimentally, and 
human studies have revealed an association 
between stromal glycolysis and poor out-
comes in DCIS and IDC.1,2 Invasion through 
the basal membrane of carcinoma cells is 
su"cient to induce stromal metabolic repro-
gramming.5 Hence, metabolic reprogram-
ming of the microenvironment is a key step 
in cancer progression, and we may be able 
to better predict which patients will develop 
IDC in the setting of DCIS, by characterizing 
stromal metabolism rather than by features of 
carcinoma cells.
Biomarkers and novel therapies target-
ing stromal metabolism in DCIS are urgently 
needed. The results of these studies may allow 
us to improve outcomes for patients with DCIS 
that will progress to IDC and avoid unneces-
sary procedures in patients with indolent 
DCIS.
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Figure 1. Two-compartment tumor metabolism: Glycolytic stromal cells “fuel” cancer cell aggressiveness during DCIS progression to invasive breast can-
cer. A catabolic tumor stroma generates and transfers high-energy glycolytic metabolites (monocarboxylates such as L-lactate) to epithelial cancer cells 
in invasive ductal carcinoma (IDC) with basement membrane invasion. Mitochondrial oxidative phosphorylation metabolism (OXPHOS) is enhanced by 
this catabolite transfer. Conversely, an intact basement membrane inhibits catabolite transfer from stroma to carcinoma cells in ductal carcinoma in situ 
(DCIS), and hence OXPHOS metabolism is reduced in carcinoma cells. Caveolin-1 and monocarboxylate transporter 4 (MCT4) expression in the stroma 
are markers of catabolite transfer to carcinoma cells and OXPHOS metabolism in carcinoma cells. Thus, Cav-1 and MCT4 are biosensors of the glycolytic 
switch that occurs in the tumor stroma during the transition to malignancy. Normal !broblasts are oxidative and are Cav-1(+) and MCT4(-). Conversely, 
cancer-associated !broblasts are glycolytic and are Cav-1(-) and MCT4(+). Modi!ed, with permission, from reference 8.
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P-Cadherin as Prognostic Factor for 
Loco-Regional Relapse in Breast Cancer
Caderina-P: Valor Prognóstico na Recidiva Loco-regional do Cancro da Mama
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RESUMO
Introdução:2FDQFURGDPDPDpRWXPRUPDOLJQRPDLVIUHTXHQWHHDSULQFLSDOFDXVDGHPRUWHQDVPXOKHUHVHP3RUWXJDO'HYLGRj
VXDUHODomRFRPDPHWDVWL]DomRjGLVWkQFLDHPRUWHVXEVHTXHQWHDUHFLGLYDORFRUHJLRQDOpXPDGDVPDLRUHVSUHRFXSDo}HVQRVHJXL
PHQWRGHVWDVGRHQWHV6mRFRQKHFLGRVGLYHUVRVIDFWRUHVFOiVVLFRVGHSURJQyVWLFRSDUDUHFLGLYDORFDOWDLVFRPRRWDPDQKRGRWXPRU
RHVWiGLRWXPRUDOJUDXKLVWROyJLFRSRVLWLYLGDGH+(5HDH[SUHVVmRGHUHFHSWRUHVKRUPRQDLV&RQWXGRH[LVWHKHWHURJHQHLGDGHQR
SURJQyVWLFRHQRFRPSRUWDPHQWRGRWXPRUHPGRHQWHVFRPHVWDGLDPHQWRVHPHOKDQWHHFRPDPHVPDH[SUHVVmRGHPDUFDGRUHVPR
OHFXODUHVGHSURJQyVWLFR'DtDGYpPDQHFHVVLGDGHGHGHVFREULUQRYRVIDFWRUHVSURJQyVWLFRV8PDGDVSRVVLELOLGDGHVpD3FDGHULQD
SUHYLDPHQWHGHVFULWDFRPRXPSRVVtYHOPDUFDGRULQGHSHQGHQWHGHSURJQyVWLFRQRFDQFURGDPDPD2REMHFWLYHGHVWHWUDEDOKRIRL
HVWXGDUDFRUUHODomRGDH[SUHVVmRGH3FDGHULQDFRPDUHFRUUrQFLDORFRUHJLRQDOGRFDQFURGDPDPD
Material e métodos:$QDOLViPRVRVUHJLVWRVFOtQLFRVGHGRHQWHVFRQVHFXWLYRVFRPFDQFURGDPDPDHWUDWDGRVQDQRVVDLQVWL
WXLomRGXUDQWHXPSHUtRGRGHDQRV2VGRHQWHVFRPUHFRUUrQFLDORFRUHJLRQDOQ VHPHYLGrQFLDRXKLVWyULDGHPHWDVWL]DomR
jGLVWkQFLDIRUDPVHOHFLRQDGRVFRPRFDVRV2JUXSRGHFRQWURORFRQVLVWLXHPGRHQWHVFRPPDLVGHDQRVGHVHJXLPHQWRVHP
SURJUHVVmRGDGRHQoDRQFROyJLFD(PDPERVRVJUXSRVIRUDPDQDOLVDGDVYDULiYHLVGHPRJUi¿FDVFOtQLFDVSDWROyJLFDVHPROHFXOD
UHV3DUDHVWXGRGDH[SUHVVmRGD3FDGHULQDIRUDPFRQVWUXtGRV7LVVXH0LFUR$UUD\VDSDUWLUGHWXPRUHVFRPEORFRVGHSDUD¿QD
GLVSRQtYHLV
Resultados2WHPSRPpGLROLYUHGHGRHQoDIRLGHPHVHVHDVREUHYLGDPHGLDDSyVDUHFRUUrQFLDIRLGHPHVHV$WD[DGHVREUH
YLYrQFLDDRVDQRVIRLGH2WDPDQKRGRWXPRUHVWDGLDPHQWRJDQJOLRQDUHJUDXKLVWROyJLFRIRUDPLGHQWL¿FDGRVFRPRPDUFDGRUHV
LQGHSHQGHQWHVGHSURJQyVWLFR$3FDGHULQDDVVRFLRXVHFRPJUDXVKLVWROyJLFRVPDLVDOWRVHWXPRUHVVHPH[SUHVVmRGHUHFHSWRUHV
KRUPRQDLV$3FDGHULQDIRLLGHQWL¿FDGDFRPRXPDPDUFDGRULQGHSHQGHQWHGHSURJQyVWLFRSDUDDUHFLGLYDOLYUHGHGRHQoDPDVQmR
SDUDDVREUHYLYrQFLDJOREDO
Conclusão: $3FDGHULQDVXUJLXDVVRFLDGDDRXWURVIDFWRUHVMiFRQKHFLGRVGHSLRUSURJQyVWLFRHDXPDUHODomRLQGHSHQGHQWHFRP
DVREUHYLYrQFLDOLYUHGHGRHQoD$3FDGHULQDSRGHYLUDFRQVWLWXLUXPDOYRWHUDSrXWLFDH[SORUDUPDVRVHXUHDOYDORUELROyJLFRDLQGD
QmRHVWiGHWHUPLQDGR6XEVLVWHDG~YLGDVREUHVHD3FDGHULQDpXPPDUFDGRULQGHSHQGHQWHGHSURJQyVLFRRXDSHQDVXPPDUFDGRU
GHXPFRQMXQWRGHFDUDFWHUtVWLFDVFOtQLFRSDWROyJLFDVUHODFLRQDGDVFRPSLRUSURJQyVWLFR
ABStRACt
Background:%UHDVWFDQFHULVWKHPRVWIUHTXHQWPDOLJQDQWWXPRUDQGWKHOHDGLQJFDXVHRIFDQFHUGHDWKLQZRPHQLQ3RUWXJDO'XH
WRLWVUHODWLRQWRDQLQFUHDVHLQGLVWDQWPHWDVWDVLVDQGVXEVHTXHQWGHDWKORFRUHJLRQDOUHODSVHLVRQHPDMRUFRQFHUQLQEUHDVWFDQFHU
ZRPHQ6HYHUDOFODVVLFSURJQRVWLFIDFWRUVDVWXPRXUVL]HQRGDOVWDJHKLVWRORJLFDOJUDGH+(5VWDWXVDQGKRUPRQDOUHFHSWRUVKDYH
EHHQLGHQWL¿HGDVWKHPRVWLPSRUWDQWIDFWRUVIRUGHWHUPLQLQJORFRUHJLRQDOUHODSVHGLVHDVHIUHHDQGRYHUDOOVXUYLYDO+RZHYHUWKHUHLV
KHWHURJHQHLW\LQSURJQRVLVDQGWXPRUEHKDYLRXULQSDWLHQWVZLWKLGHQWLFDOGLVHDVHVWDJLQJDQGDVLPLODUSDWWHUQRIH[SUHVVLRQRINQRZQ
PROHFXODUPDUNHUVKHQFHWKHQHHGWRGLVFRYHUQHZSURJQRVWLFIDFWRUV2QHRIWKHSRVVLELOLWLHVLV3FDGKHULQDOUHDG\GHVFULEHGE\
UHVHDUFKHUVDVDSRVVLEOHLQGHSHQGHQWPDUNHURISURJQRVLVLQEUHDVWFDQFHU7KHDLPRIWKLVZRUNZDVWRVWXG\LQDUHWURVSHFWLYHVHULHV
RISDWLHQWVWKHFRUUHODWLRQRI3FDGKHULQH[SUHVVLRQZLWKORFRUHJLRQDOUHFXUUHQFHLQEUHDVWFDQFHUZRPHQ
Material and methods::HDQDO\]HGWKHFOLQLFDOUHFRUGVRIFRQVHFXWLYHSDWLHQWVZLWKEUHDVWFDQFHUDQGWUHDWHGLQD8QLYHUVLW\
+RVSLWDORYHUD\HDUSHULRG3DWLHQWVZLWKORFRUHJLRQDOUHODSVHQ ZLWKRXWSULRURUVLPXOWDQHRXVGLVWDQWGLVHDVHZHUHVHOHFWHG
DVFDVHJURXS&RQWUROJURXSFRQVLVWHGRISDWLHQWVZLWKPRUHWKDQ\HDUVIROORZXSDQGZLWKRXWGLVHDVHSURJUHVVLRQ)RUERWKJURXSV
GHPRJUDSKLFFOLQLFDOSDWKRORJLFDODQGPROHFXODUPDUNHUVZHUHDQDO\]HG7LVVXHPLFURDUUD\VZHUHFRQVWUXFWHGWRVWXG\3FDGKHULQ
H[SUHVVLRQIURPWXPRUVZLWKDYDLODEOHSDUDI¿QHPEHGGHGEORFNV
Results:0HDQWLPHWRUHFXUUHQFHZDVPRQWKVDQGPHDQVXUYLYDOWLPHDIWHUUHFXUUHQFHZDVPRQWKVZLWKD\HDUVXUYLYDOUDWH
RI7XPRXUVL]HQRGDOVWDWXVDQGKLVWRORJLFDOJUDGHZHUHLGHQWL¿HGDVLQGHSHQGHQWPDUNHUVRISURJQRVLV3FDGKHULQZDVDVVRFL
DWHGZLWKKLJKHUKLVWRORJLFDOJUDGHVDQGKRUPRQHQHJDWLYHWXPRXUV3FDGKHULQZDVLGHQWL¿HGDVDQLQGHSHQGHQWSURJQRVWLFPDUNHUIRU
GLVHDVHIUHHVXUYLYDOEXWQRWIRURYHUDOOVXUYLYDO
Conclusion:3FDGKHULQZDVUHODWHGWRRWKHUNQRZQIDFWRUVRIZRUVHSURJQRVLVDQGKDGDQLQGHSHQGHQWUHODWLRQWRGLVHDVHIUHHVXU
YLYDO3FDGKHULQPLJKWFRQVWLWXWHDQRYHOWKHUDSHXWLFWDUJHWEXWLWVUHDOELRORJLFDOYDOXHLV\HWWREHGHWHUPLQHG'RXEWSHUVLVWVZKHWKHU
LWLVDQLQGHSHQGHQWPDUNHURIWXPRXUEHKDYLRXURURQO\DVXUURJDWHPDUNHURIDVHWRIFOLQLFDODQGPROHFXODUIHDWXUHVUHODWHGZLWKZRUVH
SURJQRVLV
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INtRODUCtION
 %UHDVW FDQFHU LV WKH PRVW IUHTXHQW PDOLJQDQW WXPRXU
DQG WKH OHDGLQJFDXVHRIFDQFHU UHODWHGGHDWK LQZRPDQ
ZLWKRQHPLOOLRQFDVHVDQGKDOIDPLOOLRQGHDWKVHDFK\HDU
ZRUOGZLGH&XPXODWLYH LQGLYLGXDO ULVN RI EUHDVW FDQFHU LV
HVWLPDWHGLQDSSUR[LPDWHO\LQHDFKZRPHQDQG
WKHULVNRIGHDWKPLJKWEHXSWRDSSUR[LPDWHO\LQHDFK
ZRPHQ
 /RFRUHJLRQDO UHODSVH RI EUHDVW FDQFHU LV D IUHTXHQW
FRQFHUQLQWKHWUHDWPHQWRIWKLVGLVHDVHDVLWKDVEHHQHV
WDEOLVKHG DV DQ LQGHSHQGHQW SURJQRVWLF IDFWRU IRU GLVWDQW
PHWDVWDVLV DQG VXEVHTXHQW GHDWK +RZHYHU ZKHWKHU LW
FRQVWLWXWHVDFDXVHIRUGLVWDQWPHWDVWDVLVRURQO\DPDUNHU
RIDQH[LVWLQJULVNUHPDLQVDPDWWHURIGHEDWH
6HYHUDOFOLQLFDODQGSDWKRORJLFDOSDUDPHWHUVKDYHEHHQ
XVHGWRGHWHUPLQHQRWRQO\SURJQRVLVEXWDOVRWKHQHHGRI
DGMXYDQW V\VWHPLF WKHUDSLHV 7KHPRVW FRPPRQ RI WKHVH
DUHDJHVL]HQRGDOVWDJLQJKLVWRORJLFDOJUDGHKRUPRQDO
UHFHSWRUVDQG+(5SRVLWLYH
:LWK WKHGHYHORSPHQWRIQHZPLFURDUUD\V WHFKQLTXHV
LW EHFDPH SRVVLEOH WR VLPXOWDQHRXVO\ DQDO\]H WKRXVDQGV
RIJHQHVDQGFODVVLI\WXPRXUVDFFRUGLQJWRWKHLUSUR¿OHRI
JHQHWLFH[SUHVVLRQ$VVXFKDQHZFODVVL¿FDWLRQRIEUHDVW
FDQFHU ZDV GHYHORSHG EDVHG RQ SUR¿OHV RI JHQHWLF H[
SUHVVLRQ)LYHGLIIHUHQWJURXSVZLWKSURJQRVWLFGLIIHUHQFHV
ZHUHLGHQWL¿HGOXPLQDO$OXPLQDO%EDVDOQRUPDOOLNHDQG
+(5
$OWKRXJK WKLV QHZ FODVVL¿FDWLRQZDV EDVHG RQ WKH KL
HUDUFKLFDO FOXVWHU DQDO\VLV RI JHQHWLF H[SUHVVLRQ VRPH
FXUUHQWO\DYDLODEOH LPXQRKLVWRFKHPLVWU\PDUNHUVDOORZ WKH
WUDQVODWLRQ RI WKLV FODVVL¿FDWLRQ WR WKH URXWLQH SDWKRORJ\
SUDFWLFH 6SHFL¿FDOO\ EDVHG RQ  PDUNHUV (5 35 DQG
+(5JURXSVFDQEHGLYLGHGLQWROXPLQDOW\SHSRVLWLYHIRU
(5RU35+(5SRVLWLYHRU WULSOHQHJDWLYH (535DQG
+(5QHJDWLYH7KHSURJQRVWLFHYDOXDWLRQRISDWLHQWVLQ
WKH WULSOHQHJDWLYHJURXSUHYHDOHGDW OHDVWJURXSVRI WX
PRUVRQHRIWKHPH[SUHVVLQJPDUNHUVRIEDVDOGLIIHUHQWLD
WLRQ&.(*)53FDGKHULQDQGDQRWKHUZLWKRXWH[SUHV
VLRQRIWKHVHPDUNHUVFRQVLGHUHGXQFODVVL¿HG
 /RFRUHJLRQDOUHODSVHLVDQHDUO\DQGLPSRUWDQWPDUNHU
RI GLVHDVH SURJUHVVLRQ +RZHYHU UHJDUGLQJ SDWLHQWV ZLWK
LGHQWLFDOVWDJLQJDQGDVLPLODUSDWWHUQRIH[SUHVVLRQRIPR
OHFXODUPDUNHUVWKHUHLVDVLJQL¿FDQWGLVFUHSDQF\LQGLVHDVH
SURJUHVVLRQDQGSURJQRVLVKHQFHWKHQHHGWRIXUWKHUGLV
FRYHU QHZ SURJQRVWLF IDFWRUV DQG VWUDWLI\ ULVN IRU GLVHDVH
SURJUHVVLRQ
2QH RI WKHPROHFXOHV XVHG WR FODVVLI\ WKH WXPRXU DV
EDVDOOLNHLV3FDGKHULQZKLFKLVDVVRFLDWHGZLWKLQFUHDVHG
SUROLIHUDWLRQDQGXQGLIIHUHQWLDWHGSKHQRW\SH
 8QOLNH HSLWKHOLDO FDGKHULQ (FDGKHULQ 3FDGKHULQ
H[SUHVVLRQ LV XVXDOO\ UHODWHG WR WXPRURJHQLF SURSHUWLHV
DOORZLQJ IRUFHOOXODU LQYDVLYHQHVVDQGWXPRUDODJJUHVVLYH
)DULD*et al3&DGKHULQ3URJQRVWLF)DFWRUIRU/RFR5HJLRQDO5HODSVH%UHDVW&DQFHU$FWD0HG3RUW0DU$SU
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Study population
Exclusion criteria
0DOHJHQGHU
/RVVRIIROORZXS
/DFNRISDWKRORJLFDOPDWHULDO
TMA’s
1432
patients
Cases
101
Controls
92
70 52
53 33
Fig. 16FKHPDWLFUHSUHVHQWDWLRQRIWKHFRKRUW
5HYLVWD&LHQWt¿FDGD2UGHPGRV0pGLFRVZZZDFWDPHGLFDSRUWXJXHVDFRP99
table 1   6RXUFHVDQGGLOXWLRQVRISULPDU\DQWLERGLHVXVHGLQWKLVLPPQRKLVWRFKHPLVWU\
$QWLERG\ &ORQH 0DQXIDFWXUHU ,QFXEDWLRQWLPHP 'LOXWLRQ $QWLJHQUHWULHYDOP
(5 63 1HRPDUNHUV   
35 $ 1HRPDUNHUV   
+(5 63 1HRPDUNHUV   
3FDG  7UDQVGXFWLRQ   
&. ;0 1HRPDUNHUV   
)DULD*et al3&DGKHULQ3URJQRVWLF)DFWRUIRU/RFR5HJLRQDO5HODSVH%UHDVW&DQFHU$FWD0HG3RUW0DU$SU
QHVV WUDQVODWLQJ LQWR D ZRUVW SURJQRVLV LQ EUHDVW FDQFHU
SDWLHQWV ,WV H[SUHVVLRQ LV XVXDOO\ DVVRFLDWHG ZLWK RWKHU
NQRZQIDFWRUVRIZRUVHSURJQRVLVKLJKKLVWRORJLFDOJUDGH
KLJKSUROLIHUDWLYHUDWHDQGODFNRIHVWURJHQUHFHSWRUV
2XU REMHFWLYH LQ WKLV UHWURVSHFWLYH VHULHV RI SDWLHQWV
ZDVWRHYDOXDWHWKHFRUUHODWLRQRI3FDGKHULQH[SUHVVLRQLQ
EUHDVWFDQFHUORFRUHJLRQDOUHODSVHGLVHDVHIUHHDQGRYHU
DOOVXUYLYDO
MAtERIAL AND MEtHODS
:H SHUIRUPHG D QHVWHG FDVHFRQWURO VWXG\ DQG DQD
O\]HG WKH FOLQLFDO UHFRUGV RI  FRQVHFXWLYH SDWLHQWV
WUHDWHG DQG IROORZHG DW+RVSLWDO GH6mR -RmR 8QLYHUVLW\
+RVSLWDORI3RUWR)DFXOW\RI0HGLFLQHGXULQJD\HDUSH
ULRG-DQXDU\VWWR'HFHPEHUVW7KHFDVH
JURXSFRQVLVWHGRIDOO WKHSDWLHQWV Q ZLWK ORFR
UHJLRQDO UHODSVH ZLWKRXW SUHYLRXV RU FRQFXUUHQW V\VWHPLF
SURJUHVVLRQ
/RFRUHJLRQDO UHODSVHDIWHUEUHDVWFDQFHUVXUJHU\ZDV
GH¿QHGDVWKHRQVHWRIKLVWRORJLFDOO\FRQ¿UPHGFDUFLQRPD
DWOHDVWLQRQHRIWKHIROORZLQJORFDWLRQVUHPDLQLQJEUHDVW
WLVVXH VNLQ VXEFXWDQHRXV WLVVXH RU PXVFOH RI LSVLODWHUDO
WKRUDFLFZDOOD[LOODU\VXSUDFODYLFXODURULQWHUQDOPDPPDU\
O\PSKQRGHV
$VWKHPDMRULW\RIORFRUHJLRQDOUHODSVHVRFFXUVEHIRUH
\HDUVDIWHUWKHLQLWLDOGLDJQRVLVIRUFRQWUROJURXSZHVH
OHFWHGSDWLHQWVZLWKPRUHWKDQ\HDUVRIIROORZXSZLWKRXW
GLVHDVHSURJUHVVLRQSDWLHQWVVXUJLFDOO\WUHDWHGEHWZHHQ
-DQXDU\VWDQG-XQHWK
0DOH SDWLHQWV SDWLHQWV ORVW WR IROORZXS DQG WKRVH
ZKLWKRXW PDWHULDO DYDLODEOH IRU SDWKRORJLFDO UHHYDOXDWLRQ
ZHUHH[FOXGHGIURPWKHVWXG\)LQDOFDVHJURXSFRQVLVWHGRI
SDWLHQWVRIWKHLQLWLDOVDPSOHZLWKORFRUHJLRQDO
UHODSVHFDVHVDQGSDWLHQWVRIWKHLQLWLDOVDPSOH
ZLWKRXWGLVHDVHSURJUHVVLRQFRQWUROJURXS
&ODVVLFDO FOLQLFDO DQG SDWKRORJLFDO SDUDPHWHUV ZHUH
HYDOXDWHG LQDOO SDWLHQWV DJH VL]H W\SHRI VXUJLFDO WUHDW
PHQW 710 VWDJLQJ KLVWRORJLFDO W\SH KLVWRORJLFDO JUDGH
SUHVHQFHRIDVVRFLDWHG'&,6VL]H O\PSKDWLFDQGYHQRXV
LQYDVLRQ 1RWWLQJKDP 3URJQRVWLF ,QGH[ >13,@ DQG HV
WURJHQ UHFHSWRUV0ROHFXODU FODVVL¿FDWLRQ /XPLQDO+(5
>+(55(53@ WULSOHQHJDWLYHDQG3FDGKHULQH[
SUHVVLRQZHUHVWXGLHGXVLQJLPPXQRKLVWRFKHPLVWU\ LQ7LV
VXH0LFUR$UUD\V (70$¶V)
,QRXUVHULHVRQO\FDVHVDQGFRQWUROVKDGSDUDI
¿QHPEHGGHGEORFNVDYDLODEOHIRUWKHFRQVWUXFWLRQRI70$¶V
)LJ1HZVHFWLRQVRIWKHWXPRXUVWDLQHGZLWKKHPDWR[\
OLQHRVLQZHUHXQGHUWDNHQLQWKRVHEORFNV5HSUHVHQWDWLYH
DUHDVZHUHVHOHFWHGDQGPDUNHGIRU70$FRQVWUXFWLRQ
5HSUHVHQWDWLYH DUHDV RI LQYDVLYH EUHDVW FDUFLQRPD
ZHUHFDUHIXOO\VHOHFWHGRQKDHPDWR[\OLQDQGHRVLQVWDLQHG
VHFWLRQVDQGPDUNHGRQWKHFRUUHVSRQGHQWLQGLYLGXDOSDUDI
¿Q EORFNV7ZR WLVVXH FRUHV PP LQ GLDPHWHUZHUH RE
WDLQHGIURPHDFKVHOHFWHGVSHFLPHQGRQRUEORFNDQGGH
SRVLWHG LQWRDSDUDI¿QEORFNUHFHSWRUEORFNXVLQJD70$
ZRUNVWDWLRQ70$EXLOGHUDE$EFDP&DPEULGJH8.
7ZHQW\WZR70$EORFNVZHUHFRQVWUXFWHGHDFKFRQWDLQLQJ
 WLVVXHFRUHV [ ,QHDFK70$EORFNQRQQHRSODVWLF
EUHDVWDQGOLYHUWLVVXHFRUHVZHUHDOVRLQFOXGHGDVFRQWUROV
DQG70$JXLGH UHVSHFWLYHO\$IWHU FRQVWUXFWLRQ WZRȝP
WLVVXH VHFWLRQV ZHUH FXW DQG DGKHUHG WR 6XSHUIURVW 3OXV
JODVV VOLGHV$Q+(VWDLQHGVHFWLRQ IURPHDFKEORFNZDV
UHYLHZHG WRFRQ¿UP WKHSUHVHQFHRIPRUSKRORJLFDO UHSUH
VHQWDWLYHDUHDVRIWKHRULJLQDOOHVLRQV6HFWLRQVZHUHLPPX
QRVWDLQHGZLWKSULPDU\PRQRFORQDODQWLERGLHVDJDLQVW(5
35+(5DQG3FDG,PPXQRVWDLQLQJIRU(5DQG+(5
ZHUHSHUIRUPHGXVLQJ WKHVWUHSWDYLGLQELRWLQSHUR[LGDVH
WHFKQLTXH/DE9LVLRQ)UHPRQW&$86$ZKHUHDV35DQG
3FDGLPPXQRVWDLQLQJXVHGWKH+53ODEHOHGSRO\PHU'D
NR&\WRPDWLRQ&DUSLQWHULD&$86$
$QWLJHQXQPDVNLQJIRU(535DQG+(5ZDVFDUULHG
RXW XVLQJ D GLOXWLRQ RI  IURP D FRPPHUFLDOO\ DYDLO
DEOHVROXWLRQRIFLWUDWHEXIIHUS+ 9HFWRU/DERUDWRULHV
%XUOLQJDPH&$86$DW&ZKHUHDVDGLOXWLRQRI
IURP WULVHWK\OHQHGLDPLQHWHWUDDFHWLF ('7$ VROXWLRQ ZLWK
S+ 'DNR&\WRPDWLRQZDVXVHGIRU3FDG
$QWLJHQUHWULHYDO WLPHDQWLERGLHVGLOXWLRQVDQGVXSSOL
HUVDUHOLVWHGLQ7DEOH$IWHUDQWLJHQUHWULHYDOSURFHGXUH
VOLGHVZHUHZDVKHG LQDSKRVSKDWHEXIIHUVROXWLRQ3%6
DQGVXEPLWWHG WREORFNDJHRI WKHHQGRJHQRXVSHUR[LGDVH
DFWLYLW\E\ LQFXEDWLRQRI WKHVOLGHV LQDK\GURJHQSHU
R[LGH3DQUHDF6SDLQLQPHWKDQRO6LJPD$OGULFK6OLGHV
ZHUH IXUWKHU LQFXEDWHG ZLWK D EORFNLQJ VHUXP /DE9LVLRQ
&RUSRUDWLRQ NLW IRU  PLQ DQG WKHQ LQFXEDWHG ZLWK WKH
SULPDU\ DQWLERGLHV$IWHU ZDVKLQJ VOLGHV ZHUH LQFXEDWHG
ZLWKELRWLQ\ODWHGVHFRQGDU\DQWLERG\IROORZHGE\VWUHSWDY
LGLQFRQMXJDWHGSHUR[LGDVH /DE9LVLRQ'LDPLQREHQ]LGLQH
'$%ZDV XVHG DV D FKURPRJHQ 'DNR&\WRPDWLRQ )RU
35DQG3FDGVWDLQLQJVHFRQGDU\DQWLERG\ZDVDVVRFLDWHG
ZLWK+53ODEHOOHGSRO\PHU'DNR&\WRPDWLRQDQGLPPHGL
DWHO\UHYHDOHGZLWK'$%7LVVXHVZHUHWKHQFRXQWHUVWDLQLQJ
ZLWK0D\HUCV KDHPDWR[\OLQ GHK\GUDWHG DQG FRYHUVOLSSHG
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5HYLVWD&LHQWt¿FDGD2UGHPGRV0pGLFRVZZZDFWDPHGLFDSRUWXJXHVDFRP
7DEOH&KDUDFWHUL]DWLRQRIWKHFOLQLFDODQGSDWKRORJLFDOSDWWHUQDFFRUGLQJWRJURXS
&DVHVQ  &RQWUROVQ  p
$JH 1 1 
$JH  
7\SHRI6XUJHU\ 
/XPSHFWRP\  
0DVWHFWRP\   25±±
6XUJLFDO0DUJLQ 
'LVWDQFHWRPDUJLQPP  
&KHPRWKHUDS\ 
1R  
$GMXYDQW  
3UHRSHUDWLYH  
$GMXYDQW5DGLRWKHUDS\ 
1R  
Yes  
+RUPRQDOWUHDWPHQW 
1R  
Yes   25 
7106WDJLQJ 
,  
,,D  
,,E  
,,,D  
,,,E  
+LVWRORJLFDOJUDGH 
  
   25 
   25 ±
7 
  
   25±±
   25±±
   25±±
1 
  
   25 
  
  
/\PSKDWLFLQYDVLRQ 
1R  
Yes   25 
9HQRXVLQYDVLRQ 
1R  
Yes   25 
1RWWLQJKDP3URJQRVWLF,QGH[ 
$YHUDJH13,  
(5 
1HJ  
3RV   25 
0ROHFXODU&ODVVL¿FDWLRQ 
/XPLQDO  
+(5  
7ULSOH1HJDWLYH  
3FDGKHULQ 
1HJDWLYH  
3RVLWLYH   25 
)DULD*et al3&DGKHULQ3URJQRVWLF)DFWRUIRU/RFR5HJLRQDO5HODSVH%UHDVW&DQFHU$FWD0HG3RUW0DU$SU
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5HYLVWD&LHQWt¿FDGD2UGHPGRV0pGLFRVZZZDFWDPHGLFDSRUWXJXHVDFRP101
)DULD*et al3&DGKHULQ3URJQRVWLF)DFWRUIRU/RFR5HJLRQDO5HODSVH%UHDVW&DQFHU$FWD0HG3RUW0DU$SU
XVLQJ D SHUPDQHQWPRXQWLQJ VROXWLRQ =\PHG6DQ)UDQ
FLVFR&$86$
3RVLWLYH FRQWUROV ZHUH LQFOXGHG LQ HDFK UXQ WR JXDU
DQWHH DVVD\ UHOLDELOLW\$OO FDVHV VKRZLQJ DQ XQHTXLYRFDO
QXFOHDUVWDLQLQJIRU(5DQG35LQDWOHDVWRIWKHQHR
SODVWLFFHOOVZHUHFRQVLGHUHGSRVLWLYH:HDOVRFRQVLGHUHG
SRVLWLYHFDVHVZLWKPHPEUDQRXVVWDLQLQJIRU3FDGDQGLQ
DWOHDVWRIWKHQHRSODVWLFFHOOV+(5H[SUHVVLRQZDV
HYDOXDWHG DFFRUGLQJ WR WKH 'DNR&\WRPDWLRQ +HUFHS7HVW
VFRULQJ V\VWHP&DVHVZHUH FRQVLGHUHGSRVLWLYH RYHUH[
SUHVVLRQIRU+(5ZKHQLPPXQRVWDLQLQJZDVFODVVL¿HGDV
$OOWKHVDPSOHVZHUHEOLQGHGDQGUHYLHZHGE\WKHVDPH
H[SHULHQFHGSDWKRORJLVW
6WDWLVWLFDODQDO\VLVZDVGRQHXVLQJ63666366
,QF &KLFDJR ,OOLQRLV 86$ 7KH FKLVTXDUH FRQWLQJHQF\
WHVW ZDV XVHG IRU FDWHJRULFDO YDULDEOHV DQG WKH WVWXGHQW
ZDVXVHG IRUFRQWLQXRXVYDULDEOHV$SYDOXHRI OHVV WKDQ
ZDVFRQVLGHUHGWRUHÀHFWDVLJQL¿FDQWDVVRFLDWLRQ7KH
PXOWLYDULDWHDQDO\VLVZDVSHUIRUPHGZLWKDPRGHORIELQDU\
ORJLVWLFUHJUHVVLRQ7KHWLPHGHSHQGHQWYDULDEOHVZHUHDQ
DO\]HGZLWKWKH&R[UHJUHVVLRQPRGHODQGWKH.DSODQ0HLHU
FXUYHVZHUHEDVHGRQ OLIH WDEOHV)RU WKHPXOWLYDULDWH UH
JUHVVLRQPRGHOVZHVHOHFWHGWKHYDULDEOHVZLWKVLJQL¿FDQW
DVVRFLDWLRQZLWKWKHRXWFRPHRQXQLYDULDWHDQDO\VLVDQGLQ
WKH&R[UHJUHVVLRQPRGHOZHDOVRLQFOXGHGWKHW\SHRIV\V
WHPLF WUHDWPHQW WRFKHFN IRUSRWHQWLDOFRQIRXQGLQJRQ WKH
HIIHFWRI3FDGKHULQ
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7DEOH- /RJLVWLFUHJUHVVLRQIRUORFRUHJLRQDOUHODSVH
p OR
7\SHRIVXUJHU\  
     Histological grade 0.049 3.802
     t 0.034 4.672
     N 0.014 8.849
/\PSKDWLFLQYDVLRQ  
9HQRXVLQYDVLRQ  
(5  
7DEOH 3FDGKHULQH[SUHVVLRQDFFRUGLQJWRRWKHUPDUNHUVRISURJQRVLV
3FDGKHULQ 3RVLWLYHQ  1HJDWLYHQ  p
Molecular sub-type 0.002
/XPLQDO  
+(5  
7ULSOHQHJDWLYH    
MIB-1 0.003
3RVLWLYH  
1HJDWLYH  
tNM stage 0.807
,  
,,$  
,,%  
,,,$  
,,,%    
Histological grade 0.008
  
  
  
t 0.325
  
  
  
  
N 0.779
  
  
  
  
5HYLVWD&LHQWt¿FDGD2UGHPGRV0pGLFRVZZZDFWDPHGLFDSRUWXJXHVDFRP
7DEOH&R[UHJUHVVLRQ±2YHUDOOVXUYLYDODQGGLVHDVHIUHHVXUYLYDO
'LVHDVHIUHHVXUYLYDO 2YHUDOOVXUYLYDO
p +5>&,@ S +5>&,@
3FDGKHULQ 0.047 2.108 >@  >@
7 0.004 1.822 >@ 0.003 2.317 >@
1 < 0.001 2.780 >@  >@
*UDGH 0.001 3.326 >@ < 0.001 8.541 >@
0ROHFXODUFODVV  >@  >@
&KHPRWKHUDS\  >@  >@
+RUPRQHWKHUDS\  >@  >@
$QWL+(5WKHUDS\  >@  >@
)DULD*et al3&DGKHULQ3URJQRVWLF)DFWRUIRU/RFR5HJLRQDO5HODSVH%UHDVW&DQFHU$FWD0HG3RUW0DU$SU
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RESULtS
 0HDQ DJH DW GLDJQRVLV ZDV  \HDUV 0DVWHFWRP\
ZDV WKH W\SHRI VXUJHU\SHUIRUPHGRQ WKHPDMRULW\RISD
WLHQWV DQGRI WKHSDWLHQWVZHUHFODVVL¿HGDV
VWDJH,RU,,DFFRUGLQJWR710FODVVL¿FDWLRQ3UHGRPLQDQW
KLVWRORJLFDOW\SHZDVLQYDVLYHGXFWDOFDUFLQRPDDQG
KDOIWKHSDWLHQWVKDGJUDGH,,FDUFLQRPDV1RWWLQJ
KDPJUDGLQJV\VWHP)RUW\VHYHQSHUFHQWRISDWLHQWVKDG
O\PSKDWLFLQYDVLRQDQGRQO\KDGYHQRXVLQYDVLRQ$[
LOODU\VWDJLQJZDVQHJDWLYH 1 LQ(5H[SUHVVLRQ
ZDVSRVLWLYH LQRI WKHSDWLHQWVDQG35LQRI
WKHSDWLHQWV7KHPDMRULW\RIORFDOUHODSVHVRFFXUUHGLQWKH
UHPDLQLQJEUHDVW WLVVXHRU LQ WKH WKRUDFLFZDOO DQG
RIWKHFDVHVZHUHUHH[FLVHG$IWHUPRQWKVRIPHDQ
IROORZXSRIWKHSDWLHQWVDUHDOLYH
 7KHH[SUHVVLRQRIFODVVLFDOSURJQRVWLF IDFWRUV LV OLVWHG
LQ7DEOH0DVWHFWRP\ZDVDVVRFLDWHGZLWKKLJKHUUDWHVRI
ORFRUHJLRQDOUHODSVHEXWDOVRZLWKWKHH[SUHVVLRQRIVHYHUDO
PDUNHUVRIZRUVHSURJQRVLVODUJHUWXPRXUV>77YV
IRUEUHDVWFRQVHUYLQJVXUJHU\p @QRGDOPHWDV
WDVLV>YVp@O\PSKDWLF>YV
p@DQGYHQRXV>YVp @LQYDVLRQDQG
KLJKHU710VWDJHV>VWDJH,,,,9YVp @
 7KHVSHFLPHQ¶VVXUJLFDOPDUJLQVZHUHQRWGLIIHUHQWEH
WZHHQWKHJURXSVDQGSRVWRSHUDWLYHUDGLRWKHUDS\ZDVQRW
DVVRFLDWHGZLWKDGHFUHDVHLQORFDOUHODSVHULVN
 6WDJLQJ ZDV GLUHFWO\ DVVRFLDWHG ZLWK UHODSVH ULVN DV
ZHOODVKLVWRORJLFDOJUDGHDQG13,LQGH[7KHSUHVHQFHRI
O\PSKDWLF DQG YHQRXV LQYDVLRQZDV DOVR VWURQJO\ DVVRFL
DWHGZLWKORFRUHJLRQDOUHODSVH([SUHVVLRQRI(5ZDVLGHQ
WL¿HGDVDPDUNHURIEHWWHUSURJQRVLV
 0ROHFXODUFODVVL¿FDWLRQZDVDFKLHYHGE\WKHXVHRIURX
WLQH LPPXQRKLVWRFKHPLVWU\DQG WXPRXUVZHUHGLYLGHG LQWR
FDWHJRULHV(5RU35SRVLWLYH+(5RYHUH[SUHVVLQJRU
WULSOHQHJDWLYH7KHPDMRULW\RISDWLHQWVH[SUHVVHGOXPLQDO
W\SHPDUNHUVLQERWKJURXSVRIWKHFDVHVYV
RIWKHFRQWUROV7ULSOHQHJDWLYHWXPRXUVZHUHPRUHIUHTXHQW
LQSDWLHQWVZLWKORFRUHJLRQDOUHODSVHYVDOWKRXJK
WKLVYDOXHGLGQRWUHDFKVWDWLVWLFDOVLJQL¿FDQFH7DEOH
 7KH ORJLVWLF UHJUHVVLRQPRGHO 7DEOH  LGHQWL¿HG KLV
WRORJLFDO JUDGH VL]H DQG QRGDO LQYDVLRQ DV LQGHSHQGHQW
PDUNHUVRISURJQRVLV IRU ORFRUHJLRQDO UHODSVH2QFHFRU
UHFWHGIRURWKHUSURJQRVWLFIDFWRUVWKHW\SHRIVXUJHU\ZDV
QRORQJHUUHODWHGZLWKORFRUHJLRQDOUHODSVH
3FDGKHULQZDVSRVLWLYHLQRIFDVHVDQGRI
FRQWUROVp 25 7KHUHZDVDSRVLWLYHUHODWLRQRI
3FDGKHULQH[SUHVVLRQZLWKWKHQRQOXPLQDOPROHFXODUW\SHV
DQGZLWKKLJKHUSUROLIHUDWLYHLQGH[p DVPHDVXUHG
E\0,%7KHUHZHUHQRVLJQL¿FDQW UHODWLRQVEHWZHHQ3
FDGKHULQH[SUHVVLRQDQGRWKHUSURJQRVWLFPDUNHUVZLWKWKH
H[FHSWLRQRIKLJKHUKLVWRORJLFDOJUDGH7DEOH
3FDGKHULQH[SUHVVLRQZDV UHODWHG WRDVLJQL¿FDQWGH
FUHDVHp LQGLVHDVHIUHHVXUYLYDOIURPPRQWKV
WRPRQWKV)LJ+RZHYHUWKHVHHDUOLHUUHFXUUHQFHV
ZHUHQRWUHODWHGZLWKDGHFUHDVHLQRYHUDOOVXUYLYDO
PRQWKVYVPRQWKV±)LJGHVSLWH WKHGLIIHUHQFHV
REVHUYHGLQWKH\HDUVXUYLYDOUDWHYV
0XOWLYDULDWHDQDO\VLVRISURJQRVWLF IDFWRUV IRUGLVHDVH
IUHHVXUYLYDO 7DEOH LGHQWL¿HG3FDGKHULQH[SUHVVLRQDV
DQLQGHSHQGHQWIDFWRURISURJQRVLV+5 WRJHWKHUZLWK
WKHNQRZQFODVVLFDOIDFWRUVRISURJQRVLVWXPRUVL]HQRGDO
VWDJLQJDQGKLVWRORJLFDOJUDGH)RURYHUDOOVXUYLYDOWKHRQO\
LGHQWL¿HG LQGHSHQGHQW IDFWRUVZHUH WXPRU VL]H DQG KLVWR
ORJLFDOJUDGH
DISCUSSION
 7KHUHVHDUFKDURXQGQHZPROHFXODUPDUNHUVKDVULVHG
WUHPHQGRXVO\QRWRQO\EHFDXVH WKH\KDYH WKHFDSDFLW\ WR
DGGVRPH LQIRUPDWLRQDQGHQKDQFHGLVFULPLQDQWSRZHU WR
VFRUHVDOUHDG\DYDLODEOHZLWK FODVVLFDOPDUNHUVEXW DOVR
EHFDXVHWKH\FDQEULQJVRPHQHZXQGHUVWDQGLQJRYHUWKH
RQFRORJLFDOELRORJ\RUDULVHDVQHZSXWDWLYHWKHUDSHXWLFWDU
JHWV
 7KHPDMRUOLPLWDWLRQRIWKLVVWXG\LVWKHVKRUWQHVVRIWKH
VDPSOHDVZHFRXOGRQO\UHWULHYHWXPRUVIRU70$FRQ
VWUXFWLRQ$GGLWLRQDOO\ WKLV LV D UHWURVSHFWLYH VWXG\ZLWK D
\HDUVSDQDQGGXULQJWKLVSHULRGWKHWUHDWPHQWRIEUHDVW
FDQFHUVXIIHUHGVLJQL¿FDQWYDULDWLRQV
5HYLVWD&LHQWt¿FDGD2UGHPGRV0pGLFRVZZZDFWDPHGLFDSRUWXJXHVDFRP103
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)LJ.DSODQ0HLHUFXUYHVIRUGLVHDVHIUHHVXUYLYDODFFRUGLQJWR
3FDGKHULQH[SUHVVLRQ
)LJ   .DSODQ0HLHU FXUYHV IRU RYHUDOO VXUYLYDO DFFRUGLQJ WR
3FDGKHULQH[SUHVVLRQ
6HYHUDO VWXGLHV KDYH UHSRUWHG WKH ULVN RI ORFDO UHFXU
UHQFHDIWHUEUHDVWFDQFHUWUHDWPHQWDVEHLQJ De
VSLWHWKHUDSHXWLFLPSURYHPHQWVLQWKHODVWGHFDGHRI
WKHZRPHQZLWKORFDOUHFXUUHQFHZLOOKDYHGLVHDVHSURJUHV
VLRQDQGHYHQWXDOO\GHDWK ,QRXU VHULHV ORFDO UHFXUUHQFH
UDWHZDVDQGRIWKHVHZRPHQGLHGIURP
EUHDVWFDQFHUDVLQPRVWFOLQLFDOUHSRUWHGVWXGLHV
6HYHUDO VWXGLHV KDYH UHSRUWHG HLWKHU D VLPLODU RU LQ
FUHDVHG VXUYLYDO ZLWK EUHDVW FRQVHUYLQJ VXUJHU\ ZKHQ
FRPSDUHGWRPDVWHFWRP\,QRXUVHULHVEUHDVWFRQVHUYLQJ
VXUJHU\KDVDORQJHUPHGLDQVXUYLYDOYVPRQWKV
IRUPDVWHFWRP\0DVWHFWRP\LVDOVRUHODWHGWRDQLQFUHDVHG
ULVN RI ORFDO UHODSVH 25  +RZHYHU WKHVH UHVXOWV
PD\EH WKHFRQVHTXHQFHRIDDVHOHFWLRQELDVDV WXPRUV
RISDWLHQWVZKRKDGPDVWHFWRP\ LQRXUVHULHVSUHVHQWHG
ZLWK IHDWXUHV RIZRUVH SURJQRVLV VL]H QRGDOPHWDVWDVLV
KLVWRORJLFDOJUDGH710VWDJLQJDQG13,2QFHFRUUHFWHG
IRUWKHVHIDFWRUVWKHEHQH¿WRIFRQVHUYDWLYHVXUJHU\LVQR
ORQJHUGHWHFWDEOH
7XPRUVL]Hp DQGQRGDOVWDJLQJpZHUH
WZR LPSRUWDQW IDFWRUV RI SURJQRVLV IRU ORFDO UHFXUUHQFH
ZKLFKFRQ¿UPVWKHGDWDRIVHYHUDORWKHUVWXGLHVDQG
SDWLHQWVZLWKWXPRUVODUJHUWKDQFPKDGDIROGLQFUHDVH
LQ ORFDOUHFXUUHQFHDVFRPSDUHGZLWK WXPRUVVPDOOHU WKDQ
FP 25 4 $OVR DV GHVFULEHG LQ WKH OLWHUDWXUH 
SDWLHQWVZLWKD[LOODU\LQYDVLRQKDGDQDOPRVWIROGLQUHDVH
LQORFDOUHFXUUHQFHDVFRPSDUHGWRSDWLHQWVZLWKQRGHIUHH
GLVHDVH25 $FFRUGLQJWRVRPHDXWKRUVD[LOODU\LQYD
VLRQPLJKWEHQRWMXVWDQHYHQWUHODWHGWRWXPRUSURJUHVVLRQ
EXWDELRORJLFDOPDUNHURIWXPRUDJJUHVVLYHQHVVLQGHSHQ
GHQWO\RIWXPRUVL]HUHFXUUHQFHW\SHRUWLPHWRUHFXUUHQFH
$OVRDFFRUGLQJWRVHYHUDOVWXGLHVWKHUHZDVDVLJQL¿FDQW
UHODWLRQ EHWZHHQ KLJK KLVWRORJLFDO JUDGH DQG ORFDO UHFXU
UHQFH 25  IRU *UDGH  DQG 25  IRU *UDGH 
p5HJDUGLQJDOOZHOONQRZQIDFWRUVRXUUHVXOWVZHUH
LGHQWLFDOWRRWKHUVRIVLPLODUVHULHV
 ,QRQHRIWKH¿UVWVWXGLHVDERXW3FDGKHULQH[SUHVVLRQ
LQEUHDVWFDQFHUWKHPROHFXOHZDVRQO\LGHQWL¿HGLQRI
LQYDVLYHEUHDVWFDQFHUV,QWKHIROORZLQJVWXGLHVLWVH[SUHV
VLRQ ZDV REVHUYHG LQ DSSUR[LPDWHO\  RI WXPRUV DQG
LQYHUVHO\ UHODWHG WR(FDGKHULQ H[SUHVVLRQDQGGLUHFWO\ WR
KLJKHUKLVWRORJLFDOJUDGHV:LWKWKHGHYHORSPHQWRIDQWL
3FDGKHULQPRQRFORQDODQWLERGLHVLWVH[SUHVVLRQZDVUHJLV
WHUHGLQWRRIDOOWKHLQYDVLYHGXFWDOFDQFHUV 
,Q RXU VHULHV 3FDGKHULQ ZDV H[SUHVVHG LQ  RI DOO
FDVHV3FDGKHULQZDVPRUHRIWHQSRVLWLYHLQSDWLHQWVZLWK
ORFDOUHFXUUHQFH25 p DOWKRXJKZLWKRXWDVWD
WLVWLFDOO\VLJQL¿FDQWGLIIHUHQFH
 6HYHUDO VWXGLHV UHSRUWHG WKDW WKH 3FDGKHULQ H[SUHV
VLRQLQFDQFHUFHOOVZDVGLUHFWO\UHODWHGWRRWKHUNQRZQIDF
WRUVRIZRUVHSURJQRVLVVXFKDVWXPRUVL]HKLVWRORJLFDO
JUDGH(5QHJDWLYLW\DQGQRGDOPHWDVWL]DWLRQ,Q
PXOWLYDULDWHDQDO\VLVRQO\UHODWLRQZLWKQRGDOPHWDVWL]DWLRQ
DQGKLVWRORJLFDOJUDGHKDVNHSWVLJQL¿FDQFH2WKHUUHSRUWV
IRXQGQRDVVRFLDWLRQEHWZHHQ3FDGKHULQH[SUHVVLRQDQG
WXPRU VL]HRUD[LOODU\ LQYDVLRQ7KHVHFRQÀLFWLQJ UHSRUWV
DQG GLIIHULQJ DVVRFLDWLRQ ZLWK NQRZQ SURJQRVWLF IDFWRUV
VXJJHVWV WKDW 3FDGKHULQPLJKW EH UHODWHG WR RQFRORJLFDO
SURJUHVVLRQRIEUHDVWFDQFHUEXWLWVUHDOELRORJLFDOEHKDYLRU
LVQRW\HWGHWHUPLQHG,QRXUVHULHV3FDGKHULQH[SUHVVLRQ
ZDVGLUHFWO\UHODWHGRQO\ZLWKKLVWRORJLFDOJUDGHDQG(5VWD
WXV
 6HYHUDORWKHUUHSRUWVKDYHVKRZQDGLUHFWUHODWLRQRI3
FDGKHULQZLWKRWKHUNQRZQIDFWRUVRIZRUVHSURJQRVLVVXFK
DVWULSOHQHJDWLYHW\SHDQGSUROLIHUDWLYHLQGH[,QWKLV
VWXG\ ZH DOVR FRQ¿UP WKHVH ¿QGLQJV RI D GLUHFW UHODWLRQ
EHWZHHQ3FDGKHULQH[SUHVVLRQDQGWULSOHQHJDWLYHWXPRUV
pDQGKLJKHUSUROLIHUDWLYHLQGH[p DVPHD
VXUHGE\0,%
 6HYHUDO UHSRUWV REVHUYHGDQ LQYHUVH UHODWLRQ EHWZHHQ
3FDGKHULQH[SUHVVLRQDQGKRUPRQDOUHFHSWRUV0RVWRIWKH
3FDGKHULQH[SUHVVLQJWXPRUVODFNKRUPRQDOUHFHSWRUVH[
SUHVVLRQDQGDUHSRVLWLYHIRU+(5(*)5KLJKHU
KLVWRORJLFDOJUDGHVDQGSUROLIHUDWLYHLQGH[ZKLFKDUHDVVR
5HYLVWD&LHQWt¿FDGD2UGHPGRV0pGLFRVZZZDFWDPHGLFDSRUWXJXHVDFRP
CONCLUSION
%UHDVW FDQFHU LV RQH RI WKH PRVW SUHYDOHQW GLVHDVHV
ZRUOGZLGHEHLQJWKH OHDGLQJFDXVHRIGHDWKIRUFDQFHU LQ
ZRPHQ ,Q WKH ODVW IHZ\HDUV WKHPRUWDOLW\GXHWREUHDVW
FDQFHUKDVEHHQIROORZLQJDGRZQZDUGWUHQGGXHWREHWWHU
VFUHHQLQJSURJUDPVDQGPRVWHIIHFWLYHPHGLFDOFDUH/R
FDOUHFXUUHQFHKDVEHHQGHVFULEHGDVDPDUNHURIGLVHDVH
SURJUHVVLRQ DQG DQ LPSRUWDQW ULVN IDFWRU IRU GHDWK$V D
FRQVHTXHQFHVHYHUDOVWXGLHVKDYHWULHGWRLGHQWLI\ULVNIDF
WRUVIRUORFDOUHFXUUHQFH
2QHRIWKHPRVWSURPLVLQJPDUNHUVIRUORFRUHJLRQDOGLV
HDVHSURJUHVVLRQVHHPVWREH3FDGKHULQDQGLQWKHIXWXUH
LWPLJKWHYHQFRQVWLWXWHDQRYHOWKHUDSHXWLFWDUJHW
3FDGKHULQLQRXUVWXG\ZDVUHODWHGWRRWKHUNQRZQIDF
WRUVRIZRUVHSURJQRVLVZDVPRUHIUHTXHQWLQQRQOXPLQDO
W\SH WXPRUVDQGKDGDQ LQGHSHQGHQW UHODWLRQ WRGLVHDVH
IUHH VXUYLYDO$OWKRXJK LW GLG QRW DIIHFW RYHUDOO VXUYLYDO RU
UHODSVHUDWHLWVHHPHGWREHDVVRFLDWHGZLWKHDUOLHUUHODSVH
DQGPRUWDOLW\
7KHUHDOELRORJLFDOYDOXHRI3FDGKHULQ LVVWLOOXQGHWHU
PLQHGUDLVLQJWKHTXHVWLRQWRZKHWKHULWKDVDQLQGHSHQGHQW
UHODWLRQWRWXPRUEHKDYLRURULILWFRQVWLWXWHVMXVWDQLQGLUHFW
PDUNHURIDJURXSRIFOLQLFDODQGPROHFXODUFKDUDFWHULVWLFV
UHODWHGWRZRUVHSURJQRVLV
CONFLICtS OF INtERESt
 7KHDXWKRUVGHFODUHWKHUHDUHQRFRQÀLFWVRILQWHUHVW
FUNDING SOURCES
 1RQHVWDWHG
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FLDWHGZLWKZRUVHSURJQRVLV7KHVHDXWKRUV VXJJHVW
WKDWWKHKRUPRQDOQHJDWLYHVWDWHLVDUHTXLUHPHQWWRWKHH[
SUHVVLRQRI3FDGKHULQSUREDEO\WKURXJKWKHGLIIHUHQWLDWLRQ
RI OXPLQDO W\SHFHOOV LQWRP\RHSLWKHOLDOFHOOVZKHUH3FDG
KHULQLVXVXDOO\H[SUHVVHG,WKDVEHHQVXJJHVWHGE\VRPH
DXWKRUV WKDW3FDGKHULQH[SUHVVLRQ LQEUHDVW FDQFHU FHOOV
PLJKWUHSUHVHQWWKHGLIIHUHQWLDWLRQLQDQHPEULRQDU\SKHQR
W\SHVLPLODUWRWKHGXFWDOH[WUHPLW\FHOOVZKLFKDUHKLJKO\
SUROLIHUDWLYHQHJDWLYHIRU(5DQGSRVLWLYHIRU3FDGKHULQ 
2XUUHVXOWVDVRWKHUEHIRUHVXSSRUWWKLVK\SRWKHVLVDV3
FDGKHULQH[SUHVVLRQZDVIRXQGPRUHRIWHQLQKLJKKLVWRORJL
FDOJUDGHDQG(5QHJDWLYHFDQFHUV
 $OWKRXJK VRPH VWXGLHV GHVFULEHG LPSDLUPHQW LQ VXU
YLYDO IRU SDWLHQWVZLWK3FDGKHULQH[SUHVVLRQ LQPXOWLYDUL
DWH DQDO\VLV RXU UHVXOWV RQO\ FRQ¿UP D UHGXFWLRQ LQ
GLVHDVHIUHH VXUYLYDO &R[ UHJUHVVLRQ p  ZLWKRXW
GLIIHUHQFHV IRU RYHUDOO VXUYLYDO p  1HYHUWKHOHVV
WKH.DSODQ0H\HUVXUYLYDOFXUYHVVXJJHVWWKDWWKHUHLVDQ
HIIHFW RI3FDGKHULQ RQ VXUYLYDO YLVLEOH DW \HDUV IROORZ
XSDQGIDGLQJSURJUHVVLYHO\QHDUO\XQQRWLFHGDW\HDUV
6LPLODUGDWDZHUHUHSRUWHGLQRWKHUVWXGLHVVXJJHVWLQJ
WKLVIDGHRXWRIHIIHFWLQORQJWHUPIROORZXSZKLFKH[SODLQV
WKH ODFNRIDVVRFLDWLRQZLWKRYHUDOOVXUYLYDOEXW WKHVLJQL¿
FDQWGLIIHUHQFHVRI VXUYLYDO DW \HDUV YV
0RUHVWXGLHVGLUHFWHGWRWKHXQGHUO\LQJSDWKRSK\VLRORJ\RI
3FDGKHULQZLOOEHQHFHVVDU\LQRUGHUWRXQUDYHOWKLVHIIHFW
DQGWRXQGHUVWDQGWKHPROHFXODUPHFKDQLVPVDQGVLJQDOLQJ
LQYROYHGLQWKLVSURFHVV
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Aim: Mitogen-activated protein kinase (MAPK) cascade and phosphatidylinositol 3-kinase
(PI3K) survival pathways are frequently activated in the progression of gastrointestinal
malignancies. In this study, we aimed to determine the frequency of gene mutations in
members of these pathways – Epithelial Growth Factor Receptor (EGFR), KRAS, BRAF, PIK3CA
and MLK3 in a series of 63 gastric carcinomas with high levels of microsatellite instability
(MSI).
Methods: Gene mutation analysis was performed by PCR amplification followed by direct
sequencing. In selected tumour cases, EGFR expression was evaluated by immunohisto-
chemistry. Association studies between molecular data and clinicopathologic characteris-
tics were performed.
Results: Mutations in EGFR (3 0-untranslated region [UTR] polyA repeat), KRAS, PIK3CA and
MLK3 genes occurred in 30 (47.6%), 11 (17.5%), 9 (14.3%) and 2 (3.2%) of the MSI gastric can-
cer (GC) cases, respectively. No BRAF or EGFR hotspot mutations were identified. Overall,
mutations in at least one of these genes were found in 55.6% (35/63) of gastric carcinomas.
From those mutant cases 40.0% (14/35) of them had concomitant gene mutations, always
involving EGFR polyA deletions. Interestingly, we observed significant associations between
oncogenic mutations and female gender (p = 0.046) old age of diagnosis (p = 0.001) and
intestinal subtype (p = 0.043).
Conclusion: Our results show that MSI gastric carcinoma frequently shows activation of
EGFR-MAPK and PI3K pathways. Within all alterations found, deletions of the A13 repeats
of EGFR were common, suggesting this molecular event as an important biomarker for
stratification of GC patients for treatment with EGFR inhibitors.
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1. Introduction
EGFR is a transmembrane protein that homo- or heterodi-
merizes with other EGFR family members at the cell mem-
brane.1 Receptor dimerisation causes activation of the
intrinsic cytoplasmic kinase domain, resulting in the phos-
phorylation of several tyrosine residues.2 The active EGFR
stimulates the MAPK cascade and PI3K survival pathways.1
In some neoplasias, such as in non-small cell lung cancer,
it has been demonstrated that patients with tumours har-
bouring structural alterations on the EGFR kinase domain
could benefit from the pharmacological treatment with
EGFR inhibitors.3 However, it is well known that in lung
and also colon cancer, the clinical response to EGFR inhibi-
tors depends on the tumour genetic profile. Moreover, it has
been clearly demonstrated that patients with metastatic
colon cancer harbouring mutations in EGFR downstream
molecules, namely in KRAS or BRAF genes, are resistant to
EGFR inhibitors, specifically to the anti-EGFR monoclonal
antibody cetuximab.4–7
Recently, Yuan14 found a novel mechanism for EGFR
activation occurring in colon carcinomas with MSI pheno-
type; mutations in an A13 repeat located at the 3 0 (UTR) of
gene. Further, mutations in this region of EGFR were found
to be associated with EGFR overexpression.14
In GC, and in particular in the MSI subset, data on EGFR
alterations as well as mutations on its downstream targets,
namely those belonging to the MAPK and PI3K pathways,
are very limited. Some authors reported that EGFR is over-ex-
pressed in a maximum frequency of 38% of GC8–10 and very
few cases were reported to harbour gene structural altera-
tions like gene amplification or mutations.11–13
InGC, theKRAS genemutation frequency varies between 3 to
8% and whenever present, KRASmutations normally cluster in
the MSI subset (!30% of MSI cases).15–19 In contrast, others and
we found thatBRAFmutations rarelyoccur in this typeof epithe-
lial cancer.15,20–23 We have previously reported mutations in
PIK3CA gene in MSI GC18 and recently, our group have also
reported mutations in theMLK3 gene, which is a component of
themultiproteinBRAF/RAF1complex, inMSIgastricandcolorec-
tal tumours.24,25MLK3 oncogenic mutations were found in 21%
of the MSI gastrointestinal cases and were described to be
functionally relevant.26
In thepresentstudy,weaimedto: (1)determinethefrequency
of activating oncogenic genemutations in the30-UTRA13 repeat
ofEGFR inmutationhotspots fromEGFR,KRAS,BRAFandPIK3CA,
as well as in the full coding region ofMLK3, in a series of 63 MSI
GC, and (2) to analyse the pattern of these oncogenic mutations
to understand the role played by EGFR and its downstream
targets, namely those belonging to theMAPK and PI3Kpathways
in GC progression. Mutations were screened in all cases and
associations between the molecular data and the clinicopatho-
logic features of the patients and tumours were also studied.
2. Patients and methods
2.1. Gastric cancer patients and genomic DNA extraction
To assessMSI frequency, 250 GC patientswere analysed.27–29 In
total, we selected a series of 63 MSI GC well characterized in
terms of clinicopathologic features and geographic area of
origin. Microsatellite analysis was evaluated using five quasi-
monomorphic mononucleotide repeats BAT-26, BAT-25,
NR-24, NR-21 and NR27 cases were considered MSI whenever
two or more markers showed instability on five loci consid-
ered.28 The study population was stratified according to area
of residence intoCentral Italy, representingaGChigh-risk area,
and Southern Italy, representing a GC low-risk area. Tumour
and constitutional DNAwere extracted from fresh frozen sam-
ple tissues using a standard protocol (Gentra Systems, Minne-
apolis, USA). Pathological examination allowed the selectionof
areas of neoplastic cells of more than 80%.
2.2. Somatic mutation analysis of EGFR, KRAS, BRAF,
PIK3CA and MLK3 oncogenes
For the EGFR gene, direct sequencing of the kinase domain
(exons 18, 19, 20 and 21) was performed, using a detailed pro-
tocol described by Moutinho and colleagues.13 Structural
alterations on the A13 repeat within the 3 0-untranslated
region of EGFR (3 0-UTR polyA repeat) gene were also searched,
according with the protocol recently described by Yuan14 in
MSI colon cancer. The 3 0-UTR polyA repeat was evaluated in
normal, as well as, in GC samples. Mutation analysis of KRAS
codons 12 and 13 and BRAF V600E hotspot mutation were
performed by PCR amplification and direct sequencing using
the protocol used by Oliveira.30 To search for somatic altera-
tions of PIK3CA gene, exons 9 and 20 were sequenced accord-
ing to the protocol described in detail by Velho.18 All exons
and intron-exon boundaries of MLK3 gene were screened for
mutations. Primer sequences and PCR conditions adopted
were recently described.26 Except for exon 9, a multiplex
PCR approach was used to amplify MLK3 sequence using the
QuantiTect Multiplex PCR Kit (Multiplex PCR, Qiagen, Studio
City, CA) and following the manufacturer instructions.
Purified PCR products were directly sequenced. All sequence
alterations in EGFR, KRAS, BRAF, PIK3CA and MLK3 genes were
validated with a second independent PCR.
2.3. EGFR immunohistochemistry
EGFR immunohistochemistry was evaluated on 3 lm sections
from formalin-fixed, paraffin-embedded tissue in only two
cases with A13 repeat deletion and in one wild-type sample
due to the lack of good quality paraffin material for analysis.
Epitope retrieval for EGFR was performed by proteolytic en-
zyme digestion (pepsin A, 4 g/l; Sigma–Aldrich, Germany) at
37 !C. After the antigen retrieval procedure, the slides were
washed in a phosphate buffer solution (PBS), and submitted
to blockage of the endogenous peroxidase activity by incuba-
tion of the slides in a 3% hydrogen peroxide (Panreac, Spain)
in methanol (Sigma–Aldrich). The slides were further incu-
bated with a blocking serum (LabVision Corporation kit) for
15 min and then incubated with the primary antibody anti-
EGFR (Zymed, San Francisco, CA, USA, dilution: 1/100; Clone:
31G7) during 60 min. The secondary antibody was associated
with HRP labelled polymer (DakoCytomation) and, after that,
the slides were immediately revealed with DAB. Tissues were
then counterstaining with Mayer‘s haematoxylin, dehydrated
and coverslipped using a permanent mounting solution
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(Zymed,SanFrancisco,CA,USA). Positiveandnegativecontrols
were included in order to guarantee the reliability of the assay.
2.4. Statistical analysis
Analyseswereperformedusing the Statistical Product andSer-
vice Solutions, SPSS14.0 forWindows, 2006, SPSS Inc., Chicago,
IL, USA. Statistical associations between the presence of GC
oncogenic mutations and clinicopathologic characteristics
was assessed by chi-square test for categorical variables and
Student’s t-test or ANOVA test for continuous variables. A p
value lower than 0.05 was considered significant.
3. Results
Thirty-five of 63 (55.6%) MSI GC showed oncogenic mutations
in at least one of the screened genes (EGFR, KRAS, BRAF,
PIK3CA and MLK3) (Table 1). Representative images of tumour
specific oncogenic mutations are shown in Fig. 1. Table 2,
summarizes the association studies performed between the
presence of oncogenic mutations (independently of the num-
ber and type of genes mutated per case) and the clinicopath-
ologic features of patients and tumours.
3.1. EGFR screening
We did not find pathogenic mutations in the hotspot regions
of EGFR (exons 18, 19, 20 and 21). Heterozygous polymorphic
variants of EGFR were detected in exon 20 (G>A; rs1050171)
and in exon 18 (G>A; rs55959834) in 54 and in 2 samples,
respectively. However, deletions at the A13 repeat localized
into the 3 0 UTR of EGFR were found in 30/63 (47.6%) of MSI
GC. Within the 30 mutated carcinomas, 15 (50%) showed a
mononucleotide A deletion, 12 (40%) had a dinucleotide A
deletion and, 3 (10%) a trinucleotide A deletion. All 63 normal
Fig. 1 – Representative images of all oncogenic mutations identified. (A) A10 tumour deletion localized into the 3 0 UTR of EGFR;
(B) KRAS hotspot mutations (reverse sequence); (C) PIK3CA tumour specific alterations; and (D) MLK3 gene alterations.
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Table 1 – Detailed description of oncogenic mutations identified in the 63 MSI gastric carcinomas.
Sample
code
MLK3
mutation
KRAS
mutation
PIK3CA
mutation
BRAF
mutation
EGFR hotspot
mutation
EGFR 3 0-UTR polyA
deletion
1 AU415 wt wt N515S wt wt (A)13 /(A)13
2 AB248 wt wt wt wt wt (A)13 /(A)14
3 BG191 wt wt wt wt wt (A)13 /(A)13
4 BF070 wt wt wt wt wt (A)13 /(A)13
5 BM175 wt wt wt wt wt (A)13 /(A)14
6 BL276 wt wt wt wt wt delA(A)12 /(A)13
7 BE163 wt G12D H1047R wt wt delAA(A)11/delAA(A)12
8 BM213 wt G12D wt wt wt delA(A)13/delA(A)13
9 BC355 wt G13D wt wt wt delA(A)12/(A)13
10 BM406 wt wt wt wt wt (A)13/(A)14
11 BP280 wt wt wt wt wt delA(A)12/delA(A)13
12 CD361 wt wt wt wt wt (A)13/(A)13
13 CE120 wt wt H1047R wt wt delAAA(A)10/delAAA(A)11
14 CC442 wt wt wt wt wt (A)13/(A)13
15 CI362 wt G12C H1047R wt wt delA(A)12/(A)13
16 CG072 wt wt wt wt wt (A)13/(A)13
17 CI376 wt wt wt wt wt delAA(A)11/delA(A)12
18 DM272 wt wt wt wt wt delAAA(A)10/delAAA(A)10
19 DE226 wt wt E545K wt wt (A)13/(A)14
20 DM187 wt wt wt wt wt (A)13 /(A)14
21 FF336 wt wt wt wt wt (A)13 /(A)14
22 FL141 wt wt wt wt wt delAA(A)11/delAA(A)12
23 FL208 wt wt wt wt wt delA(A)12/delA(A)13
24 FF269 wt wt wt wt wt (A)13/(A)13
25 FP285 wt wt wt wt wt (A)14/(A)14
26 FD373 wt wt wt wt wt (A)1 /(A)14
27 GA220 wt wt wt wt wt delA(A)12/delA(A)13
28 GE126 wt G12D wt wt wt delA(A)12/delA(A)13
29 GF364 wt wt wt wt wt (A)14/(A)14
30 JG153 wt wt wt wt wt (A)13/(A)13
31 LG445 wt G13D wt wt wt delAA(A)11/delA(A)12
32 LI266 wt wt wt wt wt delA(A)12/(A)13
33 MA155 wt G12D wt wt wt (A)13/(A)14
34 MG296 wt wt wt wt wt delA(A)12/(A)13
35 MI052 wt wt H1047R wt wt delAA(A)11/delA(A)12
36 MS399 wt wt wt wt wt (A)13/(A)13
37 MG359 wt wt wt wt wt (A)13/(A)14
38 ME196 wt wt wt wt wt delAA(A)10/delA(A)12
39 MM110 wt wt wt wt wt (A)13/(A)13
40 MM122 wt G12D wt wt wt delAA(A)11/delAA(A)12
41 NV424 wt wt wt wt wt (A)13/(A)13
42 NC410 wt wt wt wt wt (A)1 /(A)13
43 OG249 wt wt E545G wt wt delA(A)12/(A)13
44 PA158 wt wt wt wt wt delAA(A)11/delA(A)12
45 PB114 wt wt wt wt wt (A)13/(A)13
46 PD192 wt wt wt wt wt delAA(A)11/delAA(A)11
47 PR209 wt wt wt wt wt (A)13/(A)13
48 PD214 wt G12D wt wt wt delA(A)12/delA(A)13
49 RF421 wt wt wt wt wt (A)13 /(A)13
50 RA125 A684T wt E542K wt wt delAA(A)11/delA(A)12
51 RI107 wt wt wt wt wt delAA(A)11/delAA(A)12
52 RA393 wt wt wt wt wt delA(A)12/(A)13
53 RA270 wt G13D wt wt wt (A)13/(A)13
54 RC205 wt wt wt wt wt delA(A)12/(A)13
55 RL139 wt wt E542K wt wt (A)13/(A)14
56 SA13 5 wt wt wt wt wt (A)13/(A)13
57 SE315 wt wt wt wt wt (A)13/(A)13
58 SA259 wt wt wt wt wt (A)13/(A)14
59 TL130 wt wt wt wt wt (A)13/(A)14
60 TB146 wt wt wt wt wt delA(A)12/(A)13
61 VN174 wt wt wt wt wt (A)13/(A)14
62 VP199 69insG wt wt wt wt delAA(A)11/delAA(A)12
63 ZR195 wt G13D wt wt wt delAAA(A)10/delAAA(A)11
Total 2 11 9 0 0 30
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gastric samples showed a wild-type A13 or A14 repeat of EGFR
in a homozygous or heterozygous state. According with the
findings from the EGFR 3 0-UTR mutation screening, we veri-
fied, by EGFR immunohistochemistry, that while two EGFR
mutant GC (deletion [delAA(A)11]) showed an increased
expression of EGFR in tumour cells in comparison to the sur-
rounding normal tissue, a wild-type EGFR GC case did not
display EGFR expression in the tumour area (Fig. 2). Due to
the lack of good quality paraffin tissue, we can only consider
this data as preliminary. This result needs to be validated in a
larger series of MSI GC in order to confirm the correlation be-
tween the EGFR expression and the mutations in A13 dele-
tions in the 3 0-UTR polyA repeat of EGFR.
3.2. KRAS and BRAF mutations
KRAS mutations were observed in 17.5% (11/63) of MSI GC
cases. From these 11 cases harbouring somatic mutations,
we found that codon 12 was mutated in 63.6% (7/11) and co-
don 13 in 36.4% (4/11). All but one KRAS mutation localized
in codon 12 were G12D. All mutations in codon 13 were
G13D. KRAS mutations were more frequently found in elderly
patients (p = 0.006), but no further significant associations
were found between other clinicopathologic characteristics
and the KRAS mutation status (data not show). None of the
MSI GC cases under study showed BRAF somatic mutations
in the hotspot codon previously associated to MSI colorectal
carcinomas, the BRAF V600E.31
3.3. PIK3CA mutations
PIK3CA mutations were found in 14.3% (9/63) of the MSI GC
studied. Among the mutated cases, eight somatic mutations
were located in codons previously described as PIK3CA
hotspots (codons 542, 545 and 1047). Five PIK3CA alterations
occurred at the helical domain (codon 515, 542 and 545) and
four mutations affected the kinase domain (codon 1047)
(Table 1). A novel missense mutation (1544A>G) was identified
within the helical domain at codon 515 (N515S). None of these
mutations were present in the normal counterpart of these
cases.
3.4. MLK3 mutations
MLK3 mutations were found in two carcinomas correspond-
ing to a frequency of 3.2% (Table 1): one was a missense muta-
tion (2052G>A) localized in proline-serine-threonine rich
domain (A684T) and the other was a frameshift mutation
(c.69insG). Besides these two somatic mutations, that were
tumour specific, we identified one splice site alteration
(c.1069+10C>T) and one missense mutation (2190G>A)
(R730H) that were present in both tumour and constitutional
DNA, both with unknown pathogenic function. Moreover, we
observed two silent MLK3 sequence variants (225A>G and
2259A>T) that did not change the aminoacid residues of the
MLK3 protein (A75A and P753P, respectively) and were previ-
ously described in the normal population.26
3.5. Concomitant oncogenic mutations
We verified that within the 35 MSI GC harbouring oncogenic
mutations, 14 (40.0%) of the mutant cases showed concomi-
tant oncogenic alterations, always involving EGFR polyA
mutations. From those cases with more than one mutation,
seven had EGFR A13 repeat deletions and KRAS mutations
(7/14 – 50%), three showed EGFR polyA deletion and a PIK3CA
mutation (3/14 – 21.4%) and two had EGFR deletions and both
KRAS and PIK3CA (2/14 – 14.3%) mutations. In one case we
found an EGFR deletion and concomitant missense mutations
inMLK3 and PIK3CA and in another case an EGFR deletion and
a MLK3 mutation (Fig. 3).
4. Discussion
Despite the general advances in diagnosis, standard surgery
and chemo- and radio-therapy regimens, the overall outcome
of GC patients remains poor, with a 5-year global survival of
Table 2 – Relation between clinicopathologic features of the
63 MSI gastric carcinomas and oncogenic mutations.
Oncogenic
mutation
+ (35/63;
55.6%)a
Oncogenic
mutation
–(28/63;
44.4%)
P value
Gender
Male 10 (28.6) 18 (64.3) 0.046
Female 25 (71.4) 10 (35.7)
Mean age (±SD) 76.7 ± 7.9 67.9 ± 11.4 0.001
Tumor location
Cardia 4 (11.4) 1 (3.6) ns
Non-cardia 31 (88.6) 27 (96.4)
Lauren classification
Intestinal 31 (88.6) 19 (67.9) 0.043
Non-intestinal 4 (11.4) 9 (32.1)
Depth of invasion
pT1–T2 25 (71.4) 14 (50) ns
pT3–pT4 10 (28.6) 14 (50)
Lymph node involvement
pN0–N1 30 (85.7) 20 (71.4) ns
pN2–pN3 5 (14.3) 8 (28.6)
Extent of gastrectomy
Partial 27 (77.1) 20 (71.4) ns
Total 8 (22.9) 8 (28.6)
Lymphadenectomy
D1 15 (42.8) 12 (42.9) ns
D2/D3 20 (57.2) 16 (57.1)
Radicality of resection
R0 32 (91.4) 19 (67.9) 0.017
R1–2 3 (8.6) 9 (32.1)
Stage grouping
I–II 23 (65.7) 14 (50) ns
III–IV 12 (34.3) 14 (50)
Geographic area
High incidence 35 (100) 21 (75) 0.001
Low incidence 0 (0) 7 (25)
Numbers in parentheses are percentage.
a Fourteen GC patients carried concomitant somatic mutations.
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about 26%.32 Various multimodal therapy regimens are used
to improve the prognosis of GC patients, but no single che-
mo-therapy regimen is recognized as a global standard.33
The high prevalence of incurable disease and the poor overall
survival of GC patients create the urgent need to find new
therapeutic tools for GC treatment.
In patients with advanced GC, several clinical trials were
conducted, namely testing EGFR inhibitors. However, the
overall response to EGFR tyrosine kinase inhibitors was poor.
Among EGFR tyrosine kinase inhibitors, it has been demon-
strated that gefinitib treatment showed a particularly low re-
sponse rate (18%) in advanced GC while erlotinib was
completely inactive.34,35 Recently, more encouraging results
were obtained in GC treatment using a combination of multi-
ple chemotherapies.36–41 As example, patients treated with
cetuximab and FUFOX/FOLFOX (5-fluorouracil, oxaliplatin, fo-
linic acid) or FOLFIRI (5-fluorouracil, irinotecan and folinic
acid) had a significant higher response rate (62%) when
compared with GC patients treated with cetuximab alone
(5%).36–38 Furthermore, when cetuximab was associated with
oxaliplatin/leucovorin and 5-fluorouracil, 50% of the patients
showed a positive response rate.39,40 A similar response rate
(65%) has been reported in metastatic GC treated with cetux-
imab plus oxaliplatin/ folinic acid, in which EGFR overexpres-
sion has been documented.41 However, until now it was
impossible to predict which GC patients will respond to
anti-EGFR therapy. In other words, no predictive biomarkers
are available for clinicians to use in the stratification of GC
patients or to predict treatment benefit. Taking into account
data from treatment of colon cancer patients, where the re-
sponse to anti-EGFR therapy depends on the genetic make-
up of the tumours, namely on the EGFR activation status
and on the mutation profile of members of EGFR and MAPK
signalling pathways,42,43 we decided to study these same
players in MSI GC.
Different molecular mechanisms underlie EGFR protein
activation, such as somatic mutations or gene amplification,
both leading to an abnormal receptor function. In our series
Fig. 2 – EGFR immunohistochemistry expression in gastric carcinoma: (a) example of a EGFR A13 tract wild-type GC case
showing negative EGFR expression (amplification 100X); (b) EGFR overexpression in tumour area in a GC case displaying EGFR
A10 deletion in 50· amplification and (c) in 400· amplification.
Fig. 3 – Schematic representation of the distribution of the oncogenic mutations identified in the present study (occurring as
single events or as concomitant alterations). Oncogenic mutations were found in 35 GC cases but fourteen of them showed
more than one mutagenic event in genes belonging to the EGFR signalling pathway.
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of MSI GC, we did not find hotspot EGFRmutations. This find-
ing was not surprising as EGFR mutations have been rarely
described in GC and gene amplification was only described
in a low frequency of cases.13 Therefore, the presence of other
mechanisms directly or indirectly leading to EGFR activation
were herein investigated.
Since it was recently demonstrated that a polyA tract at
the 3 0-UTR of EGFR was prone to harbour deletions in MSI co-
lon cancer,14 we searched for this type of alterations in our
series of MSI GC. We found alterations at this site in a high
frequency (47.6%) of cases. A higher frequency (69%) was
found for this type of alteration in MSI colon cancer.14 Fur-
thermore, and similarly to EGFR 30-UTR polyA tract mutant
colon cancer cases, we also verified high level of EGFR expres-
sion in two tumour samples harbouring this type of alter-
ation. These results suggest EGFR A13 repeat mutations as a
putative molecular marker to select GC patients for anti-EGFR
therapies, namely anti-EGFR monoclonal antibodies as veri-
fied in colon cancer.14,45
As previous mentioned, in metastatic colorectal carcino-
mas, a response to anti-EGFR therapies was only observed
in patients with tumours without KRAS or BRAF muta-
tions.4,6,17,43–45 In particular, the presence of a KRASmutation
is well established as predictive of non-response to anti-EGFR
antibody and shorter patient survival.5,6 In contrast, the clin-
ical evidence concerning PIK3CAmutations is not yet straight-
forward in this cancer setting.46,47
Given the similarities in the mutation spectrum of colorec-
tal carcinomas and MSI gastric carcinomas,18 we hypothesize
that MSI GC cases without alterations in KRAS and BRAF, and
possibly in other members of the MAPK (MLK3) or PI3K (PIK3-
CA) pathways may benefit from this therapeutic approach.
Taking in account this hypothesis, we determined the fre-
quency of mutations in all these genes in order to verify their
putative importance as biomarkers for therapy assessment.
In the present study, KRAS mutations were found in 17.5%
of MSI GC cases, while no BRAF mutations were detected in
these samples, in keeping with data on record.15,16,18,20–22
These data elicit KRAS but not BRAF activation as potential
biomarkers for therapy assessment in MSI GC. Similarly to
BRAF, somatic alterations at the MLK3 gene were very rarely
found (3.2%), as previously described in another sample set-
ting of MSI GC.26 PIK3CA mutations were found in a non-neg-
lectable frequency of MSI GC cases (14.3%, respectively) and
despite no proof exists showing that mutant PIK3CA tumours
may not respond to anti-EGFR therapy, it is important to char-
acterize its mutation status. The above presented data sug-
gest, in light of the current knowledge on the treatment of
gastrointestinal cancer with anti-EGFR therapy, that MSI GC
patients: (1) can also be stratified according to the molecular
profile of their tumours; (2) present, in over 45% of the cases
mutations at the EGFR 3 0-UTR that potentially lead to EGFR
overexpression which turn these cases in a subset of poten-
tially responsive tumours to anti-EGFR treatment; (3) display
KRAS mutations in nearly 20% of the cases making these GC
patients as potentially resistant to anti-EGFR therapies; (4)
harbour PI3KCA mutations in almost 15% of the cases but
the use of this information is of limited interest, and finally;
(5) lack or display very low frequencies of BRAF and MLK3
mutations and therefore these markers will not improve a fu-
ture panel of genes to be tested in potentially eligible patients
for anti-EGFR therapy. Another layer of information that was
obtained in our multiple gene mutation screening approach,
showed that over one third (40%) of the mutant MSI GC cases
accumulate mutations in more than one gene, demonstrat-
ing, on one hand, that multiple molecules within or targeted
by the EGFR pathway are involved in GC progression; but on
the other hand, reducing the number of cases potentially ben-
efitting from anti-EGFR therapy. In detail, as 30% (9/30) of EGFR
mutated cases also display KRASmutations, thus it is predict-
able that 70% (21/30) of mutant EGFR patients will benefit
from EGFR inhibitors (Fig. 3). Furthermore, another set of
the patients harbouring EGFRmutations also displayed a PIK3-
CA mutation which, although unproved, may also result in
resistance to therapy (Fig. 3).
In GC, cases harbouring concomitant oncogenic muta-
tions in the MAPK cascade is about 3%.18 Our data showed
that 40% of cases have concomitant oncogenic mutations
(Fig. 3). In our series, the higher percentage of cases with
multiple oncogenic mutations is related to the additional
screening of the EGFR polyA tract and MLK3 gene, never eval-
uated so far. In fact, considering only PIK3CA and KRAS alter-
ations, the number of cases with concomitant mutations is
much lower and similar to the frequency reported by Velho
and colleagues.18 The accumulation of EGFR 3 0-UTR and/or
PIK3CA/KRAS/MLK3 mutations within MSI gastric carcinomas
suggest a possible synergistic effect in the signalling path-
ways associated to the activation of these genes in GC devel-
opment/ progression.
Our results support the proposal to implement a multi-
gene screening approach to predict EGFR-targeted therapy.
We show that within MSI GC three groups can be individual-
ized: Group A: cases that are wild-type for all genes under
screening (EGFR and genes of the MAPK and PI3K pathways)
– 44.4% (28/63); Group B: cases with oncogenic alterations
restricted to EGFR - 25.4% (16/63); Group C: cases with onco-
genic mutations in genes of the MAPK and PI3K path-
ways with or without concomitant EGFR alterations -30.2%
(19/63). Overall, cases from groups A and B (69.8%) are poten-
tially eligible for anti-EGFR therapy. Moreover, from the expe-
rience with colorectal cancer it is expectable that cases with
oncogenic mutations affecting MAPK and PI3K signalling
pathways GC patients will be non-responders for anti-EGFR
therapies.
The advantage to identify deletion at the EGFR A13 repeat
region is to select a novel category of patients that potentially
benefit from EGFR inhibitors as therapeutic approach. Proba-
bly other genetic mechanisms, to date unknown, can also
activated the EGFR pathway even in cases that belong, in
our series, to the wild-type EGFR group.
We verified that oncogenic mutations mostly occur in MSI
GC patient with older age at diagnosis and of the intestinal
subtype, supporting that within MSI GC different molecular
pathways are activated in order to generate specific
phenotypes.
Palli and colleagues showed in another study performed in
the same geographical region (Tuscany region) an association
between MSI, positive family history of GC and high con-
sumption of red meat and nitrates, suggesting that environ-
mental factors, such as nutritional habits may play a key
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role in inducing genomic instability and an increased risk for
GC. Our data demonstrated that oncogenic mutations related
significantly with this high incidence area and this probably is
associated with the presence of MSI phenotype.27,48
In conclusion, our results show that alterations at multiple
molecules within or targeted by the EGFR pathway are fre-
quent in MSI GC and, that within members of the pathway,
deletions of the A13 repeat of EGFR were the most common
genetic event followed by KRAS and PIK3CA mutations. Fur-
thermore, in over one third of the cases, concomitant muta-
tions occur in distinct genes, always involving EGFR. More
importantly, our results open new avenues regarding the
stratification of MSI GC patients for anti-EGFR therapies and
pinpoint a non-neglectable group of cases that may benefit
from this therapeutic approach.
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Alterations in Vitamin D signalling and metabolic
pathways in breast cancer progression: a study of
VDR, CYP27B1 and CYP24A1 expression in benign
and malignant breast lesions
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Abstract
Background: Breast cancer is a heterogeneous disease associated with different patient prognosis and responses
to therapy. Vitamin D has been emerging as a potential treatment for cancer, as it has been demonstrated that it
modulates proliferation, apoptosis, invasion and metastasis, among others. It acts mostly through the Vitamin D
receptor (VDR) and the synthesis and degradation of this hormone are regulated by the enzymes CYP27B1 and
CYP24A1, respectively. We aimed to study the expression of these three proteins by immunohistochemistry in a
series of breast lesions.
Methods: We have used a cohort comprising normal breast, benign mammary lesions, carcinomas in situ and
invasive carcinomas and assessed the expression of the VDR, CYP27B1 and CYP24A1 by immunohistochemistry.
Results: The results that we have obtained show that all proteins are expressed in the various breast tissues,
although at different amounts. The VDR was frequently expressed in benign lesions (93.5%) and its levels of
expression were diminished in invasive tumours (56.2%). Additionally, the VDR was strongly associated with the
oestrogen receptor positivity in breast carcinomas. CYP27B1 expression is slightly lower in invasive carcinomas
(44.6%) than in benign lesions (55.8%). In contrast, CYP24A1 expression was augmented in carcinomas (56.0% in in
situ and 53.7% in invasive carcinomas) when compared with that in benign lesions (19.0%).
Conclusions: From this study, we conclude that there is a deregulation of the Vitamin D signalling and metabolic
pathways in breast cancer, favouring tumour progression. Thus, during mammary malignant transformation,
tumour cells lose their ability to synthesize the active form of Vitamin D and respond to VDR-mediated Vitamin D
effects, while increasing their ability to degrade this hormone.
Background
Breast cancer is one of the major causes of death by
cancer in women worldwide [1]. Nowadays, breast can-
cer is no longer considered to be a single disease, but is
rather comprised of distinct tumour subtypes displaying
different clinical outcomes [2]. Over the lifetime of the
individual, in order to a tumour to develop it needs a
combination of low-penetrance genetic factors and
environmental aspects. Ultimately, cancer results from
alterations in the control of the complex balance of pro-
liferation, differentiation and programmed cell death [3]
and these processes appear to be regulated by intrinsic
and extrinsic factors, like niche signals, hormonal and
dietary aspects, among others [4], [5].
Vitamin D is a lipid soluble substance that belongs to
the family of secosteroid hormones. Its physiological
role has been classically associated with calcium regula-
tion and phosphate transport in bone metabolism. Apart
from this endocrine role, subsequent studies have
widened the range of functions for Vitamin D and this
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has been particularly important in the field of cancer
research. Several authors have demonstrated, in various
models of cancer (including the breast), the ability of
Vitamin D to perform autocrine and paracrine func-
tions. Specifically, it has been demonstrated the capacity
to modulate cancer features, namely proliferation and
differentiation [6], apoptosis [7], angiogenesis [8], inva-
sion and metastasis [9].
Vitamin D exerts most of its biological activities by
binding to a specific high-affinity receptor, the Vitamin
D Receptor (VDR), that was first identified in a breast
cancer cell line in 1979 [10]. The VDR belongs to the
superfamily of nuclear receptors for steroid hormones
and regulates gene expression by acting as a ligand-
activated transcription factor [11]. Several studies have
demonstrated that the VDR knockout mice display a
higher incidence rate of carcinogen-induced preneoplas-
tic breast lesions when compared with their littermates
[12], [13]. These reports highlight the importance of the
VDR deficiency in sensitizing the mammary gland to
transformation in response to a carcinogenic agent.
Immunohistochemical studies have confirmed that the
VDR is expressed in samples from normal breast tissues
[14] and also in breast cancer biopsy specimens [15].
Because the VDR is expressed in the mammary gland
and Vitamin D has been shown to display anticarcino-
genic properties, this hormone has emerged as a pro-
mising targeted therapy. But in order to keep the
homeostasis of the organism the amount of circulating
Vitamin D has to be tightly regulated. This is a very
complex process, in which the main components are the
enzymes 1a-hydroxylase/CYP27B1 (encoded by the gene
CYP27B1) and 24-hydroxylase/CYP24A1 (encoded by
the gene CYP24A1). CYP27B1 is responsible for the
synthesis of the biologically active form of Vitamin D
(1,25-dihydroxyvitamin D), whereas CYP24A1 mediates
the catabolism of Vitamin D [16]. Several studies have
focused their attention in the comparison of the levels
of these enzymes in normal and tumour tissue. It has
been observed that both CYP27B1 and CYP24A1 are
up-regulated in breast tumours when compared with
normal tissue. However, deregulated expression of
CYP24A1 seems to abrogate the effects of CYP27B1,
resulting in the degradation of Vitamin D to less active
metabolites [17]. In contrast, a recent paper has demon-
strated that CYP27B1 mRNA in breast tumours is
decreased in comparison with normal mammary tissue
[18]. Despite these findings, no reports regarding the
expression by immunohistochemistry of the VDR,
CYP27B1 and CYP24A1 in the mammary gland have
been described. The main purpose of this work was
to perform an immunohistochemical study of the
expression of the VDR, CYP27B1 and CYP24A1 in a
comprehensive series of human breast tissues comprised
of normal breast, benign mammary lesions, carcinomas
in situ and invasive breast carcinomas.
Methods
Patient’s selection and Tissue Microarray construction
We have studied a cohort of 379 benign lesion samples
and 189 cases of carcinomas in situ, collected from the
archives of the Pathology Department of General Hospital
of UNIMED in Araçatuba, Brazil. Three hundred and fifty
cases of invasive breast carcinomas were retrieved from
the archives of the Pathology Department of the Federal
University of Santa Catarina, Florianópolis, Brazil (161
cases) and from the Pathology Department of General
Hospital of UNIMED in Araçatuba, Brazil (189 tumour
samples). This last series of 189 invasive carcinomas con-
tains, in the same block, the aforementioned carcinomas
in situ. Additionally, 29 cases of normal breast tissue were
included in the study. The normal breast tissue, carcino-
mas in situ and invasive tumour samples were collected
between 1994 and 2004. The series of benign lesions was
collected between 2002 and 2006.
Representative areas of the different lesions were care-
fully selected on the H&E-stained sections, by 2 pathol-
ogists (DV and LAV) and marked on individual paraffin
blocks. Two tissue cores (2 mm in diameter) were
obtained from each selected specimen and precisely
deposited into a recipient paraffin block using a TMA
(Tissue Microarray) workstation (TMA builder, LabVi-
sion Corporation, USA). Several TMA blocks were con-
structed (40 for the invasive breast carcinomas, 22 for
the carcinomas in situ and 17 for the benign lesions),
each containing 24 tissue cores, arranged in a 4×6 sec-
tor. In each TMA block, at least 3 nonneoplastic breast
tissue cores were also included as controls and 1 core of
a non-breast sample (we have used testicular and liver
tissues). To homogenize the paraffin of the receptor
block and the paraffin of the cores extracted from the
donor blocks, the TMAs were kept at 37°C for 3 hours.
After construction, 2-μm tissue sections were cut and
adhered to Superfrost Plus glass slides. An H&E-stained
section from each block was reviewed to confirm the
presence of morphological representative areas of the
original lesions.
The present study has been conducted under the
national regulative law for the usage of biological speci-
mens from tumour banks, where the samples are exclu-
sively available for research purposes in the case of
retrospective studies.
Immunohistochemistry
Immunohistochemical staining for Oestrogen Receptor
(ER), HER2 and CK5 (Cytokeratin 5) was performed
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using the streptavidin-biotin-peroxidase technique (Lab-
Vision Corporation) in each set of glass slides compris-
ing the TMAs, whereas P-cadherin (P-cad), EGFR
(Epidermal Growth Factor Receptor) and Progesterone
Receptor (PgR) used the HRP labelled polymer (Dako-
Cytomation, USA) as described elsewhere [19]. Antigen
unmasking for VDR was performed using a solution of
pepsin A (4 g/L; Sigma-Aldrich) for 30 minutes at 37°C.
Epitope retrieval for CYP27B1 and CYP24A1 was per-
formed using a dilution of 1:100 of citrate buffer, pH =
6.0 (Vector Laboratories, Burlingame, CA, USA) at 98°C
for 30 minutes. The antigen retrieval times, antibodies,
dilutions and suppliers are listed in Table 1. Primary
antibody incubation was performed overnight at 4°C for
VDR and CYP24A1 and for 1 h at room temperature
for CYP27B1. After washes, the slides were incubated
with secondary antibody associated with HRP labelled
polymer (ImmunoLogic, The Netherlands) for VDR or
incubated with biotinylated secondary antibody (Santa
Cruz, USA) followed by streptavidin-conjugated peroxi-
dase (Labvision) during 15 min for CYP24A1 and
CYP27B1, and immediately revealed with DAB (Dako-
Cytomation). Tissues were then counterstained with
Mayer’s haematoxylin, dehydrated and cover-slipped
using a permanent mounting solution (Zymed, USA).
Positive and negative controls were included in each run
in order to guarantee the reliability of the assays. Paraf-
fin sections of a basal cell carcinoma of the skin, normal
colon and normal liver were used as positive controls for
VDR, CYP27B1 and CYP24A1 expression, respectively.
Scoring and statistical analysis
The evaluation of the immunohistochemical results was
performed by three pathologists (FS, FM and LAV). VDR
nuclear expression was evaluated using the H-score
method: intensity ranked from 1 to 3 (1 - weak, 2 - mod-
erate, 3 - strong), and extension ranked from 1 to 10 (1 -
0-10% cells, 2 - 11-20% cells and so on, until a maximum
score of 10) [20]. The scores for intensity and extension
were multiplied and the following criterion was applied:
the cases were considered negative when ranging from 1
to 4; samples ranking from 5 to 30 were considered to be
positive. Considering the lack of previous reports for the
immunohistochemical evaluation of the CYP27B1 and
CYP24A1, we considered the cases to be positive only
when cytoplasmic staining was observed. The other
markers were scored as described in previous studies
from our group [19], [21].
The Statview 5.0 software package (SAS Institute,
USA) was used for all statistical analysis. Correlations
between discrete variables were performed using the
chi-square test and analysis of variance was employed to
search for associations between continuous and discrete
variables. In all analyses, a p value < 0.05 was considered
to be statistically significant.
Cell culture and Western blotting
MDA-MB-231 breast cancer cells were grown in com-
plete Dulbecco’s Modified Eagle Medium (DMEM) in
the presence of 10% foetal bovine serum (Invitrogen,
USA). Treatments with Vitamin D 100 nM (Cayman
Chemical, USA) and ethanol (vehicle) were performed
for 72 h, while the treatment with PTH (Parathyroid
Hormone) (Sigma-Aldrich, Germany) 100 nM and water
(vehicle) were performed for 4 h. Total cell lysates were
obtained and the samples were separated in an SDS-
polyacrylamide gel. After blotting into a nitrocellulose
membrane (GE Healthcare Life Sciences, UK), staining
for CYP27B1 and CYP24A1 was performed using the
antibodies (Santa Cruz, USA) presented on Table 1
overnight at a dilution of 1:200. After washes, the mem-
branes were incubated with a mouse anti-goat HRP sec-
ondary antibody (Santa Cruz) and were revealed with
ECL (GE Healthcare Life Sciences).
RNA extraction and Real-time PCR
RNA was extracted from formalin-fixed paraffin-
embedded breast lesions using the RecoverAll Total
Nucleic Acid Isolation Kit (Ambion, USA), according to
the manufacturer’s protocol. After extraction, RNA was
quantified using NanoDrop spectrophotometer (Thermo
Scientific, USA). cDNA was synthesized using the
Omniscript Reverse Transcription kit (Qiagen, Germany)
following the manufacturer’s instructions. Finally, real-
time PCR was performed using TaqMan Gene Expres-
sion Assays (Applied Biosystems, USA), using 2 mL of
cDNA and in accordance to the manufacturer’s protocol.
The TaqMan Gene Expression Assays used were
Hs00172113_m1 (VDR), Hs00168017_m1 (CYP27B1)
and Hs00167999_m1 (CYP24A1). Reactions were per-
formed using standard cycle parameters on an ABI
PRISM Sequence 7000 Detection System (Applied
Table 1 Sources and dilutions of primary antibodies related to the Vitamin D metabolism used in this study for
immunohistochemistry
Antibody Clone Manufacturer Time of incubation (min) Dilution Antigen retrieval (min)
VDR 9A7gE10.4 Calbiochem, Germany overnight 1:50 30
CYP27B1 C12 Santa Cruz, USA 60 1:200 30
CYP24A1 C18 Santa Cruz, USA overnight 1:75 30
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Biosystems). Relative transcript levels were determined
using Human GAPDH Endogenous Control (Applied
Biosystems) as an internal reference. Differences between
the breast tissue samples were determined using com-
parative delta CT method [22]. All reactions were done in
triplicate and expressed as mean of the values from three
separate experiments.
Results
VDR, CYP27B1 and CYP24A1 immunohistochemical
staining
The expression patterns of the VDR, CYP27B1 and
CYP24A1 have been evaluated by immunohistochemistry
in 947 breast tissue samples arranged in 79 TMAs. From
this set of cases, some samples could not be assessed due
to the fact that either the core had fallen out or it did not
have enough biological material to study. In all TMAs,
positive and negative cases were obtained for each protein.
The immunostainings for these markers had been pre-
viously validated in whole tissue sections with an overall
agreement of 90%. A panel with representative immunos-
tainings for each protein in different breast tissues is
shown in Figure 1. We have observed that the VDR
displays nuclear staining, as would be expected from a
nuclear receptor which acts as a transcription factor. Con-
sidering CYP27B1 and CYP24A1 expression, nothing has
ever been described on their expression status in the
mammary gland, as far as we know. This is the first report
showing the expression of these two enzymes in breast
lesions. These proteins present cytoplasmic and granular
staining, which could reflect their mitochondrial localisa-
tion. All proteins (VDR, CYP27B1 and CYP24A1) have
been found to be expressed in all lesions studied and also
in the normal breast tissue, although at different levels.
The differential expression of CYP27B1 and CYP24A1
was technically validated. MDA-MB-231 breast cancer
cells have been treated with PTH 100 nM and Vitamin
D 100 nM and total cell lysates have been extracted.
Western blotting analysis has confirmed the expression
of CYP27B1 and CYP24A1 upon treatment with the
aforementioned hormones (Additional file 1: Figure S1).
Additionally, using a group of randomly selected tissue
samples, RNA was isolated and used in real-time PCR
to confirm the immunohistochemical results (Additional
file 2: Table S1). Our results have shown that positive
cases in the TMAs displayed cDNA amplification in the
real-time PCR and the opposite situation was observed
for cases where no staining was present in the TMAs.
Expression of the VDR, CYP27B1 and CYP24A1 in
benign lesions of the mammary gland
In order to study the VDR, CYP27B1 and CYP24A1
expression in benign lesions of the mammary gland, we
have evaluated 379 cases arranged in 17 TMAs. The
series consisted of a variety of breast lesions, namely
usual and atypical ductal hyperplasias (UDH represent
20.1%, corresponding to 76 samples; while ADH repre-
sent 5.4%, corresponding to 21 samples), columnar cell
lesions (CCL - 25.6% of cases, corresponding to 97 sam-
ples), papillomatosis (16.9% of cases, corresponding to
64 samples) and adenosis (17.2% of cases, corresponding
to 65 samples). The percentage of immunoreactive cases
for the VDR was very high (93.5%, corresponding to 259
cases out of 277). Regarding the expression of CYP27B1,
we have observed 55.8% of positive cases, corresponding
to 173 lesions out of 310. Concerning CYP24A1 expres-
sion, we have detected 62 positive cases out of 327 sam-
ples (19.0%). Amongst all lesions, ADH cases were
overall less immunoreactive to the three proteins.
We have correlated the histological classification of
the benign lesions with the VDR, CYP27B1 and
CYP24A1 expression, but no significant associations
have been found (see Table 2 for further details).
Expression of the VDR, CYP27B1 and CYP24A1 in breast
carcinomas in situ
A fully characterized series of 189 breast carcinomas
in situ arranged in 22 TMAs was assessed for the
expression patterns of VDR, CYP27B1 and CYP24A1.
For the VDR, we have observed that 62 cases out of 131
cases (47.3%) displayed staining for this protein. Con-
cerning CYP27B1 expression, we have encountered posi-
tive staining in 66.4% of the cases (91 out of 137
samples); whereas CYP24A1 expression was observed in
56.0% of the tumours (70 out of 125 cases).
We have also assessed the expression of other breast
cancer biomarkers in our cohort (ER, HER2 and PgR and
basal markers as defined by our group [19] and others
[23]) and looked for the existence of correlations between
the expression of the Vitamin D partners and these mole-
cular markers (Table 3). ER expression has been observed
in 117 cases (61.9%), HER2 protein was present in 37
cases (15.6%) and PgR expression was detected in 90 cases
(47.6%). We have also tested our series for basal markers
and have obtained the following results: EGFR expression
is present in 10 cases (5.3%), CK5 is positive in 15 cases
(7.9%) and P-cadherin was observed in 36 samples
(19.0%). Expression of the VDR correlated positively with
ER status (p = 0.0227), with a higher percentage of VDR-
positive cases among the ER-positive tumours - 74.2% (46
out of 62 cases). Additionally, we have seen that there is
an inverse correlation between the expression of the VDR
and P-cadherin (p = 0.0078). CYP27B1 expression only
presented an inverse correlation (p = 0.0295) with EGFR
expression, but the number of cases positive for EGFR was
very low. No statistically significant associations have been
observed between CYP24A1 expression and the markers
studied.
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Figure 1 Immunohistochemical staining for the VDR, CYP27B1 and CYP24A1 in the different types of breast tissue
Lopes et al. BMC Cancer 2010, 10:483
http://www.biomedcentral.com/1471-2407/10/483
Page 5 of 10
Expression of the VDR, CYP27B1 and CYP24A1 in invasive
mammary carcinomas
We have evaluated 350 cases of invasive breast carcinomas
arranged in 40 TMAs. The cohort corresponds to 189
cases of the series for which there was an in situ compo-
nent in the adjacent area of the invasive tumour and an
additional series of 161 cases of invasive breast carcino-
mas. Positive staining for the VDR has been observed in
56.2% of the cases (172 out of 306 cases). Regarding
CYP27B1 expression, 44.6% of cases were positive
(123 out of 276 samples), whereas 53.7% of cases (151 out
of 281 tumours) presented positivity for CYP24A1.
Next, we searched for associations between the
expression of Vitamin D partners and the expression of
the molecular markers mentioned in the previous sec-
tion (Table 4). We have obtained 197 cases (56.3%)
positive for ER, 70 cases (20%) for HER2 and 143 cases
(40.9%) for PgR. As for basal markers, we have observed
that 13 cases (3.7%) were positive for EGFR expression,
48 cases (13.7%) presented positivity for CK5 and 93
cases (26.6%) stained for P-cadherin.
A statistically significant association was observed
between the VDR-positive cases and ER-positive cases
(p = 0.0002). Additionally, VDR-positive cases have also
been significantly correlated with HER2-negative cases
(p = 0.0238), but this is probably due to the low number
of positive cases for HER2 in our series of mammary
carcinomas. CYP27B1 expression presented no signifi-
cant associations with any of the markers analyzed. PgR
was the only marker that displayed an inverse correla-
tion with CYP24A1: specifically, cases positive for PgR
were mostly negative for CYP24A1 (p = 0.0485).
The series of 189 tumours with both components
(carcinomas in situ and the corresponding invasive
tumour) allowed the evaluation of the expression of the
VDR, CYP27B1 and CYP24A1 simultaneously in the
Table 2 VDR, CYP27B1 and CYP24A1 expression in the various types of benign breast lesions
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
Usual ductal hyperplasia 84 (92.3) 7 (7.7) 57 (55.9) 45 (44.1) 23 (20.5) 89 (79.5)
Atypical ductal hyperplasia 9 (81.8) 2 (18.2) 4 (36.4) 7 (63.6) 1 (7.1) 13 (92.9)
Columnar cell lesions 63 (95.5) 3 (4.5) 43 (55.8) 34 (44.2) 13 (16.5) 66 (83.5)
Papillomatosis 45 (95.7) 2 (4.3) 30 (56.6) 23 (43.4) 9 (17.0) 44 (83.0)
Adenosis 49 (92.5) 4 (7.5) 32 (55.2) 26 (44.8) 13 (22.0) 46 (78)
p value 0.4847 0.7994 0.6842
Table 3 VDR, CYP27B1 and CYP24A1 and other breast cancer biomarkers expression in carcinomas in situ
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
ER + (%) 46 (35.1) 38 (29.0) 58 (42.3) 29 (21.2) 41 (32.8) 36 (28.8)
- (%) 16 (12.2) 31 (23.7) 33 (24.1) 17 (12.4) 29 (23.2) 19 (15.2)
p value 0.0227 ns ns
HER2 + (%) 9 (6.9) 14 (10.7) 18 (13.1) 7 (5.1) 9 (7.2) 12 (9.6)
- (%) 53 (40.5) 55 (42.0) 73 (53.3) 39 (28.5) 61 (48.8) 43 (34.4)
p value ns ns ns
PgR + (%) 35 (26.7) 30 (22.9) 49 (35.8) 18 (13.1) 38 (30.4) 22 (17.6)
- (%) 27 (20.6) 39 (29.8) 42 (30.7) 28 (20.4) 32 (25.6) 33 (26.4)
p value ns ns ns
CK5 + (%) 3 (2.3) 8 (6.1) 7 (5.1) 4 (2.9) 8 (6.4) 4 (3.2)
- (%) 59 (45.0) 61 (46.6) 84 (61.3) 42 (30.7) 62 (49.6) 51 (40.8)
p value ns ns ns
EGFR + (%) 1 (0.8) 5 (3.8) 2 (1.5) 5 (3.7) 5 (4.0) 3 (2.4)
- (%) 61 (46.6) 64 (48.9) 89 (65.0) 41 (29.9) 65 (52.0) 52 (41.6)
p value ns 0.0295 ns
P-cad + (%) 4 (3.1) 16 (12.2) 14 (10.2) 12 (8.8) 16 (12.8) 7 (5.6)
- (%) 58 (44.3) 53 (40.5) 77 (56.2) 34 (24.8) 54 (43.2) 48 (38.4)
p value 0.0078 ns ns
ns: not significant.
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two types of tumours (Additional file 2: Table S2). The
results obtained show that the three proteins (VDR,
CYP27B1 and CYP24A1) display a statistically signifi-
cant correlation of expression between the two sections
(carcinomas in situ and the matching invasive tumour).
Thus, positive cases in the in situ component are also
positive in the invasive component and the same is
observed for the negative cases.
Expression of the VDR, CYP27B1 and CYP24A1 according
to the type of breast lesion
The frequencies of protein expression of the VDR,
CYP27B1 and CYP24A1 in the different mammary tis-
sues are shown in Figure 2. The normal mammary
gland (29 cases), as expected, is positive for the expres-
sion of the VDR in all the cases studied (100%). The
majority of the samples also displays immunostaining
for CYP27B1 (63.6%) and, in contrast, the levels of
expression of CYP24A1 are low (29.6%). The VDR is
also highly expressed in benign lesions (93.5%) with a
reduction in the percentage of positive cases in carcino-
mas in situ (47.3%) and in invasive carcinomas (56.2%).
CYP27B1 expression does not vary greatly between the
different breast lesions. However, between in situ and
invasive carcinomas, a statistically significant decrease in
the percentage of positive cases was observed (from
66.4% in carcinomas in situ to 44.6% in invasive carcino-
mas). In contrast, the expression of CYP24A1 is
increased in carcinomas (56.0% in carcinomas in situ
and 53.7% in invasive carcinomas) compared with the
benign lesions (19.0%), which are mostly negative.
Discussion
Vitamin D mediates anti-proliferative and pro-differen-
tiation signalling in various epithelial tissues, including
Table 4 VDR, CYP27B1 and CYP24A1 and other breast cancer biomarkers expression in invasive breast tumours
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
ER + (%) 114 (37.3) 60 (19.6) 70 (25.4) 86 (31.2) 93 (33.1) 66 (23.5)
- (%) 58 (19.0) 74 (24.2) 53 (19.2) 67 (24.3) 58 (20.6) 64 (22.8)
p value 0.0002 ns ns
HER2 + (%) 26 (8.6) 34 (11.3) 31 (11.4) 25 (9.2) 29 (10.4) 30 (10.8)
- (%) 144 (47.7) 98 (32.5) 90 (33.1) 126 (46.3) 121 (43.5) 98 (35.3)
p value 0.0238 ns ns
PgR + (%) 71 (23.3) 59 (19.3) 52 (18.8) 64 (23.2) 71 (25.3) 46 (16.4)
- (%) 100 (32.8) 75 (24.6) 71 (25.7) 89 (32.2) 80 (28.5) 84 (29.9)
p value ns ns 0.0485
CK5 + (%) 27 (8.8) 19 (6.2) 15 (5.4) 24 (8.7) 27 (9.6) 16 (5.7)
- (%) 145 (47.4) 115 (37.6) 108 (39.1) 129 (46.7) 124 (44.1) 114 (40.6)
p value ns ns ns
EGFR + (%) 4 (1.3) 7 (2.3) 4 (1.5) 6 (2.2) 6 (2.1) 3 (1.1)
- (%) 166 (54.8) 126 (41.6) 118 (43.1) 146 (53.3) 145 (51.8) 126 (45.0)
p value ns ns ns
P-cad + (%) 42 (13.8) 40 (13.1) 30 (10.9) 42 (15.2) 40 (14.3) 37 (13.2)
- (%) 129 (42.3) 94 (30.8) 93 (33.7) 111 (40.2) 110 (39.3) 93 (33.2)
p value ns ns ns
ns: not significant.
Figure 2 Percentage of positive cases for VDR, CYP27B1 and
CYP24A1 in the various types of breast samples studied.
Statistical analysis shown use normal breast as reference. An
additional result is presented comparing the number of CYP27B1
positive cases between in situ and invasive carcinomas. (ns - not
significant; * p < 0.05).
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the mammary gland [6]. Therefore, it is reasonable to
assume that disruption of the Vitamin D signalling and
metabolic pathways may occur during tumour develop-
ment. To explore this hypothesis, we have evaluated a
cohort of 947 samples of human breast tissues for the
presence of VDR, CYP27B1 and CYP24A1. Specifically,
our series consisted of normal breast tissue (29 cases),
preneoplastic benign mammary lesions (379 cases),
carcinomas in situ (189 cases) and invasive breast carci-
nomas (350 cases). To the best of our knowledge, this is
the first time that the expression of the VDR, CYP27B1
and CYP24A1 has been evaluated in histological sec-
tions of mammary lesions.
The three proteins have been found to be expressed in
all breast tissues, although at different levels. VDR pre-
sented a nuclear localisation, as it would be expected for
a nuclear receptor, while CYP27B1 and CYP24A1
enzymes displayed cytoplasmic staining with a granular
pattern, which is consistent with their mitochondrial
localisation. The immunohistochemical results were
further validated and confirmed using quantitative real-
time PCR and Western blotting.
Some studies have demonstrated that the VDR protein
is expressed in samples from normal breast tissues and
also in breast cancer biopsy specimens [14,15,24,25].
Our results have shown that the VDR is expressed in
carcinomas. However, the percentage of positive cases
that we have obtained (47.3% in carcinomas in situ and
56.2% in invasive carcinomas) is lower than the 80% to
90% that had been previously described in the literature
[26,27]. This discrepancy can be explained by the devel-
opment of new detection techniques and the use of dif-
ferent scoring methods. In this study, we have used the
H-Score, the current method employed for other
nuclear receptors, like ER [20], whereas in previous stu-
dies the presence of any staining was marked as positive.
As far as we know, our study is the first to investigate
the immunohistochemical expression of the VDR in a
range of benign lesions and carcinomas in situ of the
mammary gland. The percentage of positive cases for
the VDR is higher in benign lesions than in invasive
tumours (93.5% and 56.2%, respectively), while the carci-
nomas in situ display the lowest value of all (47.3%).
There are some studies showing higher levels of VDR in
tumour tissues [18,28], but this discrepancy can be
attributed to the use of different evaluation techniques.
An interesting finding is the correlation between the
expression of the VDR and the ER in both in situ and
invasive carcinomas. In fact, the VDR is expressed in
most ER-positive cases (54.7% in in situ carcinomas and
65.5% in invasive tumours). It is thought that one of the
VDR functions is to counteract oestrogen-mediated pro-
liferation and maintain differentiation [12]. Indeed, data
support the concept that the anti-tumour effects of
Vitamin D and its analogues on ER-positive human
breast cancer cells are mediated through the down regu-
lation of the ER itself and the attenuation of oestrogen
responses, such as breast cancer cell growth [29,30].
Thus, being the VDR mostly expressed in ER-positive
carcinomas, Vitamin D or its analogues may become an
alternative therapy for these tumours in cases of resis-
tance to ER-targeted therapy.
The levels of protein expression of CYP27B1 and
CYP24A1 have not been previously studied in breast can-
cer. In colon cancer, a study using immunohistochemistry
has demonstrated that CYP27B1 is present at equally high
levels in normal colonic epithelium and colorectal cancer
[31]. For CYP24A1 it has been shown that increasing
amounts of this enzyme are present in normal colon tissue
and pre-malignant lesions. In cancer, the expression of
CYP24A1 decreases as a function of tumour cell dediffer-
entiation [32]. In breast tissues, McCarthy et al.[18] have
demonstrated that CYP27B1 mRNA expression was signif-
icantly down regulated in adjacent non-cancerous tissue
from women with breast cancer in comparison with indi-
viduals without cancer. Additionally, it has been shown
that the expression of mRNA for CYP27B1 and the VDR
was higher in carcinomas versus non-neoplastic tissue
[17]. Considering differences in expression in benign and
malignant breast tissues, we have observed an increased
expression of CYP24A1 and a decreased expression of
CYP27B1 with malignant progression. In fact, CYP27B1
was expressed in 55.8% of the preneoplastic lesions and
this percentage is decreased in invasive tumours (44.6%),
while carcinomas in situ display the highest value (66.4%)
and these differences are statistically significant. In con-
trast, CYP24A1 is augmented more than 2.5 fold in inva-
sive tumours (53.7%), compared with benign breast lesions
(19.0%) and this difference is also significant (p < 0.0001).
The in situ carcinomas exhibit the highest percentage of
positive cases (56.0%). These observations are consistent
with the results of Townsend and colleagues [17], which
have demonstrated that there was an up regulation of
CYP24A1 mRNA in breast tumour tissue, in comparison
with normal breast. It has also been described that the
CYP24A1 gene is amplified in breast cancer [33]. In con-
trast, another study has found no differences in the
expression of the VDR, CYP27B1 and CYP24A1 mRNA in
breast cancer and non-neoplastic mammary tissue [34].
These contradictory results may be explained by recent
reports where it is described that VDR and CYP24A1 are
under the post-transcriptional control of miRNAs [35,36].
Breast cancer is a process that evolves through the
accumulation of (epi)genetic events that drive uncon-
trolled proliferation and resistance to apoptosis. The
active form of Vitamin D is known for its capacity to
modulate proliferation and induce apoptosis [6]. Conse-
quently, malignant cells would need to develop
Lopes et al. BMC Cancer 2010, 10:483
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mechanisms to deregulate Vitamin D metabolic and sig-
nalling pathways in order to allow tumour development
[37]. Furthermore, it has been suggested that the Vitamin
D produced in non-renal tissues is not released into the
blood stream, but instead acts locally [38]. Therefore, the
amount of Vitamin D available in the tissue depends on
the relative amounts of CYP27B1 (synthesis) and
CYP24A1 (catabolism). Accordingly, our results show a
deregulation of these two enzymes in the different stages
of breast carcinogenesis. The crucial step of transforma-
tion introduces a clear unbalance in the Vitamin D sig-
nalling and metabolic pathways. A reduction in the
expression of the VDR in carcinomas indicates lower sen-
sitivity of the tissue to Vitamin D control. Furthermore, a
strong increase in CYP24A1 positive cases points to an
enhanced ability of the cells to degrade this hormone. In
contrast, the stable levels of CYP27B1 throughout the
transformation process, with only a small decrease in
invasive carcinomas, may reflect a lower capacity to
metabolize Vitamin D into its active form.
Conclusions
In summary, this is the first study to report the expres-
sion of the VDR, CYP27B1 and CYP24A1 in a series of
normal breast, preneoplastic mammary lesions, breast
carcinomas in situ and invasive tumours. We have cor-
related the expression of these Vitamin D partners with
the expression of a panel of tumour biomarkers.
Furthermore, we have confirmed these results by real-
time RT-PCR. Overall, our results on the expression of
the VDR, CYP27B1 and CYP24A1 suggest that there is
a deregulation of the Vitamin D metabolic and signal-
ling pathways in breast cancer, in order to favour
tumour progression. Thus, during breast malignant
transformation, tumour cells lose their ability to synthe-
size the active form of Vitamin D and to respond to
Vitamin D effects, while increasing their ability to
degrade this hormone.
Additional material
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Summary. Introduction: The most suitable immuno-
histochemical criterion to identify basal-like breast
carcinomas (BLBC), a molecular subgroup of breast
cancer associated with poor prognosis, is the triple
negative phenotype along with CK5 and/or EGFR
immunoreactivity. However, several putative basal
markers have been suggested as alternatives to identify
BLBC with more accuracy. Experimental Design: The
expression of CK5, EGFR, P-cadherin, CK14, Vimentin
and p63 were evaluated in 462 invasive breast
carcinomas to determine their sensitivity and specificity
for BLBC identification. Results: P-cadherin and CK5
showed higher sensitivity values, while EGFR, Vimentin
and CK14 were the most specific markers. The
combination of CK5 with P-cadherin, Vimentin or CK14
proved to be a reliable option for distinguishing the basal
phenotype, compared to the “gold standard” pair
CK5/EGFR. Furthermore, P-cadherin was still able to
recognize a large number of putative BLBC among the
“unclassified” group (ER-/PR-/HER2-/CK5-/EGFR-).
Conclusions: P-cadherin, Vimentin and CK14 can
recognize BLBC already identified in triple negative/
CK5 and/or EGFR+ tumors, and due to P-cadherin
sensitivity for BLBC identification this marker can
reliably recruit a large number of breast carcinomas with
basal phenotype among immunohistochemistry triple
negative/ CK5 and/or EGFR - pool of tumors. Although
they need GEP validation, our results can introduce the
idea of these markers as additional options in the daily
workup of breast pathology laboratories to identify
BLBC.
Key words: Basal-like breast cancer, P-cadherin, CK14,
Vimentin
Introduction
In the European Union, breast cancer is the most
incident form of cancer in women, with an estimated
429.900 cases diagnosed per year (28.9% of all incident
cases in women) (Ferlay et al., 2007; Milanezi et al.,
2008). Breast cancer is frequently designated as a
heterogeneous disease with divergent biological
behaviors. cDNA microarray studies have provided an
improvement in cellular and molecular understanding of
breast cancer, identifying distinct subtypes of breast
carcinomas with different molecular signatures and
clinical outcomes (Perou et al., 2000; Sorlie et al., 2001,
2003; Rakha et al., 2006a,b). The basal-like subtype has
definitely drawn the attention of the scientific
community. These tumors are characterized by a triple
negative (TN) phenotype, lacking the expression of
hormone receptors (HR) [estrogen and progesterone
receptors (ER and PR, respectively)] and HER2. Basal-
like breast carcinomas (BLBC) are associated with
P-cadherin, Vimentin and CK14 for 
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aggressive tumor behavior and shorter overall survival
when compared to the luminal and HER2-
overexpressing subtypes and there is an enthusiastic
search for molecular markers expressed in BLBC that
could be used as targets to therapy (Nielsen et al., 2004).
Histologically, they are poorly differentiated carcinomas,
present high nuclear and histological grade and
frequently show medullary and metaplastic features
(Tsuda et al., 2000; Fulford et al., 2006; Livasy et al.,
2006; Rakha et al., 2006a,b). A distinct pattern of
metastasis to brain and lungs, known to be associated
with poor prognosis, and less significant involvement of
axillary lymph nodes, has also been described in BLBC
(Tsuda et al., 2000; Banerjee et al., 2006; Fulford et al.,
2007). Nowadays, gene expression profiles (GEP) or
cDNA microarrays studies are currently considered the
“gold standard” methods for the identification of breast
carcinomas with basal phenotype, since these
technologies were the first to identify BLBC as a distinct
subgroup with a specific molecular signature (Perou et
al., 2000) and clinical identity (Sorlie et al., 2001, 2003;
van't Veer et al., 2002). However, GEP are expensive,
not easily applicable as a routine laboratory diagnostic
tool in large scale clinical-pathological analysis and have
limited value in retrospective studies using formalin-
fixed paraffin-embedded (FFPE) tissues (Cheang et al.,
2008; Reis-Filho and Tutt, 2008). Thus, the idea of
developing an immunohistochemical (IHC)-based assay
for the identification of BLBC is appealing. The
variation in the transcriptional and translational
programs of cells that accounts for the different
molecular identities of breast carcinomas also reinforces
the interest in creating an IHC-based assay for BLBC
definition. The characteristic protein expression of
tumors would be a useful surrogate of GEP, and the IHC
profile would help to standardize investigations and
uniformly identify a group of tumors with a basal-like
transcriptional program (Reis-Filho and Tutt, 2008). 
However, the most appropriate panel of antibodies to
be used, in order to identify breast carcinomas with basal
phenotype, has not reached a consensus yet. In 2008,
Tang et al. (2008) compared the different IHC
classifications that have been used to define basal-like
and non basal-like breast carcinomas; interestingly, they
showed that in high grade breast carcinomas, which is a
common feature of basal phenotype, the rates of BLBC
ranged between 19% and 76%, indicating the need for a
more consensual strategy between laboratories.
The TN phenotype criterion is used by some authors
who assume that Triple Negative tumors and BLBC are
synonymous (Kreike et al., 2007; Spitale et al., 2008). In
fact, this criterion is quite convenient, since it includes
standard biomarkers already used in the clinical
management of breast cancer. However, relying on
negative results to perform a diagnostic interpretation
may be risky due to technical failures leading to a
decrease in specificity. Other authors use high molecular
weight cytokeratins alone (CK5/6, CK14 or CK17) to
identify BLBC, claiming that BLBC and triple negative
tumors are different identities (van de Rijn et al., 2002;
Abd El-Rehim et al., 2004; Fulford et al., 2007; Rakha et
al., 2007b). In addition, since basal-like breast
carcinomas express proteins that are characteristic from
the basal/myoepihelial outer layer of the mammary
gland, such as EGFR, p63, P-cadherin, calponin, CD10,
S100 and α-smooth-muscle actin (α-SMA) (Jones et al.,
2001; Reis-Filho et al., 2003; Nielsen et al., 2004;
Livasy et al., 2006), some definitions of BLBC associate
the lack of expression of ER, PR and HER2 with the
immunoreactivity for some of these basal markers that
were already correlated with basal phenotype and poor
prognosis (Nielsen et al., 2004; Matos et al., 2005;
Laakso et al., 2006). Our group has previously
demonstrated that using a panel of antibodies for ER,
PR, HER2, CK5/6 and/or EGFR and/or P-cadherin
and/or p63 it is possible to distinguish invasive (Matos et
al., 2005) and in situ (Paredes et al., 2007b) BLBC.
However, Nielsen et al. (2004) found that expression of
CK5/6 and EGFR together with negativity for ER and
HER2 would be the immunoprofile that identifies the
same basal-like carcinomas found by cDNA
microarrays, with a sensitivity of 76% and a specificity
of 100%. This criterion is, therefore, considered the
“gold standard” immunoprofile to classify BLBC.
In this study, we aim to refine the immunohisto-
chemical criterion to identify BLBC by analyzing the
sensitivity and the specificity of the main basal markers
that have been described, namely CK5, EGFR, P-
cadherin, CK14, Vimentin and p63 and suggest possible
additional markers for BLBC identification, especially in
CK5 and EGFR negative breast carcinomas.
Materials and methods
Breast tumour samples
Formalin-fixed, paraffin-embedded tissues of 462
invasive breast carcinomas were consecutively retrieved
from the histopathology files of three Departments of
Pathology: University Hospital of the Federal University
of Santa Catarina (Florianópolis, Brazil), Hospital
Divino Espírito Santo (HDES), (Ponta Delgada, São
Miguel, Portugal), and a private Laboratory of Pathology
in Araçatuba, Brazil. All cases were reviewed by three
pathologists (FM, FS and LV) on haematoxylin and
eosin-stained (H&E) sections.
TMA construction
Representative areas of the invasive breast
carcinomas were carefully selected on the H&E-stained
sections and marked on individual paraffin blocks. Two
tissue cores (2 mm in diameter) were obtained from each
specimen and precisely deposited into a recipient
paraffin block using a TMA workstation (TMA builder
20010.02, Histopatholoy Ltd, Hungary). Forty seven
TMA blocks were constructed, each one containing 24
tissue cores, arranged in a 4x6 sector. In each TMA
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block, normal breast and testicular tissue were included
as controls. After construction, 2 µm tissue sections
were cut and adhered to glass slides (PolysineTM,
Menzel-Glasser, Germany) for the immunohistochemical
studies and a H&E-stained section from each TMA
block was reviewed in order to confirm the presence of
morphological representative areas of the original
lesions. 
Immunohistochemistry
All the immunohistochemical assays were
performed with specific monoclonal antibodies. Details
about primary antibodies, antigen retrieval and IHC
detection systems are described in Table1. Except for
EGFR, in which epitope retrieval was performed by
proteolytic enzyme digestion for 20 minutes (pepsin A, 4
g/l; Sigma-Aldrich, USA) at 37°C, all epitope retrieval
was heat-induced at 98ºC in a water-bath during 30
minutes, using a commercially available citrate buffer
solution (Vector Laboratories, USA), 1:100, pH=6.0, or
an ethylenediaminetetraacetic (EDTA) solution
(Novocastra, UK), 1:10, pH=9.0, as antigen unmasking
solutions. After the respective antigen retrieval and
washes in a phosphate buffer solution (PBS),
endogenous peroxidase activity was blocked with a 3%
hydrogen peroxide solution (Panreac, Spain) in methanol
(Sigma-Aldrich, USA) for 10 minutes. The slides were
incubated in a blocking serum (LabVision, USA) for 15
min and then incubated with the respective primary
monoclonal antibodies. Immunoassays were performed
using the streptavidin-biotin-peroxidase technique
(SABC), (LabVision Corporation, Fremont, CA, USA)
or the HRP labeled polymer (DakoCytomation, USA)
detection system, according to manufacturer ’s
instructions. All reactions were revealed with diamino-
benzidine (DAB) chromogen (DakoCytomation).
Tissues were then counterstained with Mayer ’s
haematoxylin, dehydrated and coverslipped using a
permanent mounting solution (Mounting Medium,
Richard Allan Scientific, USA). Positive and negative
controls were included in every set of reactions for each
antibody used. Normal breast ducts and lobules present
in many of the selected areas were also used as internal
controls, as well as the non-neoplastic breast tissue cores
included in each array. The evaluation of
immunohistochemistry results was performed by three
pathologists as follows: ER, PR and p63 were
considered positive whenever more than 10% of the
neoplastic cells showed nuclear staining; similarly, the
same cutoff was used for CK5, CK14 and Vimentin
cytoplasmic staining, as well as for P-cadherin
membrane staining. Membrane expression for HER2 and
EGFR was evaluated according to the DakoCytomation
HercepTest® scoring system (Reis-Filho et al., 2005).
Breast carcinomas were considered HER2-
overexpressing whenever the immunohistochemical
reaction was classified as 3+ or when gene amplification
was confirmed by Chromogenic In Situ hybridization
(CISH) in the 2+ cases, as described in other works
(Ricardo et al., 2007). For EGFR, the cases were
considered positive whenever the immunostaining was
2+ or 3+.
Hormone receptor (ER and PR) positive tumors
were considered luminal A and B whether or not they
overexpressed HER2, respectively (Sotiriou et al., 2003;
Matos et al., 2005; Paredes et al., 2007b; Spitale et al.,
2008; Tamimi et al., 2008). Cases lacking ER/PR with
overexpression of HER2 were classified as HER2
overexpressing tumors. ER-/PR-/HER2- cases with
immunoreactivity for EGFR and/or CK5 were
considered BLBC according to the gold standard
Nielsen’s criterion and cases without expression of the
five biomarkers were considered unclassified. When the
immunoreactivity for the additional basal markers,
namely P-cadherin, CK14 and Vimentin are used, the
positive cases for at least one of these markers were
considered as BLBC (P-cad and/or CK14 and/or Vim).
Since for some markers the immunohistochemical result
was not interpretable, the statistical analyses were
performed using only 387 breast tumors cases which
were classified for all the biomarkers tested.
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Table 1. Conditions of the immunohistochemical reactions performed in this study.
Primary antibodies Antigen retrieval buffer Detection method
Antigen Clone Origin Incubation time (min) Dilution
ER SP1 Neomarkers, USA 30 1:150 Citrate SABC*
PR SP2 Neomarkers, USA 30 1:300 Citrate HRP-Polymer **
HER2 SP3 Neomarkers, USA 30 1:80 Citrate SABC*
CK5 XM26 Neomarkers, USA 60 1:50 Tris-EDTA SABC*
EGFR 31G7 Zymed 60 1:100 Pepsin HRP-Polymer **
P-cadherin 56 BD Transduction 60 1:50 Tris-EDTA HRP-Polymer **
CK14 LL002 Novocastra, UK 60 1:400 Tris-EDTA HRP-Polymer **
Vimentin V9 Dako, USA 30 1:150 Citrate SABC*
p63 4A4 Neomarkers, USA 60 1:150 Citrate SABC*
* SABC: streptavidin-avidin-biotin-complex; **: HRP-Polymer (horseradish peroxidase - polymer).
Statistical analysis
Statistical analysis was performed by SPSS statistics
17.0 (SPSS Inc., Chicago, IL, USA) software program.
χ2 contingency test was used to determine associations
between groups and the results were considered
statistically significant if the p value was lower than
0.05. In order to determine which were the most
sensitive and specific biomarkers to identify BLBC, the
sensitivity and the specificity of the antibodies used were
calculated. Sensitivity measurement was defined by the
quotient between the true positive (TrueP) cases and the
sum of the true positive and the false negative (FalseN)
cases [sensitivity = TrueP/(TrueP+FalseN)]. Specificity
was measured in a similar way, by the quotient between
the true negative (TrueN) cases with the sum of the true
negatives and the false positives (FalseP) [specificity =
TrueN/(TrueN+FalseP)]. PPV (Positive Predictive
Value) and NPV (Negative Predictive Value) were
calculated as follows: PPV = TrueP/(TrueP+FalseP) and
PNV = TrueN/(TrueN+FalseN). As described before,
ER/PR/HER2 negative tumors that express CK5/6
and/or EGFR were considered BLBC. Consequently,
TrueP and TrueN cases were the BLBC tumors that were
positive or negative, respectively, to the marker or pair
of markers in analysis. Inversely, FalseP and FalseN
were non BLBC positive or negative to the basal
markers in study. 
Follow-up information was available for 282 of the
387 cases and a maximum cutoff of 77 months was
considered. Survival curves were estimated by the
Kaplan-Meier method using log-rank test to assess
significant differences for overall survival.
Results
In this series of 387 breast carcinomas, 223/387
(57.6%) and 144/387 (37.2%) cases were ER and PR
positive, respectively, and 65/387(16.8%) overexpressed
HER2. Using the ER/PR/HER2- (TN) criterion, this
series comprises 109 (28.2%) triple negative and 278
(71.8%) non-Triple Negative tumors. Considering the
molecular subtypes of breast cancer, 213 (55%) cases
were luminal A, 13 (3.4%) luminal B and 52 (13.4%)
HER2-overexpressing tumors. According to Nielsen’s
criterion, 37 (9.6%) cases presented a basal-like
phenotype and 72 (18.6%) were considered
“unclassified” by this criterion. We analyzed the
associations between CK5, EGFR, P-cadherin, CK14,
p63 and Vimentin and the BLBC versus non BLBC
(Table 2). As expected, the markers were significantly
associated with the basal phenotype (p‹0.0001), with the
exception for p63 (p=0.5403). Fig. 1 shows the
immunohistochemical staining for CK5, EGFR, P-
cadherin, Vimentin and CK14 in BLBC.
Afterwards, the sensitivity, specificity, PPV and
NPV of each biomarker for the identification of BLBC
were calculated (Table 3), except for p63 which was not
even related with basal phenotype. CK5 was the most
sensitive biomarker (91.9%), followed by P-cadherin
(67.6%). CK14 and EGFR were the most specific
markers, presenting 98.6% and 97.1% of specificity,
respectively, and vimentin was also shown to be very
specific (86.9%). 
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Fig. 1. Expression of CK5 (a), EGFR (b), P-
cadherin (c), CK14 (d) and Vimentin (e) in basal-
like breast carcinomas, defined by ER/PR/HER2
negativity and CK5 and /or EGFR positivity. 
x 200
In order to find the best combination of basal
markers with the ability to identify BLBC, we evaluated
the most sensitive and the most specific markers in pairs
(CK5, P-cadherin with CK14, EGFR or Vimentin). Since
P-cadherin presented good sensitivity and specificity
values, we also evaluated its association with CK5
(Table 4). The statistical associations considered cases
that were positive for both markers (+/+), positive for at
least one marker (+/- or -/+) or negative for both (-/-).
Table 5 shows the percentages of sensitivity, specificity,
PPV and NPV for the several pairs of markers. In these
analyses, we considered as true positive the cases that
were +/+ and positive for at least one of the markers in
the subgroup of BLBC previously distinguished by
Nielsen’s criterion, and as false positive the cases that
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Fig. 2. Distribution of P-cadherin, vimentin and CK14 expression in triple
negative tumors that were negative for CK5 and EGFR.
Table 2. Association between the expression of CK5, EGFR, P-
cadherin, CK14, p63 and vimentin with basal-like and non basal-like
breast carcinomas.
n Basal n (%) Non basal n(%) P
387 37(9.6%) 350(90.4%)
CK5 <0.0001
+ 89 34(91.9%) 55(15.7%)
- 298 3(8.1%) 295(84.3%)
EGFR <0.0001
+ 21 11(29.7%) 10(2.9%)
- 366 26(70.3%) 340(97.1%)
P-cadherin <0.0001
+ 123 25(67.6%) 98(28%)
- 264 12(32.4%) 252(72%)
CK14 <0.0001
+ 17 12(32.4%) 5(1.4%)
- 370 25(67.6%) 345(98.6%)
p63 0.5403
+ 14 2(5.4%) 12(3.4%)
- 373 35(94.6%) 338(96.6%)
Vimentin <0.0001
+ 63 17(45.9%) 46(13.1%)
- 324 20(54.1%) 304(86.9%)
Table 3. Sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) of the IHC method for the basal-
markers studied to discriminate a basal-like carcinoma. 
Sensitivity (%) Specificity (%) PPV (%) PNV (%)
CK5 91.9 84.3 38.2 99.0
EGFR 29.7 97.1 52.4 92.9
P-cadherin 67.6 72.0 20.3 95.5
CK14 32.4 98.6 70.6 93.2
Vimentin 45.9 86.9 27.0 93.8
Table 4. Association between the expression of pairs of basal markers
with basal-like and non basal-like breast carcinomas.
n Basal n (%) Non basal n(%) p
CK5/EGFR <0.0001
+/+ 11 8(21.6%) 3(0.8%)
At least one + 88 29(78.4%) 59(16.9%)
-/- 288 0(0%) 288(82.3%)
CK5/CK14 <0.0001
+/+ 11 11(29.7%) 0(0%)
At least one + 83 23(62.2%) 60(17.1%)
-/- 293 3(8.1%) 290(82.9%)
CK5/Vim <0.0001
+/+ 24 16(43.2%) 8(2.3%)
At least one + 104 19(51.4%) 85(24.3%)
-/- 259 2(5.4%) 257(73.4%)
P-cadherin/EGFR <0.0001
+/+ 13 8(21.6%) 5(1.4%)
At least one + 118 20(54.1%) 98(28%)
-/- 256 9(24.3%) 247(70.6%)
P-cadherin/CK14 <0.0001
+/+ 12 9(24.3%) 3(0.9%)
At least one + 116 19(51.4%) 97(27.7%)
-/- 259 9(24.3%) 250(71.4%)
P-cadherin/Vim <0.0001
+/+ 41 11(29.7%) 30(8.6%)
At least one + 104 20(54.1%) 84(24%)
-/- 242 6(16.2%) 236(67.4%)
P-cadherin/CK5 <0.0001
+/+ 38 23(62.2%) 15(4.3%)
At least one + 136 13(35.1%) 123(35.1%)
-/- 213 1(2.7%) 212(60.6%)
Table 5. Sensitivity, specificity, PPV and NPV of the IHC method for the
pairs of basal-markers antibodies studied to discriminate a basal-like
carcinoma.
Sensitivity (%) Specificity (%) PPV (%) PNV (%)
CK5/EGFR 100 82.3 11.4 100
CK5/CK14 91.9 82.9 10.5 99
CK5/Vim 94.6 73.4 12.0 99.2
P-cadherin/EGFR 75.7 70.6 10.2 96.5
P-cadherin/CK14 75.7 71.4 10.1 96.5
P-cadherin/Vim 83.8 67.4 11.6 97.5
P-cadherin/CK5 97.3 60.6 14.5 99.5
were positive for the two markers and the ones
expressing at least one marker in non basal-like tumors.
True negative and false negative were the -/- cases in
non basal-like and in BLBC, respectively. All the
associations were statistically significant (p‹0.0001). The
pair CK5/EGFR presented, as expected, the highest
values of sensitivity and specificity, 100% and 82.3%,
respectively. However, concerning sensitivity, the pairs
CK5/CK14, P-cadherin/CK5 and CK5/Vimentin showed
similar values to the “gold standard” CK5/EGFR pair,
with 91.9%, 97.3% and 94.6% of sensitivity,
respectively. The specificity of CK5/CK14 combination
(82.9%) was approximately equal to the one presented
by CK5/EGFR (82.3%). 
In the BLBC group, when analyzing the number of
cases that were +/+ and positive for at least one of the
markers of the pair, against the -/- cases (Table 6), it is
possible to observe that only one basal-like breast
carcinoma was negative for both markers in P-
cadherin/CK5 pair. The CK5/Vimentin pair missed the
expression in 2 cases, while CK5/CK14 did not stain
three BLBC. All the other pairs were positive in BLBC
for the two markers, or for at least one of them, in at
least 75.7% of breast carcinomas with basal phenotype.
More importantly, given the sensitivity of P-cadherin
and the specificity of CK14 and Vimentin, we also
analyzed their expression among the TN/CK5 and EGFR
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Fig. 3. Kaplan-Meier survival curves for overall survival (OS) of triple
negative breast carcinoma patient’s cohort, with a 77 months cut-off.
BLBC defined by TN/CK5 and/or EGFR+ [BLBC (CK5 and/or EGFR+)],
BLBC defined as ER/PR/HER2-, CK5/EGFR- and immunoreactivity for
P-cadherin and/or CK14 and/or Vimentin [BLBC (P-cad and/or CK14
and/or Vim)] and tumors that were negative for all the basal markers in
study were analyzed, p=0.267 (not statistically significant).
Table 6. Analyzes of the distribution of expression of the pairs of
markers in BLBC.
Basal n (%)
CK5/EGFR +/+ and at least one + 37(100%)
-/- 0(0%)
CK5/CK14 +/+ and at least one + 34(91.9%)
-/- 3(9.1%)
CK5/Vim +/+ and at least one + 35(94.6%)
-/- 2(5.4%)
P-cadherin/EGFR +/+ and at least one + 28(75.7%)
-/- 9(24.3%)
P-cadherin/CK14 +/+ and at least one + 28(75.7%)
-/- 9(24.3%)
P-cadherin/Vim +/+ and at least one + 31(83.8%)
-/- 6(16.2%)
P-cadherin/CK5 +/+ and at least one + 36(97.3%)
-/- 1(2.7%)
Table 7. Expression of P-cadherin, vimentin and CK14 in the 72 TN
tumors also negative for CK5 and EGFR.
TN/CK5 and EGFR- n=72
P-cadherin + 29(40.3%)
- 43(59.7%)
Vimentin + 18(25%)
- 54(75%)
CK14 + 5(6.9%)
- 67(93.1%)
Table 8. Distribution of histological grade among triple negative breast carcinomas of the studied series.
Histological grade
Triple negative tumors (n=103*) I II III
BLBC (CK5 and/or EGFR+) (n=34) 3 (9%) 12 (35%) 19 (56%)
BLBC (P-cadherin and/or CK14 and/or Vimentin+) (n=32) 2 (6%) 15 (47%) 15 (47%)
Unclassified (TN,CK5, EGFR, P-cad, CK14 and Vim-) (n=37) 17 (46%) 15 (40%) 5 (14%)
BLBC (CK5 and/or EGFR+) are the TN tumors that were positive for CK5 and/or EGFR and BLBC (P-cadherin and/or CK14 and/or Vimentin+) are the
TN/CK5 and EGFR- tumors immunoreactive for one of the additional markers in study: P-cadherin, CK14 and vimentin. *: Histological grade of some
cases could not be assessed because the patients were submitted to preoperative chemotherapy.
negative tumors (“unclassified” by Nielsen’s criterion).
In 38/72 (52.8%) cases, none of the biomarkers were
expressed; however, in the other 34/72 cases (47.2%),
there was the expression of, at least, one of the
biomarkers. P-cadherin was present in 29 (40.3%),
Vimentin in 18 (25%) and CK14 in 5 (6.9%) of these
tumors (Table 7). In a more detailed analysis, 15 cases
were positive only for P-cadherin, while only one and
three cases were positive for CK14 and for Vimentin
alone, respectively (Fig. 2). 
Interestingly, if we consider as BLBC these TN/CK5
and EGFR- “unclassified” cases that presented
immunoreactivity for P-cadherin, CK14 and/or Vimentin
[BLBC (Pcad and/or CK14 and/or Vimentin+)], this
series presents 71/387 (18%) of BLBC. BLBC defined
by TN/CK5 and/or EGFR+ and BLBC defined as
ER/PR/HER2-, CK5/EGFR- and immunoreactivity for
P-cadherin and/or CK14 and/or Vimentin were analyzed
separately. These two differently defined BLBC
presented a similar percentage of high histological grade
tumors [56% and 47% in BLBC (CK5 and/or EGFR+)
and in BLBC (Pcad and/or CK14 and/or Vimentin+),
respectively], (Table 8). The overall survival was similar
for the two groups as we can see in Figure 3.
Discussion
The need for a more precise diagnosis of breast
cancer that converges with the clinical outcome and the
choice of the most appropriate therapy has motivated
studies in different areas of breast cancer research. The
cDNA microarray technology is a “gold standard”
method for the recognition of the basal phenotype, but
from a practical point of view, we need to translate these
results to an accessible method. It is undeniable that the
BLBC immunohistochemistry definition requires cDNA
microarray validation, since these tumors were first
identified by this technique (Perou et al., 2000; Livasy et
al., 2006). However, from the pathologists and
oncologists point of view, the lack of molecular targets
for therapy in this subgroup of patients indicates the
urgent need for an easier and less expensive way to
identify BLBC patients. Based on this, there is an
attempt to establish an immunohistochemical surrogate
panel, easily applied on FFPE samples, which identifies
a pool of breast cancer patients who may require more
aggressive systemic therapy and that would be the most
appropriate subjects for clinical trials, specifically
targeting this molecular subgroup of breast cancer.
However, there is still no consensual definition about the
ideal IHC panel of biomarkers to distinguish the basal
phenotype. In fact, many different panels have been
used, in which CK5, EGFR, P-cadherin, CK14 and
Vimentin are included. Due to this diversity of criteria, a
wide range of percentages of BLBC are described in the
several studied series (van de Rijn et al., 2002; Foulkes
et al., 2004; Jones et al., 2004; Abd El-Rehim et al.,
2005; Arnes et al., 2005; Collett et al., 2005; Kusinska et
al., 2005; Laakso et al., 2005; Potemski et al., 2005;
Banerjee et al., 2006; Fulford et al., 2006, 2007; Kim et
al., 2006; Rakha et al., 2006a,b, 2007a,b,c; Rodriguez-
Pinilla et al., 2006, 2007; Siziopikou and Cobleigh,
2007). Nielsen et al. (2004) demonstrated that CK5 and
EGFR could reliably discriminate BLBC that were
identified by GEP, considering these two basal markers
the “gold standard” immunohistochemical panel of
antibodies to the BLBC identification, together with ER
and HER2 lack of expression. Recently, Cheang et al.
(2008) compared two BLBC immuno-panels and
concluded that the ER-/PR-/HER2- and expression of
CK5 and/or EGFR provides the more accurate definition
of BLBC and can better predict breast cancer patient’s
survival. 
However, we cannot assure which are the best
antibodies to be included in a daily practice panel for the
recognition of the basal phenotype in breast carcinomas:
should we look for the most sensitive or the most
specific ones? None of these markers are actually
pathognomonic of a basal phenotype, since they are
variably expressed in the other subgroups of breast
carcinomas, which support the search for “ideal”
biomarkers to be used in the anatomic pathology workup
and with clinical relevance.
We demonstrate herein that P-cadherin, Vimentin or
CK14 may possibly be useful biomarkers to include in
IHC panels for distinguishing BLBC. P-cadherin reveals
consistent values of sensitivity and specificity, while
Vimentin and CK14 presented high specificity values.
The three markers were able to reliably recognize the
basal phenotype, especially when associated to CK5. 
The presence of P-cadherin, an adhesion molecule
expressed in myoepithelial cells of the normal mammary
gland, was already described in invasive and in in situ
breast carcinomas with worst prognosis, namely in those
with high histological grade and basal phenotype
(Peralta Soler et al., 1999; Gamallo et al., 2001; Kovacs
and Walker, 2003; Paredes et al., 2005, 2007b). The role
of P-cadherin in breast carcinogenesis has been one of
the main fields of our research group’s interest and we
have observed that this molecule presents an inverse
correlation with HR (Peralta Soler et al., 1999; Gamallo
et al., 2001; Kovacs and Walker, 2003; Paredes et al.,
2005) and a direct correlation with EGFR (Kovacs and
Walker, 2003), HER2 and high proliferation rates,
strengthening the value of P-cadherin as a poor
prognostic indicator in breast cancer (Palacios et al.,
1995; Peralta Soler et al., 1999; Gamallo et al., 2001;
Paredes et al., 2005). The expression of P-cadherin in
neoplastic cells has already been related to a histogenetic
origin in cap cells or to the acquisition of a stem cell-like
phenotype, suggesting that P-cadherin-expressing
tumors could be associated to a stem cell origin (Peralta
Soler et al., 1999, Gamallo et al., 2001, Paredes et al.,
2007). Recently, it has been suggested that basal-like
breast carcinomas may be genuine stem/early progenitor
cell tumors of the mammary gland, relating their origin
to a more undifferentiated type of precursor cells
(Honeth et al., 2008). Also, Rakha et al. (2009)
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demonstrated more evidence of the features of dual-
lineage differentiation/stem cell phenotype of BLBC by
showing a higher frequency of CK19 expression in this
type of tumor.
CK14 does not show a differential presence in breast
carcinomas with basal phenotype identified by cDNA
microarray technology, but this cytokeratin is frequently
associated with poor prognosis (Jones et al., 2004) and
with the morphological features observed in BLBC
(Tsuda et al., 2000). For this reason, CK14 has been
included in the immunopanel used to identify BLBC by
several other authors (Laakso et al., 2005, 2006; Rakha
et al., 2006a,b; Reis-Filho et al., 2006).
Vimentin is an intermediate filament protein whose
expression in normal mammary gland is also restricted
to myoepithelial/ basal layer. Its expression has been
associated with high histological grade, lack of ER, p53
mutations, high proliferation rates (Raymond and Leong,
1989; Domagala et al., 1990a,b; Koutselini et al., 1995;
Santini et al., 1996; Thomas et al., 1999) and expression
of CK5/6 and EGFR (Korsching et al., 2005; Reis-Filho,
2005). Vimentin-expressing carcinomas have been
observed in association with sporadic and familial
BLBC and with a specific pattern of metastasis similar
to BLBC (Rodriguez-Pinilla et al., 2007). Like P-
cadherin, Vimentin was also described to be
differentially expressed by BLBC identified by GEP,
being proposed to integrate the panel of antibodies for
the identification of BLBC (Livasy et al., 2006).
Our results show that P-cadherin, CK14 and
Vimentin, together with CK5, can identify almost all
BLBC that were classified as such using the most widely
accepted IHC panel to classify BLBC: ER/PR/HER2-
and CK5 and/or EGFR+.
Triple negative phenotype by IHC is one of the
characteristic features of BLBC and several authors
claim that basal tumors are almost all TN tumors (Diaz
et al., 2007; Kreike et al., 2007). Kreike et al. (2007), in
a series of 97 TN cases, observed that 90% of these
tumors have a basal phenotype by cDNA microarray
analysis. However, the lack of expression of ER, PR and
HER2 as the sole criterion to identify these tumors is
risky (Rakha et al., 2008) because there are technique
limitations when dealing with FFPE tissue samples,
which reinforces the need for a more suitable panel.
There is a significant overlapping of features shared
by triple negative and BLBC in what concerns, for
example, the prevalence of these types of cancer in
younger patients, in African-American women (Morris
et al., 2007), their presentation as interval cancers, a
similar pattern of recurrence (Dent et al., 2007;
Tischkowitz et al., 2007), the more aggressive behavior
comparing with other types of breast cancer (Reis-Filho
and Tutt, 2008) and the biological and clinical similarity
between sporadic TN and BLBC with breast carcinomas
arising from BRCA1 mutation carriers (Reis-Filho and
Tutt, 2008). However, several studies claim that this
overlap is not complete (Bertucci et al., 2008, Rakha and
Ellis, 2009). It is known that TN carcinomas with basal
phenotype have a significant shorter disease-free
survival than TN without expression of basal markers
(Rakha et al., 2007a; Tischkowitz et al., 2007) and that
germline BRCA1 mutation carriers are more probably
found in TN tumors expressing CK5/6 and /or EGFR
than in TN with no expression of these basal markers
(Turner et al., 2007; Rakha et al., 2009). It has also been
observed in GEP that triple negative group is composed
by other subgroups of tumors with different outcomes,
namely the normal breast-like tumors (Perou et al., 2000;
Sorlie et al., 2001, 2003; Sotiriou et al., 2003; Fan et al.,
2006; Hu et al., 2006; Hennessy et al., 2009) and a
recently described subgroup of claudin-low tumors
(Herschkowitz et al., 2007; Hennessy et al., 2009). The
existence of TN tumors that do not react
immunohistochemically with any of the basal markers
routinely used has been described, and variably
designated as non basal triple negative, unclassified,
undetermined, null phenotype (Liu et al., 2008) or
TN3BKE- (Triple Negative 3 Basal Keratins and 
EGFR-) (Rakha et al., 2009). It seems extremely
important to distinguish BLBC from the whole triple
negative group, reducing the TN heterogeneity, since
their biological behavior appears to be different. The
lightening of this heterogeneity would enable patients to
benefit from their differential recognition (Rakha et al.,
2007a, 2008, 2009; Liu et al., 2008; Reis-Filho and Tutt,
2008; Tan et al., 2008; Rakha and Ellis, 2009). This
distinction is also important because TN tumors defined
by IHC tend to be clinically considered as BLBC and
selected for clinical trials (Bertucci et al., 2008),
probably misleading the effect of the drugs in the clinical
trials. 
It is interesting to emphasize that among the
analyzed TN/CK5 and EGFR- tumors that were also
negative for P-cadherin, CK14 and Vimentin,
approximately 50% of these cases presented low
histological grade (Table 8). P-cadherin was expressed
alone in a higher number (15 cases) of TN/CK5 and
EGFR negative tumors, compared with CK14 (1 case)
and Vimentin (3 cases). When P-cadherin, CK14 and
Vimentin expression are considered along with CK5 and
EGFR for the BLBC identification, 34 cases are added to
the 37 already identified BLBC (CK5 and/or EGFR+)
and the percentage of basal-like tumors in the pool of
TN cases of our series rounds the 65% (71/109). This
rate is similar to the one identified by Bertucci (Bertucci
et al., 2008), where 70% of IHQ TN tumors presented a
basal phenotype by GEP. It is worth noticing that using
P-cadherin, CK14 and Vimentin to recruit BLBC from
the pool of tumors that could not be classified using only
CK5 and EGFR as basal makers, these newly identified
BLBC are clinically similar to basal-like tumors
identified by Nielsen’s criterion, since the majority of
the cases presented high histological grade and there are
no significant differences in what concerns overall
survival of the patients. 
Although CK5 and EGFR have been consistently
used to recognize BLBC, P-cadherin, CK14 and
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Vimentin could also be recruited for an
immunohistochemical recognition of BLBC (Paredes et
al., 2002, 2007a,b; Matos et al., 2005; Livasy et al.,
2006; Rodriguez-Pinilla et al., 2007). Our results showed
that these three markers can reliably identify the basal
phenotype, especially when associated to CK5, and can
be alternative options in this setting. We also
demonstrate that P-cadherin, due to its high sensitivity,
can recognize possible BLBC among the IHC TN
tumors, probably identifying patients with poor
prognosis that can benefit from this differential
recognition. Pathologists have faced continuous changes
in the diagnostic approach of breast cancer and,
regarding its classification, it is still controversial
whether or not the histological classification should be
replaced by the “molecular” taxonomy. Therefore, it is
essential to move towards a standardized methodology
to establish an IHC panel of biomarkers to the most
appropriate recognition of basal-like breast carcinomas.
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Cytological Criteria to Predict
Basal Phenotype of Breast
Carcinomas
Rozany Mucha Dufloth, M.D., Ph.D.,1 Jacy Maria Alves, M.S.,1
Diana Martins, B.Sc.,2 Daniella Serafin Couto Vieira, M.D., M.Sc.,1
Hora´cio Chikota, M.D.,3 Luiz Carlos Zeferino, M.D., Ph.D.,4 and
Fernando Schmitt, M.D., Ph.D., F.I.A.C.2,5*
Breast carcinoma is a heterogeneous disease. It can be classified
into phenotypes based on the expression of certain proteins, with
distinct differences in prognosis. The basal phenotype is associ-
ated with worse prognosis and it still remains without specific
treatment. However, there is currently no international consen-
sus on the cytological criteria that could predict this phenotype.
The purpose of the study was to evaluate the cytological criteria
in fine-needle aspiration biopsy and to identify their association
with the basal phenotype of breast carcinoma. Fine-needle
aspiration biopsy specimens and tissue sections (mastectomy
specimen) from 74 cases of high-grade invasive ductal breast
carcinomas were consecutively retrieved from the files of three
institutions. Breast carcinomas were studied using the tissue
microarray technique, being classified into phenotypes: luminal
A, luminal B, HER2 overexpression, and basal. The cytological
criteria for all cases were reviewed blindly by two pathologists
according to five cytological criteria: cellularity, cell pattern,
presence of necrosis, nucleoli, and nuclear atypia. Exact Fisher
test was used to test the association between cytological criteria
and the phenotypes of breast carcinoma. Necrosis was present
in 64.7% of basal breast carcinomas, and 31.1% of nonbasal
breast carcinomas, and that result was statistically significant,
showing an odds ratio (OR) of 3.80. The basal phenotype, com-
pared with the luminal A, showed more necrosis (OR ¼ 6.97),
present/prominent nucleoli (OR ¼ 8.18), and cellularity more
frequently (OR ¼ 18.03). Necrosis, as well as present/prominent
nucleoli and abundant cellularity are criteria more frequently
associated to the basal phenotype of breast carcinoma. Diagn.
Cytopathol. 2009;37:809–814. ' 2009 Wiley-Liss, Inc.
Key Words: breast cancer; fine needle aspiration cytology;
basal cell cancer; cytology
Since therapeutic planning is frequently made as a preop-
erative multidisciplinary triple approach and fine-needle
aspiration cytology (FNAC) is an integral part of this, it
is important to gather as much prognostic information
from the cytological specimen as possible.1–7 This proce-
dure has become widely accepted as a first-line diagnostic
procedure for breast lesions and as a reliable diagnostic
tool with both high sensitivity and specificity with mini-
mum complications.8–12 Emerging data demonstrate that
stratification of tumors by gene-expression profiles divides
breast carcinoma into a mixture of at least two main
types, according to hormone estrogen receptor (ER)
expression. The hormone receptor-negative group has two
subtypes: human epithelial receptor 2 (HER2) overex-
pressing and basal-like. The hormone receptor-positive
group has two subtypes: luminal A and luminal B.13–15
Basal breast carcinomas represent one of the most intriguing
subtypes because there is no efficient therapy against these
lesions, which are often associated with poor prognosis.16–18
Basal breast carcinomas are thought to arise from the
basal epithelial layer of the breast duct. This subgroup
has morphology characteristics consisting of a high prolif-
erate rate, central necrosis, and pushing border.6,17,19
FNAC offers a suitable alternative to biopsy in a vari-
ety of clinical settings, in which it may be useful to
obtain material to study diagnostic, prognostic, and pre-
dictive markers. The progress of ‘‘specific’’ therapies
based on antibody response will certainly obligate the
cytologists to actively participate in the decision-making
for therapeutic options for patients.7,20
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To date, the basal subgroup has been defined by gene
arrays analysis. However, this method is very expensive.
The purpose of this study was to determine whether some
cytological criteria could predict the basal phenotype of
breast carcinoma, using as gold standard a series of breast
carcinomas classified according to the current molecular
classification by means of tissue microarray (TMA)
technique.
Methods
Breast Carcinoma Samples
FNAC specimens and tissue sections (mastectomy speci-
men) from 74 cases of histological grade III invasive duc-
tal breast carcinomas, diagnosed between 2000 and 2007,
were identified from the patient database at the depart-
ment of Pathology, Federal University of Santa Catarina,
Florianopolis, Brazil, IMP Medical Laboratory, Florianop-
olis, Brazil, and at the Hospital Sao Joao, University of
Porto, Portugal. Formalin-fixed, paraffin-embedded tis-
sues, and FNAC specimens of 74 grade III invasive ductal
breast carcinomas were consecutively retrieved from the
files of these institutes. They were examined using tissue
microarray (TMA) technology and immunohistochemistry.
The use of these specimens and data for research pur-
poses was approved by the Ethics Committee of the Fed-
eral University of Santa Catarina, Florianopolis, Brazil.
Cytological Criteria
All FNAC specimens were previously stained with Papa-
nicolaou stain and May-Gru¨nwald Giemsa stain. The
cytological parameters for all cases were reviewed by two
pathologists (F.S. and R.M.D.), through the review of the
FNAC specimens in the multihead microscope in order to
identify the presence of five individual cytological crite-
ria: cellularity, nuclear atypia, cell pattern, nucleoli, and
presence of necrosis.20 The Figures C-1–C-4 illustrate
some of the criteria analyzed in this study.
Figs. C-1–C-4. Fig. C-1. Abundant cellularity (Papanicolaou stain, 3200). Fig. C-2. Dissociated cell pattern (Papanicolaou stain, 3400).
Fig. C-3. Necrosis (May-Gru¨nwald Giemsa stain, 3400). Fig. C-4. Severe nuclear atypia (May-Gru¨nwald Giemsa stain, 3400).
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Tissue Microarray Construction
Representative areas of the invasive breast carcinomas
were carefully selected on hematoxylin and eosin (H&E)
stained sections and marked on individual paraffin blocks
by a pathologist (R.M.D.). Two tissue cores (2 mm in di-
ameter) were obtained from each selected specimen and
precisely deposited into a recipient paraffin block using a
TMA workstation (TMA builder ab1802, Abcam, Cam-
bridge, UK). Four TMA blocks were constructed, each
containing 24 tissue cores, and arranged in a 4 3 6 sec-
tor. In each TMA block, non-neoplastic breast and testicu-
lar tissue cores were also included as controls and TMA
guide, respectively. After construction, 2-lm tissue sec-
tions were cut and adhered to Super frost plus glass
slides. An H&E stained 2-lm section from each block
was reviewed to confirm the presence of morphological
representative areas of the original lesions. All markers
were assayed in TMAs.
Immunohistochemistry
The molecular phenotype was established in the paraffin
block, with the use of specific immunohistochemical
markers, through the TMA technique. Like Nielsen et al.21
we also classified each tumor in a practical way based on
its ER and HER2 expression. A total of 74 cases were
immunohistochemically interpretable to allow sample
characterization into one of five groups. If a tumor was
ER-positive, it would be classified as luminal. If a tumor
was ER-positive and HER2-negative (0, 1, or 2+), it would
be classified as luminal A. However, if it was ER-positive
and HER2-positive, it would be classified as luminal B. If
a tumor was ER-negative and HER2-positive, it would
be classified as HER2-overexpressing, and if it was both
ER- and HER2-negative but positive for at least one basal
marker (P-cadherin and/or EGRF and/or CK5), it would
be classified as basal. If a tumor did not show expression
for any of these markers, it would be classified as null
phenotype and would not be considered in the remaining
analyses.
Immunohistochemical staining for ER, HER2, and CK5
was performed using the streptavidin-biotin-peroxidase
technique (Laboratory Vision Corporation, Fremont, CA)
in each set of four glass slides comprising the TMAs,
whereas P-CAD and EGFR used the HRP-labeled poly-
mer (DakoCytomation, Carpinteria, CA). The antigen re-
trieval times, clone antibodies, dilutions, and suppliers are
listed in Table I. Positive and negative controls were
included in each run in order to guarantee the reliability
of the assays. Non neoplastic breast tissue cores, as well
as normal breast surrounding the neoplastic cells, were
considered internal controls for most of the antibodies
tested: CK5, P-cadherin, EGFR (myoepithelial cells);
ERa, (epithelial cells). All slides were analyzed by two
pathologists (F.S. and R.M.D.) in a multihead microscope
(Leica MDL, Germany).
Statistical Analysis
The data were described in absolute frequencies (n) and
relative frequencies (%) to evaluate the association of
cytological criteria. These cytological criteria were com-
pared between groups of breast carcinomas by means of
the Fisher exact test, with a confidence interval of 95%. P
values of <0.05 (two-tailed) were considered as statisti-
cally significant. Statistical analyses were performed with
SAS statistical software, Version 9.02.
Results
A total of 74 cases were immunohistochemically inter-
pretable to allow sample characterization into one of five
groups. We observed that basal type comprised 23.0% of
all tumors, whereas luminal A and luminal B comprised
35.1% and 5.4%, respectively. HER2-overexpressing
tumors represented 20.3% of the series, and null pheno-
type, 16.2% (Table II).
Table III shows cytological criteria correlated with mo-
lecular profile. Necrosis was present in 64.7% of breast
carcinomas with basal phenotype, and it was present in
31.1% of nonbasal (luminal A, luminal B, and HER2-
overexpressing) carcinomas, and this result was statisti-
cally significant, showing OR of 3.80 (P ¼ 0.0404)
(Tables III and IV).
Other cytological criteria to identify the basal pheno-
type were higher cellularity (76.5% of cases), intense
atypia (76.5% of cases), mild or moderate cohesion cellu-
lar in 64.7% of cases, and nucleoli was present in 88.2%
of cases. The frequency of these criteria, however, did not
Table I. Sources and Dilutions of Primary Antibodies Used in This Immunohistochemistry Study
Antibody Clone Manufacturer Dilution
Time of incubation
(minutes)
Antigen retrieval
(minutes)
CK5 XM26 LabVision 1:50 60 30
P-cadherin Clone 56 LabVision 1:50 60 30
EGFR 31G7 Zymed 1:100 60 30
ER SP1 LabVision 1:150 30 30
HER2 SP3 LabVision 1:80 30 30
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present a significant difference compared with frequency
observed in other phenotypes of breast carcinoma (Tables
III and IV).
Referring to the luminal A phenotype, 33.3% of the
FNAC specimens showed scant celullarity, 25.0% showed
mild atypia, 52.2% showed inconspicuous nucleoli, and
only 20.8% showed necrosis (Table IV). The basal sub-
type, compared with the luminal subtype, showed more
necrosis (OR ¼ 6.97, CI 95%: 1.72–28.25), and promi-
nent nucleoli (OR ¼ 8.18, CI 95%: 1.51–44.21). The
cytological criteria cellularity showed bordering signifi-
cance to differentiate the basal phenotype from the lumi-
nal A, showing an odds ratio (OR) of 18.03 (CI 95%:
0.96–337.81).
Discussion
Clinicians can reduce the risk of missed diagnoses of
breast carcinomas to 1% by using the triple test approach,
which is based on the correlation of clinical information,
imaging, and cytological diagnosis of FNAC to direct
patient management. Since therapeutic planning can be
made preoperatively on the basis of the cytological report,
it is important to gather as much prognostic information
from the cytological specimen as possible.20 FNAC is rec-
ommended as a first-line procedure given the ease of per-
forming the technique, the rapid turnaround time to obtain
a diagnosis, and the low cost compared with biopsy or
surgery as an initial approach.11
Table II. Frequencies of Immunohistochemically Defined Phenotypes of Breast Carcinomas in
74 Informative Tumors for the Tested Markers Using TMA
Phenotype of
breast carcinoma ER HER2
P-cadherin and/or
EGFR and/or CK5
Frequency
n (%)
Luminal A Positive Negative Positive/negative 26 (35.1)
Luminal B Positive Positive Positive/negative 4 (5.4)
Basal Negative Negative Positive 17 (23.0)
HER2-overexpressing Negative Positive Positive/negative 15 (20.3)
Nulla Negative Negative Negative 12 (16.2)
aIf a tumor did not show expression for any of immunohistochemical markers, it would be classified as
null phenotype and would not be considered in the remaining analyses.
Table III. Distribution of the Identified Individual Cytological Criteria in the Examination of the Fine-Needle Aspiration Biopsy With the Diagnosis
of Molecular Phenotype of the Breast Carcinoma
Cytological criteria
Basal Luminal A Luminal B HER2-overexpressing Nonbasalb
n % n % n % n % n %
Cellularity
Scant 0 0.0 8 33.3 1 25.0 2 13.3 11 25.6
Moderate 4 23.5 5 20.8 0 0.0 5 33.3 10 23.3
Abundant 13 76.5 11 45.8 3 75.0 8 53.3 22 51.2
Indeterminate/excludeda 0 2 0 0 2
Cell pattern
Dissociated 6 35.3 4 16.7 1 25.0 2 13.3 7 16.3
Fairly equal representation of
clustered and dissociated cells
11 64.7 12 50.0 3 75.0 10 66.7 25 58.1
Clustered 0 0.0 8 33.3 0 0.0 3 20.0 11 25.6
Indeterminate/excludeda 0 2 0 0 2
Necrosis
Present 11 64.7 5 20.8 3 75.0 6 40.0 14 31.1
Not present 6 35.3 19 79.2 1 25.0 9 60.0 29 67.4
Indeterminate/excludeda 0 2 0 0 2
Nucleoli
Inconspicuous 2 11.8 12 52.2 1 25.0 0 0.0 13 32.5
Present 3 17.6 11 47.8 2 50.0 3 23.1 16 40.0
Present and prominent 12 70.6 0 0.0 1 25.0 10 76.9 11 27.5
Indeterminate/excludeda 0 3 0 2 5
Nuclear atypia
Mild 0 0.0 6 25.0 0 0.0 0 0.0 6 14.0
Moderate 4 23.5 15 62.5 2 50.0 4 26.7 21 48.8
Severe 13 76.5 3 12.5 2 50.0 11 73.3 16 37.2
Indeterminate/excludeda 0 2 0 0 2
Total of cases 17 27.4 26 41.9 4 6.5 15 24.2 45 72.6
aIt was considered as indeterminate cytological criteria when it was not possible to characterize in the examination of fine-needle aspiration biopsy
specimen. Those cases were excluded from percentage analyses.
bLuminal A, luminal B, and HER2-overexpressing.
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In the present study we found that the presence of ne-
crosis in the cytological smears is one of the most impor-
tant cytological criteria in distinguishing basal and non-
basal breast carcinomas. Recently, Chivukula et al. found
similar results on core needle biopsies of the breast.22 In
fact, since the seminal paper of Tsuda et al.23 that
described the presence of large, central areas of necrosis
as one of the most important morphological criteria of
carcinomas with basal-like differentiation, other articles
having been confirming these findings.6,17,19,24,25 How-
ever, this is the first study that demonstrates the presence
of necrosis as important criteria on the characterization of
basal-like breast carcinomas in FNAC. Another result
from our study is that basal-like breast carcinomas pre-
sented more frequently abundant cellularity, necrosis, and
presence/prominent nucleoli if compared with the subtype
luminal A. However, it is important to highlight that the
criteria cellularity presented borderline significance, with
an OR of 18.03 (P ¼ 0.0257; CI 95%: 0.96–337.81). This
fact can have occurred due to the insufficiency of the ana-
lyzed sample in demonstrating the difference, which hap-
pens when the event is rarer or when few differences are
present between the data. In the analysis of the cellularity
of the basal and luminal phenotypes, the only category
with a clear difference was scant cellularity, with eight
cases presenting scant cellularity in luminal phenotype
and no cases in basal phenotype. The results found in this
study warrant special attention because the basal breast
carcinomas have very distinct therapeutic forms in rela-
tion to the luminal carcinoma.
Basal breast carcinomas have been reported to consti-
tute 17–23% of sporadic grade III invasive ductal carcino-
mas.5,6,26–29 These data are according to this study: we
found 23% of invasive grade III breast carcinomas pre-
senting the basal phenotype.
It has been shown in studies carried out on behalf of the
Breast Cancer Linkage Consortium that a combination of
morphology, negativity for ER and ‘‘basal’’ keratin posi-
tivity could provide a powerful predictor tool for BRCA1
mutation status and hence may be useful in selecting
patients for BRCA1 mutation testing.17 Many women with
mutations in the BRCA1 gene do not have a family history
of breast and/or ovarian cancer. Therefore, detecting a
cancer in a young woman with cytological criteria and
immunophenotype indicating a basal tumor can help alert
doctors to the possibility of a familial predisposition.
We are aware of the limitations of the present study
due to the reduced number of high-grade invasive ductal
breast carcinoma cases available for analysis and, there-
fore, more studies concerning this subject are necessary
using a larger sample of analyzed cases. However, the
cytological criteria found associated with negativity for
ER and HER2, and a positivity for basal immunohisto-
chemical markers such as CK5, P-cadherin, and EGFR,
could assist in the confirmation of diagnosis of breast can-
cer with basal phenotype. Due to the awareness of the
aggressive nature of this subtype of tumor, it is of great
clinical interest to establish its diagnosis as early as possi-
ble. Therefore, in the presence of cytological findings of
necrosis, present/prominent nucleoli, and abundant cellu-
larity, we recommend investigating the possibility of deal-
ing with a basal breast carcinomas and, if possible, trying
to confirm this diagnosis through the immunohistochemi-
cal analysis.
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